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Abstract 
 Cytochrome P450 (CYP) is a superfamily of heme-containing monooxygenase enzymes 
that metabolize a variety of endogenous and exogenous substrates.  These transformations can be 
advantageous in the role of homeostasis or clearance of foreign compounds.  However, aberrant 
CYP activity or biotransformations of procarcinogens can be detrimental to human health.  Thus 
cytochrome P450 enzymes can be both therapeutic targets and counter-targets.  In the process of 
drug discovery, in vitro evaluation of both the efficacy and selectivity of drug candidates is 
necessary before in vivo studies can be pursued.  In the case of the xenobiotic-metabolizing 
cytochrome P450 2A13 (CYP2A13), in vitro analysis was used to identify and evaluate selective 
inhibitors for reducing the risk of lung cancer in tobacco users.  Additionally, in vitro 
biochemical analysis of the steroidogenic cytochromes P450 21A2 (CYP21A2) and 11B1 
(CYP11B1) is being pursued for counter-target evaluation in the development of selective 
CYP17A1 inhibitors for the treatment of prostate cancer and the rational design of selective 
CYP11B1 inhibitors for the treatment of cortisol-dependent diseases.   
 Lung cancer is the leading cause of all cancer related deaths and results in 6 million 
annual deaths worldwide.  Since >80% of all lung cancer incidence is attributed to tobacco use 
but tobacco cessation methods are unsuccessful in 95% of users, an increased emphasis has been 
placed on lung cancer chemoprevention.  4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) is one of the most prevalent procarcinogens compounds in tobacco and is selectively 
activated by CYP2A13 metabolism in the respiratory tract.  The resulting diazonium ions are 
able to form DNA adducts and initiate lung cancer.  Therefore, the selective inhibition of 
CYP2A13 offers a novel therapeutic strategy in the chemoprevention of lung cancer.  High 
throughput screening identified the benzylmorpholine scaffold, and a small library was evaluated 
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for both binding (Kd) and inhibition (Ki) of CYP2A13 versus the 94% identical hepatic 
cytochrome P450 CYP2A6 (CYP2A6), which does not efficiently metabolize NNK.  These 
investigations identified the structural features of benzylmorpholine analogs responsible for 
selective binding and inhibition of CYP2A13 versus CYP2A6, leading to the determination of 
structure-activity relationships for the benzylmorpholine scaffold.  Docking and X-ray 
crystallography studies were further employed to identify the atomic-level interactions between 
benzylmorpholine analogs and CYP2A13 but were hampered by apparent binding in multiple 
orientations.   Nevertheless, these results could be used to design additional selective and potent 
CYP2A13 inhibitors for reducing the risk of lung cancer in tobacco users who are unable, 
unwilling, or in the process of ceasing tobacco use. 
 In a similar pursuit to identify inhibitors of CYP17A1 for the treatment of prostate 
cancer, it became important to evaluate the selectivity of potential drug candidates against 
obvious counter-targets.  CYP21A2 is involved in the biosynthesis of glucocorticoids and 
mineralocorticoids and has overlapping substrates with CYP17A1.  CYP11B1 follows CYP21A2 
in the steroid biosynthetic pathway and is also a counter-target for the development of CYP17A1 
inhibitors.  Additionally, CYP11B1’s crucial role in cortisol production also presents this 
enzyme as an independent therapeutic target for the treatment of Cushing’s disease resulting 
from cortisol overproduction.  However, biochemical studies for both human CYP21A2 and 
CYP11B1 have been limited by protein availability.  Human CYP21A2 was successfully cloned, 
expressed, purified, and crystallized for the first time, which allows for structural and functional 
studies of the human enzyme.  CYP11B1 was also successfully cloned and expressed, but more 
optimization is necessary for consistent large-scale expression and purification.  This work 
provides the necessary groundwork for a biochemical and biophysical understanding of both 
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CYP21A2 and CYP11B1 for the evaluation of these enzymes as counter-targets.  In addition 
these studies could lead to the rational design of CYP11B1 inhibitors for the treatment of cortisol 
dependent diseases.   
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Chapter 1 
Introduction 
Introduction to Cytochromes P450 
 Cytochromes P450 (CYP or P450) are heme-containing monooxygenase enzymes that 
catalyze a variety of reactions including hydroxylations and epoxidations. There are 57 human 
P450 enzymes and 58 pseudogenes that are divided amongst 18 families and 43 subfamilies.  
These enzymes metabolize a range of substrates including steroids, xenobiotics, fatty acids, 
eicosanoids, vitamins, and unknown compounds (Table 1.1).1  Families 1-3 are primarily 
responsible for the conversion of exogenous compounds, while families 4 or greater are typically 
involved in the metabolism of endogenous substrates.2  Oxidations performed by P450 enzymes 
are vital for maintaining homeostasis and for clearing toxic or foreign compounds from the body. 
 
Table 1.1. Classification of human cytochromes P450 according to their primary substrates. 
 
Steroids Xenobiotics Fatty Acids Eicosanoids Vitamins Orphan 
1B1 17A1 1A1 2C19 2J2 4F2 2R1 2A7 4F22 
7A1 19A1 1A2 2D6 4A11 4F3 24A1 2S1 4V2 
7B1 21A2 2A6 2E1 4B1 4F8 26A1 2U1 4X1 
8B1 27A1 2A13 2F1 4F12 5A1 26B1 2W1 4Z1 
11A1 39A1 2B6 3A4  8A1 26C1 3A43 20A1 
11B1 46A1 2C8 3A5   27B1 4A22 27C1 
11B2 51A1 2C9 3A7    4F11  
  2C18       
 
P450 enzymes were independently identified by Garfinkel and Klingenberg who 
observed a pigment that had an absorption maxima at 450 nm when bound to carbon monoxide 
in a reduced environment (Figure 1.1).1,3 This was unusual for heme proteins and was later found 
to be a result of heme ligation via cysteine versus histidine or tyrosine in other heme proteins.  
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Hence, the name P450 was born, and this unique spectral characteristic is still used to determine 
the concentrations of P450 enzymes.  P450 enzymes are divided into their respective families 
based upon sequence similarity.  A minimum of 40% amino acid sequence identity must be 
achieved for cytochrome P450 enzymes to belong to the same family (CYP2).  Furthermore, 
sequences with ≥ 55% amino acid sequence identity are considered to belong to the same 
subfamily (CYP2A).4  The final number in the name indicates the individual enzyme 
(CYP2A13). 
 
Figure 1.1. Reduced carbon monoxide difference spectra for a CYP2A enzyme with an 
absorbance maxima at ~450 nm. 
 
 
Cytochrome P450 Catalytic Cycle1 
 In order to perform their monooxygenase activity, cytochrome P450 enzymes require the 
presence of a redox partner.  There are two classes of redox systems.  Class I redox systems 
provide electrons via an electron transfer chain consisting of adrenodoxin (Adx) with a single 
Fe2S2 cluster and a NADPH-dependent adrenodoxin reductase (AdR) containing FAD.1  The 
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surface of Adx and AdR have complementary charge distributions that facilitate binding to each 
other through electrostatic interactions.1  The class I redox system is relevant to mitochondrial 
enzymes such as the CYP11 and CYP27 families.  Class II consists of the NADPH-dependent 
cytochrome P450 oxidoreductase (POR) that delivers electrons to P450 enzymes anchored in the 
endoplasmic reticulum.1  For both class I and class II electron delivery systems, NADPH is the 
initial source of electrons, delivering a hydride ion to the reductase enzymes for the sequential 
single electron transfer to cytochromes P450.  POR is comprised of an NADPH and FAD 
binding domain and a FMN domain connected by a linker.5 POR facilitates the transfer of 
electrons from NADPH to FAD to FMN and finally to cytochromes P450 for completion of the 
catalytic cycle.  The negatively charged POR redox partner is thought to bind to the proximal 
side of a cytochrome P450 enzyme, positioning the FMN domain near the heme for electron 
transfer.6  
 The catalytic cycle involving the activation of molecular oxygen and subsequent 
incorporation of oxygen to form metabolites involves several steps (Figure 1.2).1 Cytochromes 
P450 have an iron protoporphyrin IX coordinated to a cysteine thiolate.  In the resting state, the 
ferric heme iron is bound to a water molecule (State 1).  The binding of substrates or inhibitors 
facilitates two paths, both of which involve the displacement of the water molecule from the 
sixth coordinate position.  Nitrogen-containing inhibitors have the ability to replace water and 
directly coordinate to the heme iron via the lone pair (State 2).  Alternatively, substrates often 
bind within the active site in such a way as to displace the water molecule (State 3) but do not 
directly bind iron.  This alters the spin state and prepares the enzyme for electron acceptance by 
altering the electron potential from -300 mV to -170 mV.  A NADPH-derived electron is 
delivered to the heme via POR or Adr, reducing the iron to the ferrous species (State 4).  
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Molecular oxygen can then bind, forming ferric Fe resulting in a P450-peroxo species (State 5).  
The P450-peroxo species is further reduced by the delivery of a second electron resulting in the 
peroxoanion intermediate (State 6), which is then protonated to form the hydroperoxy complex 
(State 7).  Addition of a second proton followed by heterolytic cleavage results in the formation 
of a water molecule and the reactive iron(IV)-oxo complex (State 8).  Hydrogen abstraction from 
the substrate by the iron-oxo intermediate followed by oxygen rebound results in the transfer of a 
hydroxyl group to the substrate (State 9) forming a more hydrophilic metabolite that dissociates, 
enabling a water molecule to bind and complete the catalytic cycle.  
 There are three points at which the catalytic cycle can be uncoupled. The first point, 
called the autoxidation shunt, the superoxide anion bound to the ferric enzyme (State 5) is 
released, returning the protein to State 3. The second process is called the peroxide shunt and 
occurs at the stage in which the hydroperoxo compound is coordinated to the heme Fe (State 7).  
Dissociation and protonation of the hydroperoxo compound forms hydrogen peroxide (State 7 to 
State 3). Finally, the oxidase shunt introduces two electrons and two protons to reduce the ferryl 
iron-oxo intermediate to water (State 8 to State 3) rather than hydrogen abstraction and substrate 
oxygenation.1 These shunts consume reducing equivalents and can generate damaging oxygen 
species but do not result in productive catalysis of the substrate. 
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Figure 1.2. Catalytic cycle for cytochromes P450.1,7 
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Structural Features of Cytochromes P450 
 Mammalian cytochromes P450 are membrane bound enzymes located either in the 
endoplasmic reticulum or mitochondrial membrane. Even with a significant variation in 
sequence identity, all P450 enzymes maintain a conserved structural fold characterized by 12 
major α helices (A-L), 3-4 β sheets, and smaller variable helices designated with a prime symbol 
(Figure 1.3).8  One of the more notable helices is the I helix (Figure 1.3, yellow central helix) 
which spans the length of the protein and serves as one wall of the active site.  The heme serves 
as the floor of the active and interacts with the L helix (red).1  Active site volumes and topologies 
vary greatly among P450 enzymes and are dependent upon the placement and mobility of active 
site amino acid side chains and their surrounding helices.  Known structures reveal that the active 
sites of xenobiotic-metabolizing enzymes can vary from 250 Å3 (CYP2A6 with coumarin, PDB 
1Z10)9 to 1438 Å3 (CYP2C8 with palmitic acid, PDB 1PQ2)10 and appear to be more flexible as 
they accommodate a variety of substrates and inhibitors.8 Although there are fewer structures 
available of P450 enzymes that metabolize endogenous compounds, it appears that these 
enzymes may be more rigid than those that metabolize xenobiotic compounds as they have 
stricter selectivity and have to distinguish between substrates that may differ, for example, by a 
single hydroxyl group.8      
 To aid in expression and purification, mammalian P450 enzymes are often modified.  
These modifications have enabled numerous structure/function studies and crystal structures.11  
Native P450 enzymes are anchored to the endoplasmic reticulum or mitochondrial membrane 
through an N-terminal transmembrane helix composed of ~20 amino acids followed by a 
proline-rich sequence.1 Truncation of the N-terminal transmembrane helix in mammalian P450 
enzymes prior to this proline rich region is commonly used to generate larger quantities of more 
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soluble protein for biochemical studies and also often increases expression in E. coli.12  This N-
terminal transmembrane helix truncation does not affect intrinsic enzyme activity or the stereo- 
or regioselectivity of metabolites produced and has been one of the most pivotal modifications in 
advancing the structural knowledge of human cytochromes P450.12 However, the truncated 
enzyme remains associated with the membrane, and detergent is required for membrane 
extraction.  The F´ and G´ helices have the most hydrophobic surface and are thought to 
compose this second site of membrane association.1  Additionally, a C-terminal histidine tag is 
often added to allow for the use of affinity chromatography during purification.  The 
cytochromes P450 discussed in this dissertation have all been engineered with various N-
terminal deletions and a C-terminal histidine tag, expressed in E. coli, and extracted from the 
membrane with detergent. 
 
Figure 1.3. Structure of CYP2A13 with an N-terminal truncation.  Helices are colored from blue 
to red starting with the N-terminus.  The heme is indicated by the black sticks. 
 
	   8	  
Cytochrome P450 Enzymes and Lung Cancer Chemoprevention Characterization 
 The first of two project described in this dissertation pertains to the human xenobiotic-
metabolizing enzymes cytochrome P450 2A13 (CYP2A13) and cytochrome P450 2A6 
(CYP2A6).  Cytochromes P450 have always been of pharmacological interest as they are known 
to metabolize ~75% of drugs currently on the market with the remaining 25% percent being 
metabolized by flavin-containing monooxygenase, N-acetyltransferase, monoamine oxidase, 
esterases, and glucuronosyltransferase.13 Historically, pharmaceutical companies have avoided 
inhibiting xenobiotic metabolizing P450 enzymes for therapeutic intervention due to the risk of 
drug-drug interactions.14 However, there are 15 xenobiotic-metabolizing enzymes with >95% of 
P450 mediated drug metabolism attributed to only eight enzymes: CYP1A1/2, CYP3A4/5, 
CYP2C9, CYP2C19, and CYP2D6 (Figure 1.4).13-15 The selective inhibition of P450 enzymes 
not involved in drug metabolism is gaining attention as therapeutic targets in multiple areas, and 
inhibition of the xenobiotic-metabolizing P450 CYP2A13 could pave the way for a new 
generation of chemopreventative therapeutics. 
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Figure 1.4 Drug metabolism occurring via cytochrome P450 enzymes is dominated by 
contributions from eight major enzymes.16 
 
 
Despite the 1964 surgeon general’s warning linking tobacco use to lung cancer,17 20% of 
the U.S. population continues to use tobacco products,17 and it is estimated that 7 million of the 
current tobacco users will develop lung cancer.17 In addition, current chemotherapeutic and 
surgical lung cancer treatments are not only expensive with patient liability costs of $19,000 - 
$24,000 per year,18 but have a low 5-year survival rate of 15%,19 emphasizing the need for 
alternative methods such as preventing lung cancer formation.  Since 80% of all lung cancer 
incidence is the result of tobacco use,20 an obvious solution to reducing the risk of lung cancer 
would be to cease tobacco use.  However, nicotine is highly addictive and current tobacco 
cessation methods such as nicotine replacement therapy with products such as Nicorette, 
Nicoderm CQ, and Nicotrol, and pharmaceutical products such as Chantix and bupropion, are 
successful in only 5% of users.19	    Another solution is to reduce the in vivo formation of tobacco 
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carcinogens.  With over 55 reported carcinogens in tobacco products, this task may seem 
daunting, but targeting downstream effects and individual carcinogens in tobacco products such 
as benzo[a]pyrene (BAP) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) has 
demonstrated success in reducing the risk of tobacco-initiated lung cancer in animal models.19,21 
There are two methods by which to approach the chemoprevention of lung cancer.  The 
first method is with a suppressing agent such as myo-inositol, which blocks downstream effects 
following carcinogen exposure.  Myo-inositol is a naturally occurring glucose derivative under 
clinical development.22 In early studies, myo-inositol was shown to reduce the development of 
BAP- and NNK-induced lung tumors or lung tumor multiplicity in mice23,24 by moderating the 
serine, threonine Akt kinase pathway involved in cell survival.25 This compound recently 
completed phase I clinical trials and is currently in phase II trials.22  
The second chemopreventative approach consists of a blocking agent, which directly 
inhibits the formation of carcinogens.  Since BAP and NNK are the most prevalent 
procarcinogens in tobacco products they are prime targets for reducing metabolite formation.  
However, BAP is metabolized by CYP1A1,26 which participates in minor drug metabolism and 
would not be an optimal therapeutic target for inhibition. NNK, on the other hand, is selectively 
metabolized by CYP2A13, to form DNA alkylating agents that can result in lung cancer.  
CYP2A13 does not appear to be involved in drug metabolism, and tobacco users with natural 
occurring polymorphisms resulting in reduced CYP2A13 activity exhibit normal physiological 
characteristics but have a decreased risk for lung adenocarcinoma.27,28 Thus, a selective inhibitor 
of CYP2A13 could reduce the risk of lung cancer in tobacco users. 
 Animal studies have validated this hypothesis.  Mouse studies identified the CYP2A13 
ortholog, CYP2A5, as being responsible for NNK bioactivation,29 and lung-POR-null mice had 
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decreased NNK-induced tumors, illustrating the role of the respiratory tract in NNK 
bioactivation.30  In addition, NNK-induced tumors were reduced in rats from 70% to 5% with the 
known CYP2A inhibitor, phenethyl isothiocyanate (PEITC),31 and CYP2A13 inhibition has been 
correlated to a decrease in NNK metabolite formation and an increase in NNK glucuronidation 
and excretion.32 Thus once CYP2A13 is inhibited, an increased amount of NNK is cleared via 
nontoxic, non-carcinogenic metabolites. However, while PEITC demonstrated promising results 
in in vitro and in vivo animal studies, it is not a viable drug candidate due to undesired reactivity 
in promoting cancer in the urinary tract.33 Therefore, there is still an unmet need for a selective 
CYP2A13 inhibitor to reduce the risk of lung cancer in tobacco users who are unable or 
unwilling to cease tobacco use.  In addition, the combination of a suppressing and blocking agent 
proved twice as efficacious as each agent individually and offers a unique approach to 
chemoprevention in the future.19 
One of the major advantages of a selective CYP2A13 inhibitor is that this approach to 
chemoprevention does not necessarily require tobacco users to alter their habits to reduce their 
risk of lung cancer.  Although this has led to initial opposition, the social and economic benefits 
should be considered.  It is estimated that 70% of tobacco users desire to cease tobacco use but 
most have been unsuccessful with current cessation aids.34 In addition to the annual death toll of 
6 million individuals worldwide20 and the expensive treatment cost associated with each new 
occurrence of lung cancer (patient liability of $19,000-$24,000 per year),18 it is estimated that all 
tobacco-related diseases result in an annual loss of over $97 billion due to lost productivity and 
an additional $96 billion for direct health care costs.35 Therefore, a blocking and/or suppressing 
agent could also alleviate some of the significant societal financial burden associated with lung 
cancer.  
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The emphasis of this project was the identification and evaluation of small molecule 
inhibitors of CYP2A13 as chemopreventative agents for lung cancer in tobacco users.  High 
throughput screening was initially used to identify the benzylmorpholine scaffold.  Subsequently, 
a small library composed of both purchased and synthesized benzylmorpholine analogs (Figure 
1.5) was evaluated for both binding and inhibition of CYP2A13 versus the 94% identical 
counter-target, CYP2A6.  X-ray crystallography was used to analyze the atomic-level 
interactions between CYP2A mutant enzymes and select benzylmorpholine analogs. 
 
Figure 1.5.  The benzylmorpholine library that was evaluated for the selective inhibition of 
cytochrome P450 2A13 consisted of 24 individual compounds. 
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Advancing Knowledge of the Steroid Biosynthetic Pathway for Therapeutic Intervention 
The second project in this dissertation transitions from xenobiotic metabolizing P450 
enzymes to those involved in the steroid biosynthetic pathway.  Specifically, cytochromes P450 
11B1 (CYP11B1) and 21A2 (CYP21A2) are involved in the biosynthesis of glucocorticoid and 
mineralocorticoid steroids.  Unlike the P450 enzymes involved in xenobiotic metabolism where 
deficiencies may go unnoticed until exposure to a particular xenobiotic, aberrant P450 activity in 
both deficiencies and excessive hormone production in the steroid biosynthetic pathway can have 
severe physiological repercussions.14   
There are six cytochrome P450 enzymes involved in the conversion of cholesterol to 
progestagens, mineralocorticoids, glucocorticoids, androgens, and estrogens (Figure 1.6).1 
Deficiencies in any of these enzymes can have significant downstream effects.  Deficiencies in 
CYP11A1, which is the first step in the pathway and performs a side chain cleavage on 
cholesterol for the formation of pregnenolone, can lead to the formation of lipoid adrenal 
hyperplasia.1,36 CYP17A1 catalyzes multiple reactions required for the formation of 
glucocorticoids, androgens, and estrogens,1 and CYP17A1 deficiencies result in excess 
mineralocorticoid production leading to hypertension and/or insufficient levels of 
glucocorticoids and sex hormones.36 CYP19A1 is necessary for the formation of estrone and 
estradiol.1  Absence of CYP19A1 can lead to virilization of external genitalia in females and 
hypervirilization in males.36 CYP21A2 is necessary for the formation of 11-deoxycorticosterone 
and 11-deoxycortisol in mineralocorticoid and glucocorticoid biosynthesis, respectively.1  
CYP21A2 deficiencies are responsible for 90-95% of all cases of congenital adrenal hyperplasia 
(CAH) and result in excess androgen production.37 CYP11B1 and CYP11B2 also participate in 
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glucocorticoid and mineralocorticoid production, and deficiencies result in CAH and excess 
androgen production.1,36,38  
 
Figure 1.6. Human steroid biosynthetic pathway. Image courtesy of Dr. Emily Scott and 
modified from Mikael Häggström’s biosynthetic pathway.  
 
 
Just as deficiencies in steroidogenic enzyme activity can negatively impact human health, 
excessive or unwanted signaling resulting in hormone production can also be detrimental.  In 
prostate and breast cancer patients, the roles of CYP17A1 and CYP19A1 in the formation of 
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androgens and estrogens can enhance cancer growth.1  In addition, elevated levels of aldosterone 
mediated by CYP11B2 can contribute to hypertension and congestive heart failure,39 and 
overproduction of cortisol by CYP11B1 due to excessive regulator signaling can result in 
Cushing’s disease.1,38 However, unlike deficiencies, these disease states can often be moderated 
through inhibitors (Figure 1.7).  Abiraterone and TOK-001 have demonstrated success in 
extending survival times in prostate cancer patients through CYP17A1 inhibition and are 
becoming preferred over the classical treatment with the non-selective P450 inhibitor, 
ketoconazole.40  Tamoxifen has been the gold standard of breast cancer treatment through 
inhibition of the estrogen receptor, but new entities such as anastrozole, letrozole, and 
exemestane, which inhibit aromatase (CYP19A1), are becoming more widely used.41 
Ketoconazole and metyrapone have been used to diagnose and treat Cushing’s disease resulting 
from an overproduction of cortisol by CYP11B1,42-44 and a CYP11B2 inhibitor (LC-1699) is in 
phase II clinical trials for the treatment of hypertension.45  
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Figure 1.7. Drugs used clinically or in development to inhibit cytochromes P450 involved in the 
steroid biosynthetic pathway.40-42 The structure of LC-1699 is not available. 
 
 
The rational design of selective inhibitors for therapeutic intervention is aided by 
biochemical studies and structural knowledge of the targets.  Recent work in the Scott lab 
produced the first crystal structure of CYP17A1,46 and the combination of this structural 
knowledge with biochemical studies is facilitating the design of novel selective CYP17A1 
inhibitors for the treatment of prostate cancer.  However, selectivity of potential drug candidates 
cannot be determined without evaluation against counter-targets in the steroid biosynthetic 
pathway such as CYP21A2 and CYP11B1.  CYP21A2 is of special importance as it has substrate 
overlap with CYP17A1.1  Additionally, CYP11B1 is both a counter-target for CYP17A1 
inhibitors and a therapeutic target itself for the treatment of Cushing’s disease.44  However, there 
is a significant deficiency in the biochemical analysis of both human CYP21A2 and CYP11B1 
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due to the lack of protein availability resulting from enzyme instability or poor protein yields 
from E. coli expression and purification protocols.47,48 
The goal of my projects with CYP21A2 and CYP11B1 was to further the biochemical 
and biophysical knowledge for evaluation of these enzymes as counter-targets, and in the case of 
CYP11B1, as a therapeutic target for the rational design of inhibitors relating to cortisol-
dependent diseases.  The work described herein lays the necessary groundwork for the 
biochemical studies and encompasses the cloning, expression, and purification for both 
CYP11B1 and CYP21A2 in addition to assay development and crystal formation for CYP21A2.  
Conclusions 
 Cytochromes P450 play crucial roles in maintaining homeostasis and clearance of foreign 
chemicals in the body.  While xenobiotic biotransformations performed by these enzymes are 
typically advantageous in promoting the health of individuals, this is not always the case, as 
demonstrated by the metabolism of the tobacco procarcinogen NNK to reactive metabolites.  The 
work described in chapters 3 and 4 of this dissertation sheds light on the benzylmorpholine 
scaffold and its ability to selectively inhibit CYP2A13, and therefore has the potential to reduce 
the risk of lung cancer in tobacco users.   
However, inhibition or reduction of endogenous metabolism in the steroid biosynthetic 
pathway can have detrimental effects on otherwise healthy individuals, but can be extremely 
useful in the treatment of cancer.  The design of selective inhibitors is aided by the evaluation of 
the potential drug candidates against counter-targets.  Such targeting of enzymes in the steroid 
biosynthetic pathway has been limited.  Unfortunately, biochemical studies on some of these 
enzymes have been hampered by protein availability.  The work in chapters 5 and 6 describes the 
cloning, expression, purification, and initial metabolic characterization of the human CYP21A2 
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and CYP11B1 enzymes, which are involved in the production of mineralocorticoids and 
glucocorticoids and are important counter-targets for CYP17A1.  The study of both endogenous 
and exogenous metabolizing cytochrome P450 enzymes contributes to the knowledge of a 
structurally similar yet metabolically diverse class of enzymes and has the potential to facilitate 
the rational design of drug candidates for advanced therapy in the treatment of metabolic 
disorders. 
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Chapter 2 
Methods for CYP2A Enzymes 
Introduction 
 The methods used in this dissertation for the production and characterization of 
cytochrome P450 2A (CYP2A) enzymes and their activities are generally well-established 
techniques.  These techniques were essentially only optimized for current instrumentation.  As a 
result, the methods for these enzymes are aggregated in this chapter.  The methods involved in 
the production and characterization of the steroid cytochrome P450 enzymes 21A2 and 11B1, 
encompassed original work.  This work included method development and optimization in the 
cloning, expression, and purification protocols and thus can be found in the respective chapters 
for these individual enzymes. 
 All assays of cytochrome P450 catalysis required rat cytochrome P450 oxidoreductase 
(POR).  Production of this oxidoreductase was joint between our lab and the COBRE Protein 
Production Group. Expression of POR was conducted in our lab, by myself and other group 
members, as were the initial purifications.  I later helped transfer the purification procedures to 
the COBRE Protein Production Group.  However, even in this case, the final dialysis, 
characterization, and standardization of the purified oxidoreductase were performed in our lab by 
me and occasionally by other group members.  
Cytochrome P450 2A Expression and Purification1,2  
Transformation: A modified, ampicillin resistant pKK233-2 plasmid containing the gene for 
CYP2A6 or CYP2A13 that had an N-terminal truncation and C-terminal 4X histidine tag was 
transformed and expressed in tetracycline-resistant Topp3 Escherichia coli cells.1,2  One 
microliter of pKKCYP2AdH plasmid was incubated with 50 µl of thawed Topp3 E. coli cells 
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(Stratagene, La Jolla, CA) for 30 minutes.  Following incubation, the cells were heat shocked for 
35 seconds at 42 ˚C to induce DNA uptake, and the competent cells were plated on Luria Bertani 
(LB) media containing 50 µg/mL ampicillin.  Plates were incubated for ~16 hours at 37 ˚C.  
Expression: A single colony was inoculated into 5 mL LB broth with 50 µg/mL ampicillin and 
25 µg/mL tetracycline and incubated at 37 ˚C for 7-8 hours with shaking at 250 rpm.  Following 
incubation, 50 µl of the culture was transferred to 200 mL LB media with 50 µg/mL ampicillin 
and 25 µg/mL of tetracycline and incubated overnight at 37 ˚C at 250 rpm.  Alternatively, a 200 
mL culture can be started from a stab of a glycerol stock containing 800 µl of a previous 200 mL 
LB growth and 200 µl of sterile 80% glycerol.  A glycerol stock enables a bypass of the 
transformation procedure and was the primary source for starting many cultures in 200 mL of LB 
media. Fifteen milliliters of the overnight culture was added to sterile 1 L flasks containing 225 
mL of terrific broth media (TB media), 25 mL of TB salts, and 50 µg/mL ampicillin.  The 
cultures were incubated at 37 ˚C with shaking at 250 rpm until an OD600 of 1.0-1.5 was reached 
after ~2 hours.  After reaching the desired optical density, CYP2A expression was induced with 
the addition of 240 µg/mL isopropyl β-D-1-thiogalactopyranoside (IPTG).  At this time 80 
µg/mL of delta aminolevulinic acid (ALA) was also added to promote bacterial heme 
production.  The temperature and shaking were reduced to 30 ˚C and 190 rpm, and the cultures 
were allowed to grow for ~72 hours before harvesting by centrifugation at 6,500 x g and 4 ˚C for 
10 minutes.  Cell pellets from the 4.5 L expression were divided between two containers and 
stored at -80 ˚C. 
CYP2A Purification:1 Purified CYP2A protein was necessary for both assays and 
crystallography and was achieved by cell lysis with lysozyme, flash freeze, and sonication 
followed by a three column purification.  Harvested cells were thawed and resuspended with 
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resuspension buffer #1 (20 mM potassium phosphate, pH 7.4, 20% glycerol).  Lysozyme was 
added to the suspension to a final concentration of 0.3 mg/mL and stirred at 4 ˚C for 30 minutes 
to hydrolyze the 1,4-β-linkages between acetyl-D-glucosamine and acetylmuramic acid in the 
bacterial peptidoglycan cell wall.  The weakened cell wall was subjected to osmotic stress and 
lysis by the addition of 200 mL of 4 ˚C distilled water with stirring for 10 minutes at 4 ˚C.  The 
solution was centrifuged at 8,700 x g for 15 minutes, and the supernatant was discarded.  The 
pellet was flash frozen in a dry ice - ethanol slurry to further promote lysis.  Following flash 
freezing, a homogenous solution was achieved by resuspending and homogenizing the pellet 
with a tissue grinder on ice with ~100 mL resuspension buffer #2 (500 mM potassium phosphate, 
pH 7.4, 20% glycerol, 300 mM NaCl).  The resuspension was divided into three 50 mL aliquots 
and sonicated on ice for 3 x 30 seconds with 1 minute intervals between each round of 
sonication.  Centrifugation at 8,700 x g for 15 minutes separated the P450-containing supernatant 
from cellular debris.  Solubilization of the cytochrome P450 enzyme from membrane lipid was 
accomplished by adding Cymal-5 detergent (Anatrace, Santa Clara, CA) at two times the critical 
micelle concentration (CMC) (4.8 mM) to the supernatant and stirring at 4 ˚C for a minimum of 
30 minutes.  Ultracentrifugation at 4 ˚C and an average speed of 70,400 x g for 1 hour pelleted 
membrane lipids while the detergent-solubilized CYP2A enzyme remained in the supernatant. 
 An ÄKTA purification system was utilized to perform the affinity, cation exchange, and 
size exclusion chromatography.  Affinity chromatography with nickel nitrilotriacetic acid resin 
(Ni-NTA) was the first stage in the chromatography process.  Purification was achieved through 
the interaction between the C-terminal 4X histidine tag and the Ni2+ bound to the nitrilotriacetic 
acid resin.  Prior to sample injection, the Ni-NTA resin was equilibrated with two columns of Ni-
NTA loading buffer (100 mM potassium phosphate, pH 7.4, 20% glycerol, 0.2 M NaCl, and 4.8 
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mM Cymal-5).  Following sample loading, the Ni-NTA resin was washed with two column 
volumes of Ni-NTA loading buffer to remove unbound proteins.  The bound protein was washed 
with three column volumes of Ni-NTA 8 mM histidine wash buffer (100 mM potassium 
phosphate, pH 7.4, 20% glycerol, 0.2 M NaCl, 4.8 mM Cymal-5, 8 mM histidine).  This low 
histidine concentration wash removed weakly bound impurities, while the desired CYP2A 
protein was subsequently eluted with Ni-NTA 80 mM histidine elution buffer (100 mM 
potassium phosphate, pH 7.4, 20% glycerol, 0.2 M NaCl, 4.8 mM Cymal-5, 80 mM histidine, 
and 2 mM EDTA).  The high histidine concentration displaced the interactions between the Ni2+ 
and the cytochrome P450 C-terminal histidine tag by competing with CYP2A protein for binding 
sites on the Ni-NTA resin.   
 Nickel affinity chromatography was followed by cation exchange with a 5 mL 
carboxymethyl (CM) cellulose resin.  The protein sample was prepared for cation exchange 
chromatography by diluting the protein collected from affinity chromatography 5-fold with CM 
wash buffer (5 mM potassium phosphate, pH 7.4, 20% glycerol, and 1 mM EDTA) augmented 
with 4.8 mM Cymal-5 to reduce the ionic strength.  Inclusion of the Cymal-5 in the buffer at this 
stage was critical as it helped stabilize the protein in the absence of a high salt concentration. 
After equilibrating the CM column with three column volumes of CM wash buffer, the protein 
sample was loaded onto the column.   The bound protein was washed with 10 column volumes of 
the low salt CM wash buffer and then eluted with 4 column volumes of a high salt CM elution 
buffer (50 mM potassium phosphate, pH 7.4, 20% glycerol, 500 mM NaCl, and 1 mM EDTA).   
 Size exclusion chromatography was the final step in the purification of the CYP2A 
enzymes and required that the eluted fractions from the CM column were concentrated to 
approximately 1 mL.  The concentration step was necessary as low volume sample injection 
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result in a tighter protein band as the protein traverses the 120 mL column, which is run with CM 
elution buffer.  All chromatography steps were monitored by UV/Vis absorbance at 280 nm for 
general protein and at 393 nm and 417 nm for ligand-bound and water-bound P450 enzyme, 
respectively. The final protein concentration was evaluated by absolute absorption spectra and 
reduced carbon monoxide difference spectra as described later in this chapter. 
Rat Cytochrome P450 Oxidoreductase (POR) Expression and Purification 3 
 Purified cytochrome P450 oxidoreductase (POR) is necessary for electron delivery to all 
cytochrome P450 enzymes to support catalysis and product formation during metabolism assays.  
Expression and purification were accomplished following published procedures.3 
Expression: The HMS174 (DE3) cell line (Novagen) and pETOR262 plasmid were used to 
express rat POR.  LB media (100 mL) containing 50 µg/mL kanamycin was inoculated from a 
HMS174(DE3)/pETOR262 glycerol stock and incubated overnight at 37 ˚C with shaking at 250 
rpm.  A 0.5 mL aliquot of the overnight culture was transferred to each of eighteen 1 L flasks 
containing 225 mL of TB media, 25 mL TB salts, and 50 µg/mL kanamycin.  These cultures 
were incubated at 37 ˚C with shaking at 250 rpm until an OD550 > 0.8 was reached after 4 hours.  
IPTG at a final concentration of 0.5 mM was used to induce POR expression, and both the 
incubation temperature and shaking were reduced to 30 ˚C and 190 rpm.  Cultures were grown 
for ~48 hours before harvesting by centrifugation at 6,500 x g and 4 ˚C for 10 minutes.  Cell 
pellets were stored at -80 ˚C. 
Purification: Purification was completed at 4 ˚C with a BioRad ECONO system.  Harvested cells 
were thawed and resuspended with 150 - 200 mL buffer A (75 mM Tris pH 8.0, 250 mM 
sucrose, and 0.25 mM EDTA).  Lysozyme was added to a final concentration of 20 µg/mL and 
stirred at 4 ˚C for 30 minutes to facilitate cell lysis.  The suspension was centrifuged at 4400 x g 
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for 30 minutes at 4 ˚C to pellet the resulting spheroplasts.  Pellets were resuspended with 100 mL 
of affinity buffer (50 mM Tris, pH 7.7, 0.1 mM EDTA, pH 8.0, 0.05 mM DTT, 10% glycerol, 
and 0.1% Triton X-100) via a tissue grinder on ice. The solution was divided into three 50 mL 
aliquots on ice and sonicated 10 times for 10 seconds with 20 seconds intervals between each 
pulse.  Combined aliquots were stirred for 3 hours at 4 ˚C to allow sufficient time for optimal 
reductase solubilization from the membranes by the triton X-100 detergent.  The lysis solution 
was ultracentrifuged at 87,600 x g for 45 minutes at 4 ˚C to pellet membranes.  The POR-
containing supernatant was diluted to 7 mg/mL in affinity buffer and applied to a 100 mL bed 
volume of DE-52 resin at 1 mL/min for anion exchange chromatography.  Prior to sample 
addition, the resin was prepared by soaking the DE-52 resin with 8-10 bed volumes of 100 mM 
Tris, pH 7.7, decanting the solution, and repeating four times.  The resin was washed with 10 bed 
volumes of distilled water and checked to ensure the pH remained at 7.7.  The water was 
decanted and the resin was resuspended in a 1:3 ratio of resin to water solution, which was used 
to pack the column.  Column equilibration was achieved with 500 mL of affinity buffer.  
Following sample loading, the bound protein was washed with 500 mL of affinity buffer.  A 600 
mL gradient elution of 0 – 350 mM KCl in affinity buffer was used for elution.  The yellow 
elution fractions were combined and flavin mononucleotide (FMN) was added to a final 
concentration of 1 µM.  
 The second and final column was a 2´,5´-ADP sepharose 4B affinity column.  The resin 
was prepared by suspending 1 gram of resin in ~20 mL of water.  Once the resin had settled, the 
water was discarded, and 10 mL of affinity buffer was used to resuspend the resin and pack the 
column.  The column was equilibrated with 120 mL of affinity buffer at 0.5 mL/min, and the 
protein sample was loaded at 0.15 mL/min.  POR-containing yellow fractions eluted with 2-4 
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mM 2´-adenosine monophosphate were pooled and dialyzed versus 1 L of dialysis buffer (30 
mM potassium phosphate, pH 7.7, 20% glycerol, 0.1 mM EDTA, and 2.0 µM FMN) for every 3 
L of expression culture.  The two rounds of dialysis each had a minimum duration of 8 hours. 
 Activity of the purified POR was evaluated by monitoring cytochrome c reduction since 
one unit of POR reduces one micromole of cytochrome c per minute.  Two microliters of a 1:50 
– 1:100 diluted POR protein sample was added to 978 µL of 300 mM potassium phosphate, pH 
7.7, 0.05 mM cytochrome c, and 0.1 mg/mL nicotinamide adenine dinucleotide phosphate 
(NADPH) in a cuvette.  The reaction was monitored at the λmax for reduced cytochrome c (550 
nm) on a Shimadzu UV-2501PC UV/Vis Spectrophotometer.  The following equation was used 
to determine the final protein concentration.  
(Average absorption per mL)
21*0.002 mL sample
X dilution factor = units
mL
÷ 4 units
nmol
=
nmol
mL
 
Absolute Absorption Spectra 4   
A UV-2501PC UV/Vis spectrophotometer (Shimadzu Scientific Instruments, Inc., 
Columbia, MD) was used to determine the concentration of cytochrome P450 present in protein 
samples.  Eight hundred microliters of buffer were pipetted into a 1 cm path length cuvette and 
placed in the spectrophotometer.  The absorbance was zeroed at 700 nm and a baseline scan from 
700 - 250 nm was performed prior to the addition of 100 µL of the P450 protein sample.  The 
protein sample was mixed by inversion and the cuvette was reinserted into the 
spectrophotometer.  Absorbance was zeroed at 700 nm and scanned from 700 - 250 nm.  A 
rearrangement of Beers Law to C = (ε x l) / A, where C is the concentration, ε is the absorptivity 
coefficient of 0.1 µM-1 cm-1, l is the path length of 1 cm, and A is the absorbance, was used to 
determine the micromolar concentration of the P450 protein.  The absorbance was based on the 
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Soret peak maximum between 393 nm – 424 nm, which depended on the liganded state of the 
protein. 
Reduced Carbon Monoxide Difference Spectra 4 
Reduced carbon monoxide difference spectra were used to determine the concentration of 
cytochrome P450 protein with a λmax = 450 nm, which is the active form, and λmax = 420 nm, 
which is thought to be a catalytically inactive form.  One hundred microliters of protein sample 
was diluted into 800 µL of buffer, followed by the addition of a few grains of sodium dithionite 
for enzyme reduction.  The reaction mixture was mixed by inversion, and the absorbance was 
zeroed in a UV-2501PC UV/Vis Spectrophotometer (Shimadzu Scientific Instruments, Inc., 
Columbia, MD) at 500 nm and across a baseline from 500 - 400 nm.  Carbon monoxide was then 
bubbled through the protein sample until 50 bubbles were observed.  The reduced P450 carbon 
monoxide solution was scanned from 500 – 400 nm and monitored for peak formation at 420 
(inactive protein) or 450 nm (active protein).  As necessary, scans were repeated over time until 
the peak at 450 nm no longer increased. 
Analysis: The protein concentration was determined using Beer’s law in the same manner as the 
absolute absorption assay with the exception of an extinction coefficient of 0.091 µM-1 cm-1 was 
used for the analysis of the 450 nm peak. 
Spectral Ligand Binding Assays 5-7  
The spectral properties of cytochromes P450 enable the use of this chromophore in a 
ligand binding assay.  Thus determination of the spectral dissociation constant, Kd, for various 
cytochrome P450 ligands can be easily measured.  Shifts in maximum absorption attributed to 
the properties of the iron d orbitals and alterations in spin determine the spectral properties that 
are observed with different ligands. The resting state of the ferric heme has a water molecule 
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bound at the sixth position and is in a low spin state with a λmax of ~420 nm in the absolute 
spectrum.  Ligands have the ability to displace this water molecule, resulting in spectral shifts 
indicative of their mode of binding.  A type I ligand displaces the water molecule resulting in a 
high spin pentacoordinate state (λmax ≈ 393 nm in absolute spectra).7,8 Ligands with an available 
nitrogen or sulfur atom can coordinate to the heme iron, replacing the water, and stabilizing the 
low spin hexacoordinate state.  Such ligands are called type II ligands (λmax ≈ 424 nm).7,8 
Stabilization of this position leads to lower energy and results in the red shift in the spectral 
peak.9 There is one additional mode of binding which is classified as a reverse type I.  A reverse 
type I ligand stabilizes the low spin, water bound state and a λmax is observed at 420 nm in 
difference mode.10  Titrating a cytochrome P450 enzyme and monitoring the difference spectra 
can be used to determine the spectral dissociation constant.  In the difference spectrum mode, a 
type I ligand will demonstrate increasing absorbance at approximately 385 nm and decreasing 
absorbance at 420 nm, while a reverse type I ligand will have opposing increasing and 
decreasing absorbance at the identical wavelengths.  In this difference spectrum mode, type II 
ligands will have increasing absorbance at 424-435 nm and decreasing absorbance from 390 – 
410 nm.  In such titrations the concentration of the ligand solvent, often ethanol or 
dimethylsulfoxide, is maintained below 2% in order to minimize solvent effects on the P450 
protein. 
CYP2A protein was diluted to a final concentration of 1 µM in 100 mM potassium 
phosphate buffer.  Eight hundred microliters of the protein solution were aliquotted into two 
cuvettes with a 1 cm path length and placed into the UV-2501PC UV/Vis spectrophotometer 
(Shimadzu Scientific Instruments, Inc., Columbia, MD) in the sample and reference positions.  
Absorbance was zeroed at 500 nm and across a baseline from 500 – 300 nm.  An absorption scan 
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from 500 – 300 nm was used to determine the quality of the baseline.  If necessary, the baseline 
procedure was repeated until the absorption at all wavelengths was zero.  A titration of the 
CYP2A protein sample was accomplished by sequential ligand additions to the sample cuvette 
and a equivalent volume addition of solvent to the reference cuvette.  Following each ligand 
addition, the solution was mixed and equilibrated for 8 minutes at 20 ˚C prior to collection of the 
spectrum across 500 – 300 nm. Iterative spectra were collected until changes in absorbance 
maxima and minima were no longer observed. 
GraphPad Prism5 (Graphpad Software, San Diego, CA) was used to apply nonlinear 
least-squares regression fitting was used to determine the Kd with the equation shown below. 
Y = !Amax
2P
"
#
$
%
&
'* P + L +Kd ( (P + L +Kd )
2 ( 4*P*L)( )   
where Amax is the maximum absorption, P is the path length, and L is the ligand concentration.   
Imidazole-containing compounds were observed to bind very tightly and required 
modification of both the assay and the analysis.  The protein concentration was reduced to 0.1 
µM, and cells with a 5 cm path length were used to compensate for the decreased absorbance 
changes.  As above, the absolute difference between the absorbance maxima and minima were 
calculated from a set of such titration spectra, plotted versus ligand concentration, and fit to 
determine the spectral equilibrium dissociation constant, Kd.  In addition the tight binding 
equation was used to account for ligand depletion in determining the Kd for these compounds: 
[ML]= !b+ b*b! 4ac( ) / 2a
a = !1, b = Kd + Ltotal + Amax, c = !1*Ltotal *Amax
 
where [ML] is total binding, Kd is the equilibrium dissociation constant, Ltotal is the total ligand 
concentration, and Amax is the maximum absorption.  
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Coumarin Metabolism Assay11,12  
 Evaluation of the inhibition constants for the benzylmorpholine library was achieved by 
monitoring a coumarin metabolism assay.  Coumarin is a selective substrate for the CYP2A 
enzymes and is metabolized to 7-hydroxycoumarin (Figure 2.1).5 Monitoring the formation of 7-
hydroxycoumarin, which is fluorescent, enables an evaluation of the potency and selectivity of 
the potential benzylmorpholine inhibitors by determining the inhibition constant (Ki) with both 
recombinant purified CYP2A enzymes. 
 
Figure 2.1. Coumarin metabolism by CYP2A enzymes results in the formation of 7-
hydroxycoumarin.   
 
 
 Since cytochromes P450 require the presence of POR for electron delivery during 
metabolic reactions, the CYP2A enzyme (50 pmol) was first incubated with POR (200 pmol) for 
50 minutes on ice to maximize the association of these enzymes.  This reconstituted protein 
system (RPS) was mixed with 0-90 µM coumarin and varying inhibitor concentrations in 
reaction buffer (50 mM Tris, HCl, pH 7.4 and 5 mM MgCl2).  Following a 3 minute incubation 
at 37 ˚C 1 mM NADPH, the electron source for POR, was added to initiate the catalytic reaction.  
The 250 µL reaction was allowed to proceed for 10 minutes before being stopped by 
precipitation of the protein with 75 µl of 10-20% trichloroacetic acid (TCA).  Two hundred 
microliters of buffer and 100 µl of 1.6 M glycine (pH 10.4) were added to each tube to increase 
the pH of the solutions, followed by centrifugation at 4,400 x g for 6 minutes to pellet the 
O O O OHO
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precipitated protein.  Because 7-hydroxycoumarin production was so high from CYP2A6, these 
samples required an additional 5-fold dilution to avoid overwhelming the High Pressure Liquid 
Chromatography (HPLC) fluorescence detector.   
Standard samples resembled the reaction samples.  A concentration range of 7-
hydroxycoumarin (0-3 µM for CYP2A13 reactions or 0-20 µM 7-hydroxycoumarin for CYP2A6 
reactions) was combined with 10-20% TCA in reaction buffer.  These standards were incubated 
at 37 ˚C for 3 minutes before NADPH addition to a final reaction volume of 250 µL.  Following 
a 10 minute incubation at 37 ˚C, the standards were placed on ice and diluted with 200 µL buffer 
and 1.6 M glycine before centrifugation at 4400 x g for 6 minutes.  Like the samples, standards 
for the CYP2A6 samples were additionally diluted 5-fold. 
Reaction and standard samples were transferred to HPLC vials, and 10 µL of the 
CYP2A6 samples or 15 µL of the CYP2A13 samples were injected onto a C18 reverse phase 
100 mm Luna Column (Phenomenex, Torrance, CA) using a mobile phase consisting of 60% 
solvent A (0.2% acetic acid) and 40% solvent B (100% methanol) at 0.8 mL/min.  Following 
reverse phase chromatography, the separated reaction components were analyzed through 
fluorescence detection with an excitation wavelength of 355 nm and an emission wavelength of 
460 nm on a Prominence HPLC system (Shimadzu Scientific Instruments, Inc., Columbia, MD), 
with 7-hydroxycoumarin eluting at 6.3 minutes. 
 
 GraphPad Prism5 (Graphpad Software, San Diego, CA) was used to analyze the results 
with the Michaelis-Menten formula: Y =
Vmax * S[ ]
Km + S[ ]
 where Vmax is the maximal velocity, Km is the 
Michaelis-Menten constant and [S] is the substrate concentration.  The results were further 
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evaluated based upon their Km, Vmax, and mode of inhibition and analyzed with the appropriate 
formula shown below. 
Competitive inhibition: Y =
Vmax * S[ ]
KmObs + S[ ]
 and KmObs = Km 1+
[I]
Ki
!
"
#
$
%
& where Km Obs is the observed 
Km, [I] is the inhibitor concentration, and Ki is the inhibition constant. 
Noncompetitive inhibition: Y =
Vmaxapp * S[ ]
Km + S[ ]
 and Vmaxapp =
Vmax
1+ [I]
Ki
!
"
#
$
%
&
where Vmax app is the apparent 
maximal velocity. 
Uncompetitive inhibition: Y =
Vmaxapp * S[ ]
Kmapp + S[ ]
, Kmapp =
Km
1+ [I]
!Ki
!
"
#
$
%
&
, and Vmaxapp =
Vmax
1+ [I]
!Ki
!
"
#
$
%
&
 
Mixed model inhibition: Y =
Vmaxapp * S[ ]
Kmapp + S[ ]
, Kmapp = Km *
1+ [I]
Ki
!
"
#
$
%
&
1+ [I]
!Ki
!
"
#
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%
&
, and Vmaxapp =
Vmax
1+ [I]
!Ki
!
"
#
$
%
&
 
Unknown metabolite affecting Ki determination 
 The determination of inhibition constants in recent CYP2A13 data sets has been affected 
by the formation of a second, unknown product detected in only the lowest substrate sample (5 
µM) when no inhibitor was present.  This unknown product, which was not present in control 
samples, unfortunately altered the initial activity, decreasing the slope and subsequently 
increasing the Km value.  Since the Km value is used to determine the inhibition constant, the Ki 
value was significantly impacted.  In one example, when Prism5 was used with automatic outlier 
exclusion analysis, it detected the 5 µM coumarin sample as an outlier, and the Ki value was 19.7 
± 1.2 µM.  However, when the 5 µM coumarin point was included, the Ki value was increased to 
31.8 ± 3.1 µM.  This same trend was observed for two additional data sets where the Ki values 
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increased from 219.2 ± 18.7 µM to 393.1 ± 49.0 µM and from 2.1 µM to 9.2 µM when the 5 µM 
coumarin point was included (Figure 2.2).  The Ki values reported in this dissertation for 
compounds 9, 15, and 22 (Figure 1.5) excluded the outlier.  However, while the 5 µM coumarin 
sample affects the Ki value, it did not alter overall whether the benzylmorpholine analogs were 
low or high micromolar inhibitors. 
 
Figure 2.2. Comparison of the A) inclusion and B) exclusion of the 5 µM coumarin sample in 
the absence of inhibitor with CYP2A13 and 22.  The Km and Ki values vary between the 
inclusion or exclusion of the 5 µM coumarin point. 
	    
 
Inhibitors:  
 High throughput screening of a chemibridge library (36,000 compounds) first identified 
the benzylmorpholine scaffold as potentially selective CYP2A inhibitors.  A small library of 
purchased and synthesized benzylmorpholine compounds was compiled for evaluation with 
spectral ligand binding assays and inhibition of coumarin 7-hydroxylation. 
Purchased analogs: The benzylmorpholine analogs 4-(2-fluorobenzyl)morpholine (2), 4-(2-
chlorobenzyl)morpholine (3), 4-(2-bromobenzyl)morpholine (4), 4-(2-
methylbenzyl)morpholine (5), 4-(2-chloro-6-fluorobenzyl)morpholine (7), 4-(2,6-
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dichlorobenzyl)morpholine (8), 4-(2,3-dichlorobenzyl)morpholine (12), 4-(2,4-
dichlorobenzyl)morpholine (13), 4-(2,3-dichlorobenzyl)-2,6-dimethylmorpholine (14), 4-
(naphthalen-1-ylmethyl)morpholine (15), and 4-(2-chlorobenzyl)thiomorpholine (16) were 
purchased from Chembridge Chemicals (San Diego, CA).  
Synthesis Procedures: The parent 4-benzylmorpholine compound and remaining analogs were 
synthesized using one of the following procedures.  The synthesis and analytical results for 4-
benzylmorpholine (1)13 and 4-(4-chlorobenzyl)morpholine (11)14 were previously reported in the 
literature and correlated with the compounds that I synthesized.  1H NMR spectra corresponding 
to the remaining synthesized compounds can be found in the appendix. 
Procedure A: Morpholine (1.0 mmol) or methyl piperazine (1.1 mmol) was reacted with 1.1 
mmol of the appropriate substituted benzaldehyde reagent with 1.6 mmol triacetoxyborohydride 
in 5 mL dry tetrahydrofuran. The reactions were stirred under argon for 20 hours at room 
temperature in a miniblock apparatus (Mettler Toledo Bohdan, Vernon Hills, IL) before 
quenching with sodium hydroxide, extracting with ether, drying with magnesium sulfate, and 
solvent removal under vacuum.15 Scheme 2.1 illustrates the procedure described above.  
 
Scheme 2.1. Synthesis of benzylmorpholine analogs by reductive amination as described in 
Procedure A. 
 
 
 
Procedure B:16  Five millimoles of imidazole was dissolved in 6 mL of dried dimethyl ether 
under inert gas and combined in a reaction vessel containing 6 mmol sodium hydride on ice.  Six 
and one half millimoles of a substituted (bromomethyl)benzene was added once the temperature 
N
H
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of the reaction was at room temperature, and after 4 hours the product was extracted with ethyl 
acetate, washed with water, dried with magnesium sulfate, and the solvent removed under 
vacuum.  Scheme 2.2 shows Procedure B. 
 
Scheme 2.2. Synthesis of benzylimidazole analogs through reductive amination as described in 
Procedure B. 
 
 
 
 
Procedure C: 2-Chlorophenethyl bromide (1.3 mmol), morpholine (1.0 mmol), and potassium 
carbonate (2.0 mmol) were combined in 4 mL of dry acetonitrile, which were stirred at 80 ˚C 
overnight.   The product was extracted with ethyl acetate, washed with sodium bicarbonate, dried 
with magnesium sulfate, and the solvent removed under vacuum. Scheme 2.3 provides a 
summary of the reaction described above. 
 
 
Scheme 2.3. Synthesis of benzylmorpholine analogs through SN2 bimolecular nucleophilic 
substitution. 
 
 
 
 
Analysis: All compounds were purified by silica gel chromatography and analyzed by 1H and 13C 
NMR on a Bruker 400 MHz instrument (Bruker, Billerica, MA) and LCMS on a Waters 2795 
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HPLC and Waters LCT Premier TOF mass spectrometer (Waters, Milford, MA).  MestReNova 
was used to analyze the 1H and 13C NMR data.  Purity was determined by HPLC analysis 
through monitoring the UV area percent at 214 nm.  For the HPLC analysis, an Acquity BEH C-
18 column was used with a mobile phase consisting of a 5-95% organic gradient with solvents A 
(99% water (pH 9.8 ammonium hydroxide), 1% acetonitrile) and B (99% acetonitrile, 1% water) 
and a flow rate of 0.6 mL/min. 
Synthesized Analogs: 
 
4-(2-Ethylbenzyl)morpholine (6).  Procedure A with 2-ethylbenzaldehyde afforded the desired 
oily compound 6 with a yield of 77.9 mg (35%) and a purity of >99.9%. MS (m/z): [M+H] was 
calculated to be 206.15 and 206.15 was found.  Compound 6 had an HPLC retention time of 2.11 
minutes.  1H NMR (400 MHz, chloroform-d) δ 7.35 - 7.12 (m, 4H), 3.79 - 3.67 (m, 4H), 3.52 (s, 
2H), 2.78 (q, J = 7.5 Hz, 2H), 2.48 (dd, J = 5.8, 3.7 Hz, 4H), 1.27 (t, J = 7.5 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 143.62, 135.29, 130.18, 128.63, 127.40, 125.38, 67.17, 60.93, 53.73, 25.41, 
15.37. 
 
 
4-(2-Chloro-6-methylbenzyl)morpholine (9).  2-Chloro-6-methylbenzaldehyde and Procedure 
A yielded 55.6 mg (27%) of 9, which was an oil with 98.0% purity. MS (m/z): [M+H] was 
calculated to be 226.09 and 226.10 was found, 9 had an HPLC retention time of 2.22 minutes.  
1H NMR (400 MHz, chloroform-d) δ 7.31 - 7.19 (m, 1H), 7.14 - 7.07 (m, 2H), 3.73 - 3.60 (m, 
O
N
O
N
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6H), 2.57 - 2.49 (m, 4H), 2.47 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 141.02, 135.64, 133.77, 
129.00, 128.11, 126.99, 67.22, 56.55, 53.66, 53.27, 19.92. 
 
4-(3-Chlorobenzyl)morpholine (10). Compound 10 was synthesized using Procedure A and 3-
chlorobenzaldehyde resulting in 25 mg (44.7%) of an oil and 97.7% purity. MS (m/z): [M+H] 
was calculated to be 212.08 and 212.09 was found.  The HPLC retention time was 1.67 minutes.  
1H NMR (400 MHz, chloroform-d) δ 7.37 (d, J = 2.0 Hz, 1H), 7.33 - 7.05 (m, 3H), 3.81 - 3.62 
(m, 4H), 3.49 (s, 2H), 2.46 (dd, J = 5.7, 3.7 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 140.06, 
134.20, 129.51, 129.06, 127.33, 127.18, 66.97, 62.80, 53.58. 
 
1-(2-Chlorobenzyl)-4-methylpiperazine (17).  Compound 17 was synthesized through the use 
of Procedure A with 2-chlorobenzaldehyde to yield an oil with a yield of 168.8 mg (75%) and a  
purity of 95.6%. MS (m/z): [M+H] was calculated to be 225.11 and 225.12 was found. The 
HPLC retention time for compound 17 was 1.69 minutes. 1H NMR (400 MHz, chloroform-d) δ 
7.49 (dd, J = 7.5, 1.9 Hz, 1H), 7.36 (dd, J = 7.7, 1.5 Hz, 1H), 7.31 - 7.15 (m, 2H), 3.65 (s, 2H), 
2.58 (s, 4H), 2.48 (s, 4H), 2.31 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 135.95, 134.29, 130.65, 
129.40, 128.03, 126.52, 59.19, 55.21, 53.13, 46.09. 
 
 
O
N
Cl
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1-(2,6-Dichlorobenzyl)-4-methylpiperazine (18).  Procedure A was used with 2,6-
dichlorobenzaldehyde to synthesize 18.  The result was 184.1 mg (71.0%) of an isolated oil with 
a purity of ≥99.9%. MS (m/z): [M+H] was calculated to be 259.07 and 259.08 was found.  
Compound 18 had an HPLC retention time of 1.88 minutes. 1H NMR (400 MHz, chloroform-d) 
δ 7.26 (d, J = 8.0 Hz, 2H), 7.09 (dd, J = 8.5, 7.5 Hz, 1H), 3.73 (s, 2H), 2.60 (s, 5H), 2.43 - 2.34 
(m, 3H), 2.24 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 136.94, 134.41, 128.69, 128.27, 56.34, 
55.14, 52.93, 46.03. 
 
4-(Thiophen-2-ylmethyl)morpholine (19).  Thiophene-2-carbaldehyde was used with 
Procedure A to synthesize 19.  The procedure resulted in 130 mg (71%) of an oil with 98.9% 
purity. MS (m/z): [M+H] was calculated to be 184.07 and 184.08 was found. A retention time of 
1.39 minutes was observed with HPLC analysis. 1H NMR (400 MHz, chloroform-d) δ 7.24 (dd, 
J = 5.0, 1.3 Hz, 1H), 6.94 (ddd, J = 7.4, 4.4, 2.2 Hz, 2H), 3.75 - 3.68 (m, 6H), 2.53 - 2.45 (m, 
4H). 13C NMR (101 MHz, CDCl3) δ 141.12, 126.44, 126.19, 125.18, 66.95, 57.52, 53.32. 
 
4-((3-Chlorothiophen-2-yl)methyl)morpholine (20).  Procedure A was used with the reagent  
3-chlorothiophene-2-carbaldehyde to afford 20, which was an oil with a yield of 150 mg (70%) 
at a purity of ≥99.9%.  MS (m/z): [M+H] was calculated to be 218.03 and 218.04 was found.  
N
N
Cl
Cl
O
N
S
O
N
S
Cl
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Compound 20 had an HPLC retention time of 1.72  minutes. 1H NMR (400 MHz, Chloroform-d) 
δ 7.23 (d, J = 5.3 Hz, 1H), 6.87 (d, J = 5.3 Hz, 1H), 3.85 - 3.65 (m, 6H), 2.67 - 2.38 (m, 4H). 13C 
NMR (101 MHz, chloroform-d) δ 133.84 , 127.39 , 124.48 , 123.60 , 66.92 , 54.66 , 53.27 . 
 
4-(1-(2-Chlorophenyl)ethyl)morpholine (23). Procedure A was modified for the synthesis of 
23. 2-Chloroacetophenone (1.1 mmol) was exchanged for a substituted benzaldehyde, and 1.5 
mmol acetic acid was added to the reaction.  The modified procedure resulted in a low yield of 
48.1 mg (21%) of an oil with ≥99.9% purity. MS (m/z): [M+H] was calculated to be 226.09 and 
226.10 was found, and this compound had an HPLC retention time of 1.88 minutes.  1H NMR 
(400 MHz, chloroform-d) δ 7.60 (dd, J = 7.8, 1.8 Hz, 1H), 7.35 (dd, J = 7.9, 1.4 Hz, 1H), 7.31 - 
7.23 (m, 1H), 7.18 (dd, J = 7.7, 1.8 Hz, 1H), 3.89 (q, J = 6.6 Hz, 1H), 3.72 (dt, J = 5.8, 3.6 Hz, 
4H), 2.57 (dt, J = 9.8, 4.6 Hz, 2H), 2.41 (ddd, J = 11.3, 5.8, 3.3 Hz, 2H), 1.31 (d, J = 6.6 Hz, 
3H).  13C NMR (101 MHz, CDCl3) δ 141.86, 133.61, 129.46, 128.43, 127.74, 126.98, 67.23, 
60.46, 51.33, 19.38. 
 
1-(2-Chlorobenzyl)-1H-imidazole (21).  Procedure B was used with 1-(bromomethyl)-2-
chlorobenzene to synthesize 21.  Compound 21 was an oil with a yield of 30.7 mg (17%) and 
≥99.9% purity. MS (m/z): [M+H] was calculated to be 193.05 and 193.05 was found.  
Compound 21 had an HPLC retention time of 1.50 minutes. 1H NMR (400 MHz, chloroform-d) 
δ 7.57 (s, 1H), 7.41 (dd, J = 7.7, 1.6 Hz, 1H), 7.33 - 7.18 (m, 2H), 7.10 (s, 1H), 6.99 - 6.88 (m, 
O
N
Cl
Cl
N
N
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2H), 5.23 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 137.63, 134.03, 133.06, 129.81, 129.76, 
129.67, 128.95, 119.37, 48.32. 
 
1-(2,6-Dichlorobenzyl)-1H-imidazole (22).  Compound 22 was synthesized with 2-
(bromomethyl)-1,3-dichlorobenzene and Procedure B.  The resulting product was an oil with a 
yield of 171.3 mg (75%) and a purity of ≥99.9%. MS (m/z): [M+H] was calculated to be 227.01 
and 227.01 was found. Also, a retention time of 1.50 minutes was observed during HPLC 
analysis. 1H NMR (400 MHz, chloroform-d) δ 7.61 (s, 1H), 7.39 - 7.24 (m, 2H), 7.17 (dd, J = 
8.8, 7.4 Hz, 1H), 6.98 (d, J = 14.9 Hz, 2H), 5.33 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 137.57, 
136.18, 131.58, 130.60, 129.11, 128.83, 119.10, 45.47. 
 
 
4-(2-Chlorophenethyl)morpholine (24).  Compound 24 was synthesized through the use of 
Procedure C.  This procedure afforded 129 mg (58%) of an oil with a purity of ≥99.9%.  MS 
(m/z): [M+H] was calculated to be 226.09 and 226.10 was found. Compound 24 had a retention 
time of 1.77 minutes during HPLC analysis. 1H NMR (400 MHz, Chloroform-d) δ 7.39 - 7.03 
(m, 4H), 3.88 - 3.62 (m, 4H), 3.00 - 2.83 (m, 2H), 2.65 - 2.40 (m, 6H). 13C NMR (101 MHz, 
CDCl3) δ 137.74, 133.98, 130.75, 129.47, 127.61, 126.82, 66.97, 58.73, 53.60, 30.90. 
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Chapter 3 
Benzylmorpholine Structure-Activity Relationships with CYP2A Enzymes 
Introduction 
 The process of drug development begins with the identification of a problem and an 
understanding of the gaps in current therapeutic strategies.  Once these gaps have been identified, 
alternative methods can be devised for the design and development of novel therapeutic entities. 
In vitro evaluation of drug candidates with the target of interest can lead to the determination of 
structure-activity relationships (SAR). This process was used to address the problem of lung 
cancer with the identification and evaluation of small molecules for the selective inhibition of 
cytochrome P450 2A13. 
Lung cancer is the leading cause of all cancer related deaths resulting in over 6 million 
annual deaths worldwide.1 The low 5-year survival rate of 15% illustrates the need for alternative 
therapeutic strategies.2 Since tobacco use is the cause of 80% of lung cancer incidence,3 current 
methods of preventing lung cancer involve tobacco cessation techniques, but these methods are 
unsuccessful for 95% of users.2 An alternative strategy that has previously not been 
commercially explored is to block the activation of tobacco procarcinogens. 4-
(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is one of the most prevalent 
procarcinogens in tobacco products and is selectively activated to carcinogens by CYP2A13 in 
the respiratory tract.  Therefore, the selective inhibition of CYP2A13 offers a novel therapeutic 
strategy in reducing the risk of lung cancer in tobacco users. 
CYP2A13 is one of two functional human xenobiotic metabolizing CYP2A enzymes, and 
is 94% identical to the hepatic CYP2A6.4 Both enzymes are located on chromosome 19, and 
while there is an additional CYP2A enzyme, cytochrome P450 2A7, no activity has been 
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reported for this enzyme.4 The CYP2A enzymes share activity towards a number of substrates 
and inhibitors such as nicotine, cotinine, NNK, methoxypsoralen, phenethyl isothiocyanate 
(PEITC), 2´-methoxyacetophenone, coumarin, and aflatoxin B1.5-7 There are only 32 out of 494 
amino acids that differ between the CYP2A enzymes, but these differences cause varying 
metabolic rates for the common substrates listed above.6-8  Extensive studies have been 
performed on the differential metabolism of the tobacco procarcinogen NNK as it is selectively 
metabolized by CYP2A13 and has a significant role in the development of lung cancer.8-11 
NNK is predominantly formed during the tobacco curing process,12 but in vivo 
conversion of nicotine to the ring-opened metabolite NNK could also occur (Scheme 3.1).13 
Following exposure, NNK can undergo metabolism at one of two positions by CYP2A13 
(Scheme 3.2). First, CYP2A13 performs an α-methyl hydroxylation to form the unstable α-
hydroxymethyl-NNK (26) intermediate, which spontaneously decomposes to form formaldehyde 
and 4-(3-pyridyl)-4-oxobutane 1-diazohydroxide (28).  Intermediate 28 further decomposes to 
form a 4-(3-pyridyl)-4-oxobutane 1-diazonium ion (32) and the stable keto alcohol (31) (keto 
alcohol kcat = 0.646 min-1µM-1).  Alternatively, CYP2A13 performs the α-methylene 
hydroxylation of NNK to result in an unstable α-methylenehydroxy-NNK (27) intermediate, 
which decomposes to methanediazohydroxide (29) and keto aldehyde (30) (keto aldehyde kcat = 
0.185 min-1µM-1).8,9 Methanediazohydroxide further decomposes to a methanediazonium ion 
(33). The two diazonium ions (32 and 33) formed from the CYP2A13-mediated hydroxylation 
reactions of NNK in the respiratory tract are able to form O6-(pyridyloxobutyl)deoxyguanosine 
(34), 7-(pyridyloxobutyl)deoxyguanosine (35), O6-methyl-deoxyguanosine (36), and 7 methyl-
deoxyguanosine (37) DNA adducts (Scheme 3.2) and result in lung cancer initiation.9,14 
Meanwhile CYP2A6 has a significantly reduced catalytic efficiency of 0.003 min-1µM-1 for the 
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α-methylene hydroxylation and no detectable α-methyl hydroxylation,8 further illustrating the 
primary role of CYP2A13 in NNK metabolism.  Thus inhibiting CYP2A13 in the respiratory 
tract could reasonably be expected to significantly decrease NNK derived DNA adduct levels in 
human smokers. 
 
Scheme 3.1.  In vivo metabolism of nicotine by CYP2A enzymes to form cotinine, nornicotine, 
or amino ketone, which could result in the formation of NNK.13 
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Scheme 3.2.  Metabolism of NNK by CYP2A13 results in the formation pyridyloxobutyl (blue) 
and methyl (red) DNA adducts that can initiate lung cancer.9 
 
 
 
Identifying selective inhibitors is one of the major challenges in drug development, but 
this is even truer for xenobiotic metabolizing cytochrome P450 enzymes, which have substantial 
substrate overlap with other P450 enzymes.  However, selectivity is vital among cytochromes 
P450 because non-selective inhibitors increase the risk of adverse drug-drug interactions.  
Identification of inhibitors and initial selectivity determination for CYP2A13 was achieved by 
analyzing compounds with both of the CYP2A enzymes, the lung CYP2A13 and the 94% 
identical hepatic enzyme cytochrome CYP2A6.4  Although CYP2A6 does not efficiently 
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metabolize NNK, it does metabolize other xenobiotic compounds and thus its inhibition would 
be undesirable.15  It was thought that differentiating between these two very similar enzymes 
would be the biggest challenge as the other human P450 enzymes are <55% identical and 
therefore less likely to have substrate overlap with our compounds. 
The benzylmorpholine scaffold that is the basis of the compounds examined herein was 
originally identified by high throughput screening.  Three compounds (Figure 1.5 compounds 3, 
5, and 7) with this scaffold structure were originally identified as selective inhibitors of 
CYP2A13 versus CYP2A6. The specific characteristics accounting for this selectivity were 
unknown.  Beginning with the benzylmorpholine scaffold, analogs were purchased or 
synthesized to generate a small library of 24 compounds to explore the SAR (Figure 1.5).  These 
compounds were evaluated to identify structural features relevant for potent and selective 
inhibitors of CYP2A13. Specifically, the benzylmorpholine library was evaluated to determine 
the spectral binding constants (Kd) and inhibition constants (Ki) for the CYP2A enzymes. These 
results enabled the assignment of structure-activity relationships (SAR) for the benzylmorpholine 
scaffold with CYP2A13 and thus aid in the rational design and optimization of potential 
chemopreventative drug candidates. 
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Materials and Methods 
Chemicals and Reagents:  Coumarin and 7-hydroxycoumarin were purchased from Sigma 
Aldrich (St. Louis, MO) and Acros (via Fisher Scientific, Pittsburgh, PA), respectively.	  	  
Construction of the benzylmorpholine library compounds is described in chapter 2. 
Protein Expression and Purification: Recombinant purified CYP2A protein and reductase were 
produced using the methods described in chapter 2.  
Assays: Assays for spectral ligand binding and inhibition of coumarin 7-hydroxylation are also 
described in detail in chapter 2.  
Results  
Spectral Dissociation Constants for CYP2A13 and CYP2A6 
 Titration of CYP2A13 and CYP2A6 with the benzylmorpholine analogs (Figure 1.5 or 
Table 3.1) demonstrated either type I or type II spectral shifts.  Type I spectral shifts occur when 
a ligand binds in the P450 active site and displaces a water molecule coordinated to the heme 
iron.  The displacement is observed by a transition of the iron from the hexacoordinate low spin 
state with water bound (λmin = 420 nm) to a pentacoordinate high spin state (λmax = 385 nm) 
(Figure 3.1A).  Compounds 1-20, 23, and 24 were type I ligands with CYP2A13 and compounds 
2-9, 12-15, 17-20, and 23-24 were type I ligands for CYP2A6.  Alternatively, type II binding 
spectra was observed for 1, 10, 11, and 16 with CYP2A6 and 21 and 22 with both CYP2A13 and 
CYP2A6.  Type II spectral shifts are characterized by a λmax at ~433 nm and a trough at 393 - 
413 nm (Figure 3.1B).   Type II ligands coordinate to the heme iron resulting in a transition from 
the hexacoordinate low spin water-bound state to the nitrogen- or sulfur-bound hexacoordinate 
low spin state.16   
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Figure 3.1 A) Titration of CYP2A13 enzyme with 8, a classical type I ligand.  B) Type II 
spectral shift observed with CYP2A13 and 21. 
 
 
 
 
  
Analysis of the binding spectra of CYP2A6 and CYP2A13 with various 
benzylmorpholine compounds revealed not only the type of spectral shift, but also the ligand 
binding constants (Kd) and binding selectivity between the two CYP2A enzymes.  Table 3.1 
summarizes this information for all 24 compounds.   
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The unsubstituted 4-benzylmorpholine parent compound (1) bound weakly and rather 
non-selectively to CYP2A13 and CYP2A6 with Kd values of 116 µM and ≥300 µM, 
respectively. A Kd value for CYP2A6 with 1 could not be definitively determined due to poor 
binding and background absorption, but a spectral shift was observed at a ligand concentration of 
≥300 µM (Figure 3.2A).  In addition, compound 1 was a type I ligand with CYP2A13, but 
appeared to be primarily a type II ligand of CYP2A6 when the ligand concentration was ≥300 
µM.  This shift was also observed with 10 (Figure 3.2B).  However, in both cases there is little 
change in absorbance and high background absorbance. 
 
Figure 3.2. Titration of CYP2A6 with A) 4-benzylmorpholine (1) and B) 10 indicating a type II 
spectral shift at concentrations ≥300 µM, but due to weak binding and interference of 
background absorption, the spectral binding constant could not be determined. 
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Comparison with the benzylmorpholine parent compound revealed that substitution at the 
ortho (two) position on the benzene ring was crucial for low micromolar and selective binding to 
CYP2A13 (Table 3.1, compounds 2-6).  Compounds 2-6 contain substitutions with varying 
electronegativity, size, and lipophilicity.  While the electronegative fluorine atom in 2 increased 
the affinity for the benzylmorpholine analog with CYP2A13 by 1.6-fold over the parent 
compound (1), it had a decreased affinity for CYP2A13 in comparison to compounds 3-6.  
Compounds 3-6 confer low micromolar binding to CYP2A13 ranging from 4.5-18.6 µM.  A 
minimum Kd value of ≥575 µM (6) or no observable binding with CYP2A6, as indicated by the 
lack of a spectral shift (Figure 3.3), was observed at concentrations equivalent to or greater than 
the maximum concentration tested with CYP2A13.  The individual trials for CYP2A13 with 
compounds 5 (13.8 µM, 23.3 µM) and 6 (3.9 µM, 5.1 µM) had >20% variation, but the values 
were all in the low micromolar range.  A minimum Kd value was reported for 6 because of a poor 
curve fit when plotting the change in absorption versus ligand concentration.  A λmax was 
observed at 385 nm with a λmin at 420 nm, but an exact Kd value could not be determined.  Small 
changes in absorbance and poorer curve fit were frequently observed for Kd values with CYP2A6 
due to poor binding.  Thus with the exception of 1 and 10, a ‘≥’ symbol denotes a minimum 
dissociation constant for the remainder of the results. 
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Figure 3.3. Lack of spectral shift during titration of CYP2A6 with benzylmorpholine ligands is 
indicative that the compounds such as 2-5, 7, and 18 do not cause a spectral shift, suggesting that 
they do not bind in the active site. 
 
 
Disubstitution at both ortho positions on the benzene ring (Table 3.1, compounds 7-9) 
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5.9 ± 3.4 µM).  In addition, increased binding to CYP2A6 was observed with dissociation 
constants of ≥ 300 µM for 10 and ≥ 245 µM for 11 indicating a decrease in selective binding 
between the CYP2A enzymes to ≥1.5 and ≥5.8-fold, respectively.  The spectral shift for 10 with 
CYP2A6 mimicked 1 with a transition from a type I to a type II ligand at concentrations ≥300 
µM (Figure 3.2B).  This same shift was also observed once with 11, but two out of the three 
trials for 11 demonstrated only type I binding allowing for the determination of the minimum Kd 
value of ≥245 µM.   
Disubstitution resulting from the combination of an ortho substituent with either meta or 
para substitution (12, 13) increased the affinity and selectivity for CYP2A13 over either the meta 
or para substituents alone.  The Kd values for CYP2A13 were 30.8 ± 8.1 µM for 12 and 34.2 µM 
for 13.  Titration of CYP2A6 led to dissociation constants of ≥305 µM for 12 and ≥198 µM for 
13, which were 9.9- and 5.8-fold higher, respectively, than the corresponding singly substituted 
meta (10) or para (11) compound.  Thus these compounds were more selective for CYP2A13, 
but not as selective as the  ortho monosubstituted compounds.  Additionally, 13 had significant 
background absorption with CYP2A6, and the Kd value was determined by the differential 
absorbance between the λmin at 420 nm and the baseline.  The addition of methyl groups on the 
morpholine ring, 14, did not decrease the dissociation constant, 37.0 µM for CYP2A13, in 
comparison to 12.  These results indicated that overall substitution at the meta and para positions 
oppose selective binding to CYP2A13 with increasing affinity for CYP2A6, while dimethylation 
on the morpholine ring had no effect. 
 A series of ring analogs were analyzed to identify additional opportunities to improve 
selectivity of ligands for CYP2A13 versus CYP2A6 (Table 3.1, compounds 15-22).  A 
naphthalene analog, 15, was designed to take advantage of hydrophobic interactions within the 
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CYP2A13 active site.  Compound 15 bound CYP2A13 with a Kd value of 41.8 µM when 
determined with duplicate samples with less than 4% variation.  However, a third assay, which 
likely used an older inhibitor stock solution, reported a Kd value of 121 µM.  Additionally, 
compound 15 had high background absorption during the titration of both CYP2A13 and 
CYP2A6 and bound too weakly to CYP2A6, as evidence by a weak spectral shift, to accurately 
determine a Kd value.  The thiomorpholine analog, 16, had a spectral binding constant of 8.3 ± 
4.1 µM with CYP2A13 and was a type I ligand (Figure 3.4A).  However, this ligand also bound 
to CYP2A6 with a Kd value of 154 µM.  In contrast to CYP2A13, with CYP2A6 16 caused a 
type II spectral shift indicating a direct coordination of the sulfur atom to the heme, which 
suggests a different binding mode between the two enzymes (Figure 3.4B). Additionally, 16 was 
the tightest binder to CYP2A6 with the exception of 21 and 22, but was still 18-fold more 
selective for CYP2A13.  Substitution of the morpholine ring for a methyl piperazine in 17 and 18 
added steric bulk and an additional positive charge to the morpholine analog and decreased the 
affinity for CYP2A13 with Kd values of 306 µM and ≥362 µM, respectively.  Compound 17 
displayed a weak spectral shift with CYP2A6, but no spectral shift was observed with 18.  
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Figure 3.4. Titration of CYP2A enzymes with the thiomorpholine analog, 16.  A) Titration with 
CYP2A13 resulted in a type I spectral shift, while 16 bound to B) CYP2A6 displays a type II 
spectral shift.  
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not significantly impact the binding to CYP2A6, Kd = ≥239 µM, which resulted in a 22.3-fold 
selectivity for CYP2A13.  Additionally, due to the higher concentrations necessary for the 
titration of CYP2A6 versus CYP2A13, both 19 and 20 had high background absorbance, and the 
Kd value for CYP2A6 was determined using only the λmin at 420 nm.  The imidazole analogs, 21 
and 22, were chosen because nitrogen-containing inhibitors are known to bind tightly to P450 
enzymes through a direct coordination to the heme iron.  As expected, compounds 21 and 22 
bound tightly to CYP2A13 and CYP2A6 and displayed type II spectral shifts.  Equilibrium 
dissociation constants of ≤0.1 µM were observed with CYP2A13 for both 21 and 22.  However, 
the binding constants with CYP2A6 were also submicromolar at 0.1 µM (≤0.10 µM and 0.17 µm 
for the individual trials) and 0.9 µM for 21 and 22, respectively.  Thus, while the incorporation 
of imidazole for the morpholine ring significantly increases the affinity for CYP2A13 and 
CYP2A6, selective binding between these enzymes was eliminated. 
 In order to examine the spatial relationship between the rings and the tolerability of 
CYP2A13 to bulk on the carbon linker, the remaining analogs had alterations to the carbon linker 
between the morpholine and benzene rings (Table 3.1, compounds 23-24).  Addition of a methyl 
group in 23 did not have a significant impact on binding to CYP2A13 (Kd = 7.6 ± 2.8 µM) in 
comparison to 3, and 23 bound weakly to CYP2A6 (Kd = ≥538 µM).  Expanding the linker to 
two carbons, 24, had a negative impact on CYP2A13 binding, increasing the binding constant to 
160.4 µM, but this compound still had minimal binding with CYP2A6, Kd = ≥ 604 µM.  These 
results indicate that lengthening the ligand was detrimental for CYP2A13 binding, but additional 
steric bulk between the rings is tolerated.   
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Inhibition Constants for CYP2A13 and CYP2A6 
 Inhibition of CYP2A13 and CYP2A6 was evaluated by monitoring decreases in the 
formation of 7-hydroxycoumarin resulting from coumarin metabolism.  Evaluation of enzyme 
activity in the presence of a high inhibitor concentration (1 mM) in addition to the determination 
of preliminary IC50 values were used as an initial screen of the benzylmorpholine library and to 
guide subsequent inhibition studies.  Based on the spectral ligand binding assays, it was 
anticipated that the benzylmorpholine ligands would inhibit CYP2A13, and the determination of 
IC50 values (Figure 3.5) aided in the selection of appropriate inhibitor concentrations for 
inhibition constant (Ki) determination.  However, the generally weak binding of many of the 
benzylmorpholine compounds to CYP2A6 meant that this library was best evaluated at 1 mM 
inhibitor concentration with CYP2A6 to enable the prioritization of the library for Ki 
determination with this enzyme.  Additionally, this method was used with CYP2A13 to prioritize 
compounds such as 1, 10, 11, 15, 17, and 24 that bound weakly to CYP2A13 (Figure 3.6).  The 
last three columns of Table 3.1 summarize the Ki values and degree of selectivity for the CYP2A 
enzymes. 
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Figure 3.5. For CYP2A13, preliminary IC50 values were determined to guide the selection of 
appropriate inhibitor concentrations for full steady-state inhibition studies with the 
benzylmorpholine compounds.  Data shown below is for the inhibition of CYP2A13 by 4. 
 
 
Figure 3.6. Since many benzylmorpholine compounds did not bind with very high affinity to 
CYP2A6 and occasionally to CYP2A13, compounds were first evaluated to determine inhibition 
at a single inhibitor concentration (1 mM) to prioritize potent inhibitors and guide further 
inhibition studies.  In this example, inhibitor 15 displays the greatest degree of inhibition with 
CYP2A13 and would receive the highest priority for inhibition studies. 
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Overall, the trends observed with enzyme kinetics resemble those with the Kd values.  
The parent compound (1) was not selective between the CYP2A enzymes with Ki values of 477 
µM for CYP2A13 and 329 µM for CYP2A6.  As previously observed, the ortho substitution on 
the benzene ring was necessary for potent and selective inhibition of CYP2A13.  Among 
compounds 2-6, compound 2 had the highest dissociation constant and also had the highest 
micromolar inhibition constant with CYP2A13 (Ki = 379 µM) and minimal inhibition of 
CYP2A6 (Ki = ≥1000 µM), resulting in a selectivity of ≥2.6-fold for CYP2A13.  Compounds 3-6 
had inhibition constants ranging from 16.9 µM to 66.9 µM resulting in ~>15-50-fold selectivity 
for CYP2A13 over CYP2A6 with the most selective compounds sporting a bromine or ethyl 
substituent at the two position.  Disubstitution at both ortho positions maintained low micromolar 
inhibition with Ki values of 38.1 µM, 18.1 µM, and 19.7 ± 1.2 µM with CYP2A13 for 7-9, 
respectively.  However, unlike the singly substituted compounds, the disubstitution analogs also 
better inhibited CYP2A6 with Ki values ranging from 248 µM to 296 µM, thus reducing the 
selectivity to 7.5 – 15-fold.  
 Analogs with a substitution on the benzene ring at the meta or para position (10, 11) were 
poor inhibitors of CYP2A13 and CYP2A6 and were not selective for either enzyme.  Compound 
10 inhibited CYP2A13 with a Ki = 260 µM and CYP2A6 with Ki = 352 µM.  Compound 11 had 
inhibition constants of 458 µM with CYP2A13 and 448 µM with CYP2A6.  Disubstitution with 
a chlorine atom at the ortho position (12, 13) somewhat rescued the inhibition activity and 
selectivity for CYP2A13 with Ki values of 88.9 µM (12) and 113 ± 14.0 µM (13) for CYP2A13 
and 836 µM (12) and 995 µM (13) for CYP2A6.  In this context, the ortho substitutions 
increased selectivity for CYP2A13 from ~1- to ~9-fold.   
	   67	  
 The various ring analogs, 15-22, provided additional information about the 
benzylmorpholine scaffold.  The naphthalene analog, 15, was a relatively poor inhibitor of both 
CYP2A13 and CYP2A6 with respective Ki values of 219 µM and 500 µM.  Compared to 3, 
replacement of the morpholine ring with a thiomorpholine ring (16) resulted in decreased 
inhibition with CYP2A13 (Ki = 59.0 µM) and increased inhibition of CYP2A6 (Ki = 483 µM).   
As anticipated from the binding studies, the methylpiperizine analogs (17, 18) did not inhibit 
CYP2A13 or CYP2A6 with Ki values ≥1000 µM for both CYP2A enzymes. Inclusion of a 
chlorine atom at the ortho position on the thiophene analogs (19, 20) increased selectivity for 
CYP2A13 from 2.1- to 7.9-fold by increasing the inhibition of CYP2A13 from 131.1 µM (19) to 
54.7 µM (20) while simultaneously decreasing inhibition of CYP2A6 from 270 µM to 433 µM, 
for 19 and 20, respectively.  The imidazole ring substitutions (21, 22) significantly increased the 
inhibition of CYP2A13 resulting in Ki values of 2.8 µM with 21 and 2.1 µM for 22, but the 
selectivity was eliminated as the inhibition constants for CYP2A6 were 2.9 µM and 0.9 µM for 
21 and 22, respectively.   
 Evaluation of the linker analogs (23 and 24) continued with the trend of the inhibition 
results resembling those from the binding studies.  Compound 23, which had an additional 
methyl group on the one carbon linker between the morpholine and benzene rings, inhibited 
CYP2A13 with a Ki value of 15.9 µM which was lower than 3 due to an increase in hydrophobic 
interactions with CYP2A13.  Compound 23 also had an inhibition constant of 98.5 µM with 
CYP2A6.  These results indicated that this compound was a potent inhibitor of CYP2A13 but not 
as selective as other benzylmorpholine analogs with only a 16-fold preference for CYP2A13 
versus ≥25-fold for 3.  Increasing the chain length by one carbon (24) decreased the inhibition of 
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CYP2A13 compared to 3 (Ki = 604 µM) and was also a poor inhibitor of CYP2A6, as indicated 
by a Ki value of ≥ 1000 µM. 
Competitive and Mixed Inhibition 
 All but six benzylmorpholine analogs were competitive inhibitors of both CYP2A13 and 
CYP2A6. Compounds 14, 21, and 22 were mixed inhibitors of CYP2A13, and compounds 6, 15, 
and 16 displayed mixed inhibition of CYP2A6.  Figure 3.7 provides example results of the 
observed competitive and mixed inhibition.  Compounds 6 and 14 had the highest alpha values 
of 13.3 and 19.6, respectively, indicating these inhibitors bound significantly more tightly to the 
enzyme (E) state than the enzyme-substrate (ES) state.  However, the remaining compounds had 
alpha values between 2.0-3.9 indicating that binding affinity was more similar for the E and ES 
states.  
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Figure 3.7.  Representative inhibition of the CYP2A enzymes with benzylmorpholine inhibitors.  
A) Michaelis Menten kinetics of a competitive benzylmorpholine analog (3) with CYP2A13.  B) 
Lineweaver Burk plot of the competitive inhibitor. C) Michaelis Menten kinetics and D) 
Lineweaver Burk plot results from the mixed benzylmorpholine inhibitor 15 with CYP2A6. 
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Discussion 
Ortho (C2) substitution on the benzene ring 
 A substituent at the ortho position on the benzene ring proved to be the most vital feature 
in conferring selective binding and inhibition of CYP2A13 versus CYP2A6.  Compounds 3-9, 
and 16 illustrated this point with CYP2A13 with Kd values ranging from 1.1 µM – 18.5 µM, Ki 
values between 16.9 µM – 66.9 µM, and selective inhibition of ~5-≥57-fold for CYP2A13 over 
CYP2A6.  Analysis of the various ortho substituents provides insight into the features 
contributing to the selectivity of the benzylmorpholine analogs.  
 In using 1 and 3 as reference compounds, it appears that the size and lipophilicity of the 
substituent play a major role in selective binding and inhibition of CYP2A13, while 
electronegativity and inductive effects have a minor role.  When comparing compounds 2 and 3, 
the fluorine atom in compound 2 is more electronegative, less lipophilic, and occupies a smaller 
portion of the active site than chlorine.  These differences resulted in reduced affinity and 
inhibition for CYP2A13 with 2 versus 3.  Comparison of 2 versus the parent compound (1), 
which were of similar size, indicated that electronegativity, inductive effects, and overall 
increased lipophilicity may slightly enhance binding and inhibition as 2 displayed small 
increases in both affinity and inhibition of CYP2A13.  However, with less than a 2-fold 
difference in the Kd and Ki values, this assumption may not be definitive.  Further comparison of 
compounds 4 and 6 which had either electron withdrawing or electron donating substituents that 
were comparable in both size and lipophilicity, revealed similar binding and inhibition results to 
each other and to 3.  These comparisons support the conclusion that the size and lipophilicity of 
the substituent were more important for interactions within the hydrophobic active site, but 
electronic effects may also play a role.  
	   71	  
 Disubstituted compounds 7-9 demonstrated a slight increase in affinity for CYP2A13 but 
lost selectivity since binding and inhibition of CYP2A6 was increased.  These results were 
interesting as CYP2A6 has an overall smaller active site volume than CYP2A1317 and does not 
demonstrate a spectral shift with 7, yet competitive inhibition was observed.  This could be due 
to the lack of displacement of the water molecule during binding assays. 
Meta and Para (C3 and C4) substitution on the benzene ring 
 Substitutions at the meta or para positions on the benzene ring opposed the objective of 
finding selective inhibitors for CYP2A13.  Compounds 10 and 11 had reduced affinity and 
inhibition of CYP2A13 with increasing affinity and inhibition of CYP2A6 in comparison to 
compound 3.  These substitutions were not selective for either CYP2A enzyme.  However, the 
addition of an ortho substituent (12, 13) was able to rescue some affinity and selectivity for 
CYP2A13, further illustrating the importance of the ortho substituent.  Additional di-methyl 
substitution on the morpholine ring as shown in 14 had minimal effects on Kd values, but 
substitution had a greater effect in decreasing the inhibition of both CYP2A13 and CYP2A6. 
Ring Substitutions 
 Multiple ring analogs demonstrated a wide range of binding and inhibition constants.  
Replacing the morpholine ring with imidazole (21, 22) resulted in extremely potent but non-
selective analogs.  Not surprisingly, the nitrogen of the imidazole ring coordinated to the heme as 
demonstrated by the type II spectral shift.  This bond greatly enhanced the affinity of the 
compounds, but selectivity between the CYP2A enzymes was lost as a result.  While the type II 
ligand characterization was anticipated for the imidazole compounds (21 and 22) due to the 
accessible nitrogen atom, it was unexpected to observe a type II spectral shift for 16 with 
CYP2A6 versus a type I spectral shift with CYP2A13.  It was unknown as to what active site 
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features resulted in the different binding modes.  Docking studies in chapter 4 were used to 
evaluate the differences between the CYP2A enzymes with 16.  
The sulfur atoms in the thiophene rings of compounds 19 and 20 differed from 16 in that 
only type I spectral shifts were observed for these compounds.  The thiophene ring mimics a 
benzene ring, and it was expected that 19 and 20 would correlate with 1 and 3, respectively.  
These results were observed with an increase in binding and inhibition of CYP2A13 with 19.  
The remaining analogs with substitution of the morpholine ring for a methylpiperazine 
ring (17, 18) resulted in poor affinity and inhibition of both CYP2A enzymes due to either the 
disruption of optimal interactions within the active site and/or charge addition.  It was 
hypothesized that the methyl group would disrupt a hydrogen bond with N297, a hypothesis later 
tested by X-ray crystallography (see chapter 4).  In addition, incorporation of the 
methylpiperazine ring would have introduced a second positive charge on the ligand at 
physiological pH.  This charge may not have been well tolerated and therefore result in the poor 
binding and inhibition that was observed. 
Linker Substitutions 
 Attachment of a methyl group to the one carbon linker (23) yielded a compound that 
maintained comparable affinity and inhibition of CYP2A13 as 3, but decreased selectivity since 
23 also inhibited CYP2A6.  These trends were not observed with 24 when the linker was 
extended to an ethyl group between the morpholine and benzene ring.  Instead, a decrease in both 
affinity and inhibition was observed.  Decreased affinity for CYP2A13 could be due to the poor 
fit of the longer molecule within the active site, while the methyl group on the linker in 23 did 
not significantly clash within the active site but rather may have had additional van der Waals 
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interactions with hydrophobic residues of the active site.  However, it remains unknown which 
enantiomer of 23 was more potent as assays were performed with a racemic mixture. 
 Compilation of the binding and inhibition studies has enabled the determination of 
structure-activity relationships (SAR) for the benzylmorpholine scaffold (Figure 3.8).  The 
results led to the conclusion that the substitution at the ortho position of the benzene ring was the 
most vital feature of the benzylmorpholine scaffold promoting selective binding and inhibition of 
CYP2A13.  Disubstitution at both ortho positions enhanced affinity.  Meta and para substitutions 
on the benzene ring, linkage extension between the rings, and exchange of the morpholine ring 
for a methylpiperazine ring proved to be the most detrimental alterations in achieving selective 
binding and inhibition.  By altering various parts of the benzylmorpholine small molecule 
scaffold, we were able to identify the key structural aspects of the benzylmorpholine scaffold 
that contribute to its CYP2A inhibition.  This knowledge forms the basis for rationally 
optimizing drug candidates for selective inhibition of CYP2A13. 
 
Figure 3.8. Structure-activity relationships for the benzylmorpholine scaffold as determined by 
spectral ligand binding assays and inhibition studies. 
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Conclusions 
 Assays evaluating ligand binding and the inhibition of coumarin metabolism were 
effective for evaluating a small library of 24 benzylmorpholine analogs and determining 
structure-activity relationships.  Thus far, the benzylmorpholine analogs have proven successful 
as selective inhibitors of CYP2A13 and could be used as chemopreventative agents for tobacco 
users by inhibiting the bioactivation of the tobacco procarcinogen, NNK.  The use of a 
chemopreventative agent would reduce the health care costs associated with lung cancer and the 
number of premature deaths.  While this is not a replacement for tobacco cessation, tobacco 
users could use a CYP2A13 inhibitor while smoking or in concurrent use with most cessation 
aids and therefore reduce the risk of lung cancer in tobacco users who are unable, unwilling, or 
in the process of ceasing tobacco use.   
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Chapter 4 
CYP2A Crystallography 
Introduction  
Protein crystallography is a useful technique for evaluating the atomic level interactions 
between proteins and their ligands.  The resulting three-dimensional structures can provide 
insight into the amino acid residues controlling ligand selectivity.  This information can be 
applied to the rational design of drug candidates.  In addition, once a crystal structure has been 
determined, as in the case of the CYP2A enzymes, new drug candidates can often be evaluated 
using docking studies as a preliminary step in the evaluation of interactions within the active site 
in the overall process of drug optimization.  Docking studies and co-crystal structures of 
CYP2A13 with a benzylmorpholine ligand could aid in the rational drug design of potent 
CYP2A13 inhibitors to reduce the risk of lung cancer in tobacco users. 
Cytochrome P450 2A13 is 94% identical to the hepatic CYP2A6, yet these enzymes have 
some substrate selectivity and metabolize a variety of common substrates at different rates.1-3 
The known CYP2A structures have only minor global differences resulting in a root mean square 
deviation of all the Cα carbons of ~0.5 Å (CYP2A13, PDB 2P85; CYP2A6, PDB 1Z10), but 
differ by 32 amino acids with 10 of those residues within or surrounding the active site (Figure 
4.1).4 For these two structures with indole and coumarin, respectively, these differences result in 
an active site volume for CYP2A13 of ~300 Å3, which is 15-20% greater than CYP2A6 (~250 
Å3).4  Both CYP2A enzymes are extremely hydrophobic, with the roof of the CYP2A13 active 
site being lined with six phenylalanine residues (F107, F111, F118, F209, F300, and F480).4 
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Figure 4.1. Active site residues that differ between CYP2A13 and CYP2A6 are highlighted in 
blue in the CYP2A13 structure (PDB 2P85). 
 
 
Site-directed mutagenesis and functional and structural studies have identified key 
residues that control the binding of diverse CYP2A ligands.3,5 Exchange of the active site 
residues between the human CYP2A enzymes illustrates this point.  For example, CYP2A6 
metabolizes coumarin with a higher catalytic efficiency compared to CYP2A13, but replacement 
of the CYP2A13 residues alanine and histidine at positions 117 and 372 for the residues found at 
these sites in CYP2A6, valine and arginine (CYP2A13 A117V and H372R), increases the 
catalytic efficiency of CYP2A13 for coumarin.6 Furthermore, these same substitutions in 
addition to the incorporation of the CYP2A6 residue into the CYP2A13 enzyme at position 208 
(S208I) decreased metabolism of the CYP2A13 substrate NNK to be more like that of wild type 
CYP2A6 for NNK.7  Phenacetin is a specific substrate for CYP2A13, and does not bind and is 
not metabolized by CYP2A6 at all.  Individually, the CYP2A13 mutants containing CYP2A6 
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residues S208I, A213S, F300I, A301G, M365V, and G369S each decrease binding and 
metabolism of the CYP2A13 substrate phenacetin.3,5 However, incorporation of several of these 
CYP2A13 residues in CYP2A6 imparts CYP2A6 with the ability to metabolize phenacetin.  
Specifically, the CYP2A6 quadruple mutant I208S/I300F/G301A/S369G was able to bind and 
metabolize phenacetin with similar Kd, Km, and kcat as CYP2A13.  This so called “quad mutant” 
also binds substrates such as phenethyl isothiocyate and 2´-methoxyacetophenone more similarly 
to CYP2A13 than wild type CYP2A6.3,5  
In addition, there are two conserved amino acids between the CYP2A enzymes that are 
important for the positioning of substrates within the respective active sites.   First, N297 is the 
only polar residue within the active site and is important for the metabolism of NNK in 
CYP2A138 and the orientation and stabilization of coumarin in CYP2A6 through hydrogen bond 
interactions.9 Second, the side chain of L370 is also known to rotate for positioning of 
substrates.5,10 In compiling the knowledge of these residues from previous mutagenesis studies, it 
appears that substrate selectivity may be controlled by the steric bulk of the different amino acid 
residues and limited flexibility in movement in the side chains.3-5,10 This contrasts with many 
other mammalian cytochrome P450 enzymes where active site cavities appear to be more 
flexible depending on the bound ligand. 
The ultimate goal of this study was to understand how these residues interact with 
benzylmorpholine compounds to impart the observed selectivity between the human CYP2A 
enzymes.  In order to accomplish this, we desired to determine a co-crystal structure of 
CYP2A13 with one of our selective benzylmorpholine inhibitors. Figure 4.2 displays the 
compounds used in the crystallography experiments described herein.  We anticipated that a co-
crystal structure would facilitate the rational design of benzylmorpholine inhibitors by 
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suggesting ways to maximize interactions within the CYP2A13 active site over the CYP2A6 
active site, further enhancing selectivity for CYP2A13. 
 
Figure 4.2. Structures of the benzylmorpholine analogs used for protein crystallography with the 
CYP2A enzymes.  Numbering of the structures correlate with chapters 1-3. 
 
 
Materials and Methods 
Docking studies: Surflex11 was used to dock the benzylmorpholine compounds 2-5, 7-8, 12-13, 
and 16 with both CYP2A13 (PDB 2P85) and CYP2A6 (PDB 1Z10). Structures for these 
compounds are shown in chapters 1-3.  Ligand files used in the docking studies were prepared in 
Sybyl with energy minimization and assignment of Gasteiger and Marsili charges.  Sybyl was 
also used to prepare the CYP2A files by extraction of the published ligand, assignment of 
Gasteiger and Marsili charges, addition of a 3+ charge to the ferric heme iron, and deletion of an 
artificial hydrogen bond to the heme at the 6th coordinate position resulting from a program error.  
Next, molecular fragments such as CH4, C=O, and N-H were placed into the active sites of the 
CYP2A enzymes where 1 Å3 void volumes were identified.11 Placement of each fragment was 
scored based upon hydrophobic and polar complementarity and entropic and solvation terms.11,12 
Fragments with scores above a threshold were used to generate a pseudo-molecule called a 
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protomol, which was then used for alignment of the ligands in the active site during docking.  
The resulting ligand poses were scored using the criteria described above and ranked from 
highest to lowest scores, with the highest test scores indicating the most favorable interactions. 
These scores also take into account inappropriate interactions and penetrations within the ligand 
and between the ligand and the CYP2A protein.  Docking scores for the top ten results were 
recorded and the ligand poses were viewed with PyMOL.13  
However, it is important to note that the docking results may not be optimal.  During 
Sybyl ligand preparation, a positive charge was not assigned to the nitrogen of the ligand 
morpholine ring, as it should have been.  At physiological pH and in the buffers that are 
described in this dissertation, the morpholine nitrogen, which has a pka of ~10, would be 
protonated.  Therefore the docking results may not be entirely accurate without the proper charge 
assignment.  
Site-Directed Mutagenesis: The QuikChange Site Directed Mutagenesis Kit (Agilent 
Technologies, Santa Clara, CA) was used with the forward primer 5´-
GGCTATGGCGTGGCATTCAGCAACGGGGAGCG-3´, reverse primer 5´- 
CGCTCCCCGTTGCTGAATGCCACGCCATAGCC-3´, and the pKKCYP2A6 
I208S/I300F/G301A/S369G “quad mutant” DNA template to create the CYP2A6 
V117A/I208S/I300F/G301A/S369G “pent mutant”, while also incorporating a silent mutation 
that removed a BbsI restriction site from the parent plasmid.  The mutagenesis reaction was 
transformed into XL1-Blue supercompetent cells.  The cells were plated on LB media containing 
50 µg/mL ampicillin for selection of cells containing the mutated plasmid and incubated for 16 
hours at 37˚ C.  Individual colonies were grown overnight in 5 mL LB media containing 50 
µg/mL ampicillin. The QIAprep Spin Miniprep Kit was used to purify the plasmid. The entire 
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CYP2A6 pent mutant gene was sequenced by Idaho State University Molecular Research Core 
Facility with pKK forward (5´-GCGCCGACATATAAACGGTTCTGGC-3´) and reverse (5´ 
GCAAATTCTGTTTTATCAGACCGC-3´) primers to verify the presence of intended mutations 
and absence of undesired mutations. 
Protein Expression and Purification:  The CYP2A13, CYP2A6 quad mutant, and CYP2A6 pent 
mutant proteins were expressed and purified with the protocols described in chapter 2 with minor 
changes, including purification with either 4.8 mM Cymal-5 (Anatrace, Santa Clara, CA) or 
0.5% Anapoe-35 (Anatrace, Santa, Clara, CA).   
Spectral Ligand Binding Assays: The spectral ligand binding constants of the CYP2A6 mutant 
enzymes with the benzylmorpholine compounds 3, 6, 7, and 9 were determined in duplicate 
using the procedures described in chapter 2.  
Kinetic Analysis: Inhibition of coumarin metabolism by the CYP2A mutant enzymes using 
compounds 3, 6, 7, and 9 was evaluated following the protocol described in chapter 2.   
Protein Crystallography: 
 First, a detergent (0.2 % Anapoe-X-405, 0.5% Anapoe-35, 4.8 mM Cymal-5, 3.4 M 
Cymal-1, or 3 mM n-dodecyl-N,N-dimethylglycine) was added to the purified CYP2A protein 
solution with 5 mM of 3, 5 mM of 6, 7 mM of 7, or 5 mM of 9, which were the highest inhibitor 
concentrations that could be achieved in the buffer solution.  Next, twenty-four well plates and 
hanging drop vapor diffusion equilibration were used to grow P450 crystals. A 3:1 or 1:1 ratio of 
11 mg/mL or 50 mg/mL CYP2A solution to well solution was equilibrated against 750 µl 
precipitant solution and incubated at room temperature.   
 High throughput crystal screening was performed with Wizard III and Wizard IV crystal 
screens (Emerald Bioscience, Bainbridge Island, WA), ninety-six well plates were used with 
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sitting drop vapor diffusion. In this case, the CYP2A protein solution included either 0.2 % 
Anapoe-X-405 or 4.8 mM Cymal-5 with either 5 mM of 3 or 7 mM of 7.  A 1:1 ratio of 50 
mg/mL CYP2A to precipitant solution was equilibrated against 75 µL of precipitant solution and 
incubated at room temperature.   
Precipitant conditions that produced crystals are described in the results section and 
summarized in table 4.1.  Crystals that were of suitable size (minimum length of ~ 0.05 µm) and 
morphology were flash cooled with liquid nitrogen after soaking in a cryoprotectant solution 
consisting of 350 µl of precipitant solution, 350 µl of CM elution buffer (50 mM KPi, pH 7.4, 
20% glycerol, 0.5 M NaCl, and 1 mM EDTA), and 300 µl of ethylene glycol.  X-ray diffraction 
data sets were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) on beam 
lines 9-2, 11-1, or 12-2. 
CYP2A6 structures (PDB 1Z10 or PDB 2FDV) were used as search models to solve the 
CYP2A6 mutant structures with molecular replacement using the software Phaser,14 and the 
resulting log-likelihood gains were >13,000 for all of the structures.  COOT15 and REFMAC516 
in the CCP4 suite17 were used to perform iterative rounds of model building and refinement on 
the CYP2A models. WHAT-IF18 and PROCHECK19 were used to validate the CYP2A6 quad 
mutant structure with 3 bound.  The remaining structures will be fully validated if the ligand 
density is of publishable quality.  Voidoo20  was used to determine cavities using a probe radius 
of 1.4 Å.  
Results  
Docking 
 Docking studies were performed to gain insights into the orientations of 
benzylmorpholine analogs. Three examples with three different benzylmorpholine ligands 
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(Figure 4.3) are used to summarize the type of data that was observed.  These three compounds 
were chosen as they represented a variety of experimental observations.  Compound 4 
represented a substitution at the ortho position on the benzene ring and was selective for 
CYP2A13 as it did not appear to bind to CYP2A6.  Compound 7 is a disubstituted ligand that 
was still selective for CYP2A13 but less so (7.5-fold).  The last compound, 16, was chosen for 
its unique difference in binding modes between the CYP2A enzymes.  In discussing each set of  
docking results, the roles of amino acid residues F209 and F300 (CYP2A13) or I300 (CYP2A6) 
are highlighted for later comparisons with the X-ray crystallography data.  
 
Figure 4.3. Structures of the benzylmorpholine analogs that are discussed as examples for the 
docking results. 
 
 
Compound 4 selectively binds and inhibits CYP2A13 (Kd = 6.3 µM, Ki  = 17.6 ± 3.1 µM) 
versus CYP2A6 (Kd = no spectral shift, Ki  = ≥1000 µM), with a ≥56-fold preference for the 
inhibition of CYP2A13.  However the docking scores did not qualitatively reflect the in vitro 
experimental results as the higher docking scores pertained to CYP2A6 compared to CYP2A13 
(Figure 4.4).  Thus selectively was not apparent from comparison of the scores.   
In the top 10 poses ranked by the highest docking scores, which were reflective of the 
best interactions within the active site, there were two proposed ligand-binding orientations of 4 
with CYP2A13 and one orientation with CYP2A6.  The most frequently observed CYP2A13 
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pose placed the oxygen of the morpholine ring 2.81 Å away from N297, where a potential 
hydrogen bond could be formed (Figure 4.5A).  This orientation would be consistent with a type 
I ligand and experimental data from the spectral ligand binding assays.  Additionally, the second 
pose resulted in two of the best docking scores with 4 and CYP2A13 and placed the oxygen of 
the morpholine ring 2.52 Å above the heme iron. The single orientation observed with CYP2A6 
also placed the oxygen of the morpholine ring above the heme Fe with a slightly closer distance 
of 2.14 Å (Figure 4.5B).  These latter poses may or may not cause a spectral shift, as bound 
water does not cause a shift with a λmax at 418 nm, resulting in an inconsistency with either 
CYP2A13 or CYP2A6 experimental data as 4 binds CYP2A13 but does not appear to bind or 
inhibit CYP2A6.   These results demonstrated the difficulty in generating reliable docking results 
even with a benzylmorpholine analog that was known to be selective for CYP2A13.   
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Figure 4.4.  Comparison of docking scores for 4 with both CYP2A13 and CYP2A6 
demonstrating preferential docking of 4 with CYP2A6.  
 
 
 
Figure 4.5. Primary ligand binding orientations for 4 (cyan) with A) CYP2A13 and B) CYP2A6 
resulting from docking studies. 
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The second docking example is for the disubstituted compound 7 in both CYP2A13 and 
CYP2A6.  Unlike 4, 7 demonstrated in vitro binding to both CYP2A enzymes but is 7.5-fold 
more selective for CYP2A13 versus CYP2A6.    However, comparison of the docking scores 
from the top 10 poses did not reflect the in vitro data (Figure 4.6).  The scores were more similar 
between the two enzymes than observed for 4, but still with a slight preference for CYP2A6.  
This demonstrates that the relative docking scores did not reflect the selectivity of 7 between the 
CYP2A enzymes. 
 In these docking studies, 7 displayed two orientations in CYP2A13 with almost 
equivalent scores (Figure 4.7A).  Both orientations place the morpholine ring closer to the heme 
than the substituted benzene ring, but the molecules are rotated horizontally almost 180˚ from 
one another.  In addition the placement of the chlorine and fluorine substituents vary.  Both 
ligand orientations might be expected to result in the experimentally observed type I ligand shift, 
but neither takes advantage of N297 for hydrogen bonding.   
Within the top 10 poses, 7 adopted three different orientations with CYP2A6.  The first 
ligand orientation represented the six lowest docking scores and placed the morpholine ring 
towards N297, which could result in the type I spectral shift consistent with experimental data.  
The remaining two orientations represented by the top four docking scores placed the 
morpholine ring near the heme.  In one case, the oxygen of the morpholine ring was placed 
directly above the heme Fe as seen with 4 and may or may not produce the expected type I 
spectral shift.  The third and final orientation with CYP2A6 placed a carbon atom above the 
heme (Figure 4.7B), which could be consistent with the type I binding shift observed.  Overall, 
the results with 7 did not instill confidence in the docking studies as they were unable to 
accurately portray the selectivity of 7 between the CYP2A enzymes. 
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Figure 4.6.  Comparison of docking scores for 7 with both CYP2A13 and CYP2A6 
demonstrating preferential docking with CYP2A6.  
 
 
Figure 4.7. Ligand binding orientations for 7 (cyan) with A) CYP2A13 and B) CYP2A6 
resulting from docking studies. 
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The third and final docking example was with compound 16.  This benzylmorpholine 
analog was chosen due to its unique differences in binding mode between the CYP2A enzymes.  
With CYP2A13, 16 was a type I ligand, but when CYP2A6 was titrated with 16, spectral shifts 
for a type II ligand were observed.  With the exception of the imidazole analogs (21 and 22), 16 
was also the tightest binding compound with CYP2A6, but it remained 18-fold more selective 
for CYP2A13 (Kd = 8.3 ± 4.1 µM) than for CYP2A6 (Kd = 150 µM).  However, this selectivity 
was not strongly reflected in the relative docking scores (Figure 4.8).  While these scores did 
demonstrate a slight preference for CYP2A13, the selectivity did not compare very well with the 
18-fold difference observed during in vitro experimentation.   
Three orientations of 16 were observed with CYP2A13, two of which were consistent 
with the type I spectral shifts observed during in vitro binding studies. The orientations 
consistent with experimental results placed the benzylmorpholine ligands with the morpholine 
ring angled towards N297 (3.4 Å) (Figure 4.9A) or with the morpholine above but not 
coordinating to the heme iron (3.18 Å).  Both of these orientations could be expected to produce 
a type I spectra.  However, the third orientation may not correlate with the experimental data as it 
placed the oxygen of the morpholine ring 2.48 Å above the heme iron, which could result in a 
type II spectral shift as observed for CYP2A6.   For CYP2A6, only one of the ten orientations 
predicted 16 in a position to coordinate to the heme iron with a distance of 2.6 Å between the 
heme iron and the thiol moiety (Figure 4.9B), which would result in the experimentally observed 
type II spectral shifts.  The remaining 9 orientations placed the thiol near the roof of the active 
site between N297 and I300.  Thus, only 10% of the predictions for 16 with CYP2A6 were 
consistent with experimental observations.     
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Figure 4.8.  Comparison of docking scores for 16 with both CYP2A13 and CYP2A6. 
 
  
Figure 4.9. Ligand binding orientations for 16 with A) CYP2A13 and B) CYP2A6 from docking 
studies that could correlate with experimental results. 
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 Overall, these three examples revealed that using docking studies to predict the ligand 
binding orientations of the benzylmorpholine library within the CYP2A active sites were often 
not consistent with observations from in vitro studies.  The docking results were inconclusive as 
to enzyme selectivity in addition to poor correlation with experimental data.  However, some of 
this poor correlation may be attributed to the lack of a positive charge on the ligand that should 
have been present during docking studies.  Regardless, alternative methods are needed to 
understand the CYP2A active site features that are responsible for benzylmorpholine selectivity.  
X-ray crystallography offers an alternative technique in analyzing the atomic-level interactions 
between a CYP2A enzyme and a benzylmorpholine ligand. 
Crystallography with CYP2A13 
 X-ray crystallography was used to elucidate the atomic interactions between CYP2A13 
and benzylmorpholine analogs.  Compounds 3 and 7 were chosen as they represented singly and 
disubstituted benzylmorpholine analogs that were selective for CYP2A13.  As described in the 
methods, protein solutions with either compound were equilibrated versus a precipitant using 
hanging drop vapor diffusion.  Many modifications of protein, detergents, buffer, and precipitant 
were made to generate benzylmorpholine bound structures, which are discussed below and 
summarized in Table 4.1. 
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 Initial CYP2A13 crystallization began with a precipitant solution that had previously 
been used to crystallize CYP2A13, CYP2A6, and CYP2A6 mutant enzymes (30% polyethylene 
glycol 3350, 0.175 M Tris pH 8.5, and 0.2 M ammonium sulfate).10 CYP2A13 was purified with 
0.5% Anapoe-35, concentrated to 11 mg/mL, and Anapoe-X-405 added to a final concentration 
of 0.2% prior to hanging drop vapor diffusion, resulting in rod-shaped crystals (Table 4.1A) that 
diffracted to 3.25 Å with 3 and 3.35 Å with 7.  However, no ligand density was observed within 
the active site.  Since we were interested in structures with density for benzylmorpholine ligands, 
further refinement was not pursued on these 3 Å structures.   
 Optimization of the precipitant solution was the next step in the crystallography process.  
Variations of precipitant components in twenty-four well plates confirmed that 30% PEG 3350 
was the optimal PEG concentration, but crystals grew in a range of Tris pH 8.5 and ammonium 
sulfate concentrations that might yield an increase in resolution and ligand occupancy.  The 
increase in ammonium sulfate concentrations from 0.2 M to 0.25 M yielded similar crystals that 
diffracted to 3.15 Å with 3, but only minimal electron density was observed for the 
benzylmorpholine ligand in the active site following molecular replacement and refinement 
(Table 4.1B).  In other words some electron density was present in the active site in a 2|Fo|-|Fc| 
map at 1 σ, but the size of the density was insufficient to place a ligand.  Microseeding was also 
used in an attempt to obtain larger, thicker crystals but only small rod clusters or micro clusters 
resulted (Table 4.1C).  The poor results with microseeding was perhaps not surprising as the 
thickness and size of the crystals rather than nucleation has been the primary issue in obtaining 
high resolution diffraction data.   
 Since the CYP2A13 rods proved unsuccessful in providing a co-crystal structure, 
additional precipitant solutions previously observed to yield CYP2A13 hexagonal crystals were 
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used (20% PEG 400, 0.1 M sodium HEPES, pH 7.5, and 0.2 M magnesium chloride).  Under 
these conditions, hexagonal rod shaped crystals that were screened had a space group of P3 with 
unit cell dimensions of 95.15 Å, 95.15 Å, and 527.24 Å and angles of 90˚, 90˚, and 120˚.  
Although a smaller unit cell and increased symmetry are desirable, if a co-crystal structure 
resulted from this work, it would be worthwhile to pursue refinement of the data.  The majority 
of the experimentation with hexagonal rod crystallization technique used a precipitant solution 
comprised of 20% PEG 400, 0.1 M sodium HEPES, pH 7.5, and 0.2 M magnesium chloride.  
Additional changes included an increase in protein concentration from 11 mg/mL to 50 mg/mL, 
a decrease in the drop ratio of CYP2A13 to precipitant solution from 3:1 to 1:1, and either 4.8 
mM Cymal-5 or 0.2% Anapoe-X-405 was added to the protein solution prior to hanging drop 
vapor diffusion.  Combination of the changes described above resulted in large hexagonal rods 
(Table 4.1D).  However, these crystals only weakly diffracted during screening, and an estimated 
resolution could not be determined. 
 High throughput screening with commercially available Emerald Biosciences Wizard III 
and Wizard IV sparse matrix screens originally yielded hexagonal torpedo-like crystals with 
Wizard III #27 (30% PEG 400, 0.1 M sodium HEPES, pH 7.5, 0.2 M magnesium chloride) 
(Table 4.1E) and needle clusters with Wizard IV #14 (40% PEG 400, 0.1 M Tris, pH 8.5, and 0.2 
M lithium sulfate).  Optimization of the Wizard III #27 components did not result in better 
crystals from the original hit, which diffracted to only 7.91 Å.   Wizard IV #14 (40% PEG 400, 
0.075 M Tris, pH 8.5, and 0.2 M lithium sulfate) component optimization resulted in thin plates 
that were too fragile to harvest (Table 4.1F). 
 Cytochrome P450 stability and crystallization are sensitive to detergents used in both 
purification and crystallography, so detergent screens were performed next.  Detergents from 
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Hampton research detergent screens 1-3 were added to either 0.5% Anapoe-35 or 4.8 mM 
Cymal-5 purified protein and equilibrated against the hexagonal rod solution (20% PEG 400, 0.1 
M Tris, pH 8.5, and 0.2 M lithium sulfate) or clustered rod solution (30% PEG 3350, 0.175 M 
Tris, pH 8.5, and 0.2 M ammonium sulfate).  All combinations contained either 5 mM 3 or 7 mM 
7.  Three detergents yielded interesting results.  Cymal-5 purified protein with the hexagonal rod 
solution yielded larger hexagonal rods than previously seen with 0.006 mM n-hexadexyl-β-D-
maltoside (Table 4.1G) and hexagonal cones with 15 mM n-dodecyl-N,N-dimethylglycine 
(Table 4.1H).  Meanwhile, 0.5% Anapoe-35 purified CYP2A13 with 15 mM n-dodecyl-N,N-
dimethylglycine resulted in short hexagonal rods (Table 4.1I).  Unfortunately crystals harvested 
from these conditions diffracted only to ≥3.31 Å with the best crystals.  Since using the same 
detergent during purification and crystallography can sometimes yield higher quality crystals, 
purifications were attempted with n-dodecyl-N,N-dimethylglycine at 2-5 times the critical 
micelle concentration (3 – 8 mM), but the purification failed due to significant protein 
precipitation and only resulted in 1.2 nmol of P420 after cation exchange chromatography. 
 The detergent screens with the clustered rod solution yielded only one solution that 
resulted in diffraction-quality crystals.  While most crystals with the clustered rod solution were 
short rods (Table 4.1J), CYP2A13 purified in 0.5% Anapoe-35 and crystallized with 3.4 M 
Cymal-1 resulted in a flat rod (Table 4.1K).  A data set was collected to 3.05 Å, but 
unfortunately only minimal ligand density was observed following refinement.  When CYP2A13 
was purified with 4.8 mM Cymal-5 and combined with 3.4 M Cymal-1 prior to hanging drop 
vapor diffusion, the crystals were spiky clusters that only weakly diffracted to 3.64 Å (Table 
4.1L).  A purification was not performed with Cymal-1 due to the cost of the detergent. 
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 Since the detergent screens were unable to produce a co-crystal structure, an alternative 
approach was the use of sucrose buffer (0.5 M sucrose, 0.125 M potassium phosphate, pH 7.4, 
and 1 mM EDTA) with or without additional detergent.  This method proved successful in 
solving the X-ray crystal structure of cytochrome P450 2E1.21,22 CYP2A13 purified with 0.5% 
Anapoe-35 was exchanged into sucrose buffer and crystal conditions were screened without 
detergent or with 0.2 % Anapoe-X-405, 4.8 mM Cymal-5, 3.4 M Cymal-1, or 3 mM n-dodecyl-
N,N-dimethylglycine in the presence of 5 mM 3 or 7 mM 7 (Table 4.1M).  Only 3 mM n-
dodecyl-N,N-dimethylglycine with 7 resulted in crystals.  However, these long rods were 
twinned and only diffracted to 6.38 Å. 
An alternative approach to obtaining better diffraction data was the use of macroseeding 
in order to grow thicker crystals.  Macroseeding experimentation used varying protein 
concentrations with 7 equilibrated against 20% PEG 400, 0.1 M Tris pH 8.5, and 0.2 M lithium 
sulfate but only yielded microcrystals (Table 4.1N).   
 Finally, crystal growth can be sensitive to different ligands.  For this reason, 
benzylmorpholine ligands 6 and 9 were substituted for 3 and 7 in hanging drop vapor diffusion 
crystallization trials. An 11 mg/mL CYP2A13 protein solution was equilibrated against 30% 
PEG 3350, 0.175 M Tris, pH 8.5, and 0.25 M ammonium sulfate.  Crystals with compound 6 
bound to CYP2A13 diffracted to 3.42 Å (Table 4.1O), while 9 diffracted to ≥3.0 Å (Table 4.1P), 
but this resolution was too low to warrant data collection.  The combined results from the 
CYP2A13 crystallography attempts illustrated the need for alternative methods to understand the 
structural basis for benzylmorpholine selectivity between CYP2A13 and CYP2A6.   
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CYP2A6 I208S/I300F/G301A/S369G (quad) mutant and CYP2A6 
V117A/I208S/I300F/G301A/S369G (pent) mutant validations 
 Despite numerous attempts, crystal structures with CYP2A13 and a bound 
benzylmorpholine could not be obtained.  However the CYP2A6 wild type enzyme has 
crystallized more readily in our hands. For this reason, the focus was shifted to the CYP2A13-
like enzymes CYP2A6 I208S/I300F/G301A/S369G (quad) mutant and CYP2A6 
V117A/I208S/I300F/G301A/S369G (pent) mutant with select benzylmorpholine analogs.  The 
four mutations incorporated into the CYP2A6 quad mutant were previously demonstrated to 
impart CYP2A6 with CYP2A13 activity regarding phenacetin metabolism and have been used 
successfully for crystallography.5  Additionally the V117A mutation impacts substrate binding 
and metabolism6 and was incorporated into the CYP2A6 quad mutant to create an even more 
CYP2A13-like enzyme in terms of its function, while potentially retaining the advantageous 
crystallization likely facilitated by CYP2A6 surface residues.  
To determine if the CYP2A6 quad and pent mutants could be realistic surrogates in 
structural analysis of benzylmorpholine binding, we first had to determine if the CYP2A6 quad 
and pent mutants interacted with select benzylmorpholine analogs more like the CYP2A13 or 
CYP2A6 wild type enzymes.  Selective benzylmorpholine compounds already used for 
crystallography (3, 6, 7, and 9) were evaluated with the CYP2A6 quad and pent mutant proteins 
for binding (Table 4.2) and inhibition (Table 4.3).  The CYP2A6 quad mutant had a spectral 
equilibrium dissociation constant of 6.9 µM for compound 3, which compared well to the 
CYP2A13 Kd value of 5.9 ± 3.4 µM, but not to CYP2A6 as no spectral shift was observed with 
this enzyme (Table 4.2).  The Ki value of the CYP2A6 quad mutant with 3 was 78.7 µM, which 
was 2-fold higher than the CYP2A13 value of 39.7 ± 4.3 µM but much more comparable to 
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CYP2A13 than CYP2A6 (Ki = ≥1000 µM) (Table 4.3).  In addition, 3 was a mixed inhibitor of 
the CYP2A6 quad mutant, rather than a competitive inhibitor as observed for 3 with CYP2A13.  
Similar trends were observed for compounds 6, 7, and 9. All of the compounds were type I 
ligands and bound to the CYP2A6 quad mutant with Kd values more similar to those observed 
for CYP2A13 than those observed for CYP2A6.  However, while 6 and 7 were competitive 
inhibitors and their Ki values more closely resembled CYP2A13, 9 was a mixed inhibitor with 
the CYP2A6 quad mutant and had a Ki value between that of CYP2A13 and CYP2A6.  
 
Table 4.2 Equilibrium dissociation constants for wild type CYP2A13 and CYP2A6 proteins as 
well as the CYP2A6 quad and pent mutants designed to mimic the CYP2A13 active site 
interactions with select benzylmorpholine analogs. 
Compound Structure Kd (µM)a,b,c 
  
2A6 2A13 2A6 Quad 
2A6 
Pent 
3 
 
No 
Spectral 
Shift 
5.9 ± 3.4 
(I) 
6.9+ 
(I) 
3.5* 
(I) 
6 
 
≥575.4 
(I) 
4.5 
(I) 
4.1** 
(I) - 
7 
 
No 
Spectral 
Shift 
5.2 
(I) 
12.3* 
(I) 
1.9** 
(I) 
9 
 
515 
(I) 
1.1 
(I) 
3.7** 
(I) - 
a CYP2A6 quad and pent mutant individual trials differed by * ≤1 µM, **≤2.1 µM, or + ≤3 µM 
b (I): Type I Ligand 
c- Assay was not performed 
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Table 4.3. Inhibition constants for wild type CYP2A13 and CYP2A6 proteins as well as the 
CYP2A6 quad and pent mutants designed to mimic the CYP2A13 active site interactions with 
select benzylmorpholine analogs. 
Compound Structure Ki (µM)a,b,c,d 
  
2A6 2A13 2A6 Quad 
2A6 
Pent 
3 
 
≥1000 39.7 ± 4.3 (C) 
78.7+ 
α=5.8 
(M) 
76.4 
(C) 
6 
 
818.3 
α=13.3 
(M) 
16.9 
(C) 
29.3 
(C) - 
7 
 
286.8 
(C) 
38.1 
(C) 
30.5 
(C) 
46.7 
(C) 
9 
 
296.1 
(C) 
19.6* 
(C) 
109.3 
α=4.5 
(M) 
- 
 
 a + Standard error was 27% rather than ≤20% 
b (C): Competitive Inhibition; (M), Mixed Inhibition 
c - Assay was not performed 
d *See chapter 3 for explanation 
 
Insertion of the V117A mutation into the CYP2A6 quad mutant created the CYP2A6 
V117A/I208S/I300F/G301A/S369G pent mutant.  The binding and inhibition by select 
benzylmorpholine ligands (3 and 7) with the CYP2A6 pent mutant were largely comparable with 
the binding and inhibition of the CYP2A6 quad mutant and CYP2A13 wild type enzyme (Table 
4.2 and Table 4.3).  Specifically, the dissociation constants of 3.5 µM and 1.9 µM with 3 and 7, 
respectively, compared well to the CYP2A13 values.  Compound 3 inhibited the CYP2A6 pent 
mutant with a Ki of 76.4 µM, and a Ki value of 46.7 µM was determined for 7.  While there are 
some differences between CYP2A13 and the CYP2A6 quad and pent mutants, these results 
indicated that overall the benzylmorpholine inhibitors resemble binding and inhibition of 
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CYP2A13 more than CYP2A6, suggesting that a structure of the CYP2A6 quad and pent 
mutants with a benzylmorpholine inhibitor might facilitate understanding of the selectivity of 
these compounds for CYP2A13. 
Comparisons of the catalytic efficiency of coumarin metabolism with the CYP2A6 quad 
and pent mutants may provide insight as to the slight differences in the inhibition data between 
the CYP2A6 mutant and CYP2A13 wild type enzymes.  In comparing the kcat values, the 
CYP2A6 pent mutant (1.29 ± 0.03 min-1) resembled CYP2A13 (1.29 ± 0.03min-1) while the 
CYP2A6 quad mutant (9.93 ± 1.03 min-1) was more similar to CYP2A6 (8.61 ± 0.20 min-1) 
(Table 4.4).  However, the Km values varied between the enzymes from ~6-14 µM with the 
CYP2A6 pent mutant having the lowest Km value while the CYP2A6 quad mutant had the 
highest value.  An overall comparison of the catalytic efficiency between the enzymes revealed 
that the CYP2A6 quad (0.47 min-1µM-1) and CYP2A6 pent mutants (0.26 min-1µM-1) had values 
between CYP2A13 (0.11 min-1µM-1) and CYP2A6 (0.66 min-1µM-1).  The higher turnover rate 
by the mutant enzymes in comparison to wild type CYP2A13 may be the cause of the higher Ki 
values as a higher concentration of inhibitor is required to compete with the faster substrate 
turnover.   
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Table 4.4. Comparison of experimentally determined steady-state kinetic parameters for the 
metabolism of coumarin by CYP2A13 and CYP2A6 wild type enzymes and the CYP2A6 quad 
and pent mutants. 
Enzyme kcat (min-1) Km (µM) kcat/Km  (min-1µM-1) 
CYP2A13  1.29 ± 0.03 11.7 ± 1.05 0.11 
CYP2A6 8.61 ± 0.20 13.98 ± 1.10 0.66 
CYP2A6 quad 
mutant 9.93 ± 1.03 21.07 ± 6.5 0.47 
CYP2A6 pent 
mutant 1.44 ± 0.05 6.32 ± 0.89 0.26 
 
 
Crystallography for the CYP2A6 I208S/I300F/G301A/S369G (quad) mutant and CYP2A6 
V117A/I208S/I300F/G301A/S369G (pent) mutant with select benzylmorpholine inhibitors 
Crystallography experimentation with the CYP2A6 quad mutant began with 3 and the 
CYP2A13 precipitant solution that yielded the highest diffraction quality crystals (30% PEG 
3350, 0.175 M Tris, pH 8.5, and 0.2 M magnesium chloride).  The CYP2A6 quad enzyme was 
purified with either 0.5% Anapoe-35 or 4.8 mM Cymal-5 and resulted in rods with varying 
morphologies (Table 4.5 A and B), and data sets were collected to 2.1 Å and 2.15 Å.   
 Additional experimentation with the CYP2A6 mutant included a purification with 4.8 
mM Cymal-5 and hanging drop vapor diffusion with compounds 6, 7, and 9.  Crystals grew well 
when purified with either 0.5% Anapoe-35 or 4.8 mM Cymal-5, but the addition of 0.2% 
Anapoe-X-405 prior to the formation of the hanging drop resulted in the best crystals.  Data sets 
were collected with 6 to 2.25 Å (Table 4.5C), 7 to 1.9 Å and 2.0 Å (Table 4.5D), and 9 to 2.02 Å 
and 2.06 Å (Table 4.5E).    The CYP2A6 pent mutant also co-crystalized well with 3 (Table 
	   106	  
4.5F) and 7 (Table 4.5G) using the same conditions as the CYP2A6 quad mutant, and data was 
collected to 2.21 Å (3) and 2.06 Å (7).  Like CYP2A6 (but unlike CYP2A13), all of the 
structures contained 4 molecules in the asymmetric unit with appreciable ligand density in at 
least two of the molecules.  These resolution limits were determined by evaluating the 
multiplicity, Rpim, and mean (I/σ) with a minimum of ~90% completeness.  The CYP2A6 quad 
structures were solved first, and as such, some of the data collection statistics were at the upper 
or lower limits of acceptable values.  However, the data collection statistics for the CYP2A6 pent 
structures were more conservative and well within acceptable limits.  Data collection and 
refinement statistics can be found in tables 4.6 and 4.7 for the CYP2A6 quad and pent mutants, 
respectively, and the structural details are described below. 
T
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Table 4.6. Current refinement statistics for the CYP2A6 quad mutant co-crystallized with 3, 6, 7, 
and 9. 
 
CYP2A6 I208S/I300F/G301A/S369G 
Ligand 3 6 7 9 
Crystal data 
    Space group P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1 
Unit Cell 
    a, b, c (Å) 70.5, 159.2, 103.9 70.5, 159.2, 103.6 70.3, 158.8, 103.8 70.7, 160.3, 103.9 
α, β, γ  (˚) 90.0, 92.1, 90.0 90.0, 92.1, 90.0  90.0, 92.1, 90.0 90.0, 91.9, 90.0  
Molecules per AU 4 4 4 4 
Data Collection 
    
Resolution Limits (Å) * 
42.6-2.1 
 (2.21-2.1) 
43.6-2.25  
(2.31-2.25) 
46.4-1.9  
(1.95-1.90) 
31.13-2.02  
(2.07-2.02) 
Total observations* 914,929 (119,824) 408,463 (29,631) 673,430 (49,110) 1,129,928 (77,209) 
Unique observations* 125,603 (17,312) 108,886 (8,019) 178,184 (13,165) 150,561 (11,140) 
Completeness (%)* 94.6 (89.3) 100.0 (100.0) 99.9 (100.0) 99.8 (100.0) 
Multiplicity* 7.3 (6.9) 3.8 (3.7) 3.8 (3.7) 7.5 (6.9) 
Rpim * 0.04 (0.588) 0.05 (0.338) 0.061 (0.581) 0.058 (0.467) 
Mean (I/σ) * 12.9 (1.7) 8.2 (1.8) 8.8 (1.8) 8.4 (2.1) 
Refinement Statistics 
    Resolution (Å) 29.66-2.1 43.60-2.25 41.01-1.9 31.13-2.02 
No. of reflections 119,224 103,387 169,163 141,039 
R/Rfree (%) 21.6/27.2 21.3/27.6 21.0/25.5 23.7/28.5 
Rmsd bond lengths (Å) 0.023 0.022 0.024 0.023 
Rmsd bond angles (˚) 1.933 1.934 1.890 1.962 
Number of atoms/ 
Average B-factor 15,325/40.98 15,433/35.72 15,344/32.53 15,409/35.95 
Protein 15,017/41.09 14,938/36.11 14,929/32.85 14,924/36.16 
Heme 172/32.03 172/27.31 172/24.06 172/26.86 
Ligand 42/48.10 45/69.68 45/42.64 30/51.44 
Water 88/37.93 123/36.72 190/31.17 283/41.77 
     
* Parentheses indicate highest-resolution shell   
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Table 4.7. Current refinement statistics for the CYP2A6 pent mutant co-crystallized with 3 and 
7. 
	  
CYP2A6 V117A/I208S/I300F/G301A/S369G 
Ligand 3 7 
Crystal data 
  Space group P 1 21 1 P 1 21 1 
Unit Cell 
  a, b, c (Å) 70.8, 160.5, 103.8 70.4, 159.0, 103.7 
α, β, γ  (˚) 90.0, 92.0, 90.0 90.0, 92.0, 90.0 
Molecules per AU 4 4 
Data Collection 
  Resolution Limits (Å) * 42.57-2.21 (2.27-2.21) 47.49-2.06 (2.11-2.06) 
Total observations* 640,871 (46,434) 1,014,236 (65,828) 
Unique observations* 113,519 (8,266) 136,738 (9,805) 
Completeness (%)* 98.3 (97.6) 97.6 (94.8) 
Multiplicity* 5.6 (5.6) 7.4 (6.7) 
Rpim * 0.079 (0.403) 0.042 (0.330) 
Mean (I/σ) * 7.4 (2.4) 15.0 (3.6) 
Refinement Statistics 
  Resolution (Å) 41.14-2.21 43.40-2.06 
No. of reflections 107,772 129,508 
R/Rfree (%) 22.6/28.2 20.9/25.6 
Rmsd bond lengths (Å) 0.021 0.023 
Rmsd bond angles (˚) 1.876 1.86 
Number of atoms/  
Average B-factor 15,327/41.65 15,342/32.74 
Protein 15,030/41.61 14,870/32.64 
Heme 172/31.53 172/24.48 
Ligand 56/85.69 30/86.70 
Water 59/50.27 141/35.56 
   
* Parentheses indicate highest-resolution shell  
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Overall comparison of CYP2A13, CYP2A6, CYP2A6 quad mutant, and CYP2A6 pent mutant 
structures 
To detect any changes that the mutations might have had on the global enzyme structure, 
the Cα backbones from the CYP2A13 (PDB 2P85), CYP2A6 (PDB 2FDV), CYP2A6 quad 
mutant, and CYP2A6 pent mutant structures were overlaid.  Only minor global differences were 
observed. The root mean square deviations from the CYP2A13 wild type structure ranged from 
0.336 – 0.374 Å for all Cα carbons, confirming the similarity of the structures (Figure 4.10). 
 
Figure 4.10. Structural overlay of CYP2A13 (maroon), CYP2A6 (green), CYP2A6 quad mutant 
(blue), and CYP2A6 pent mutant (yellow) enzymes. 
 
 
 
 
   
 RMSD (Å) 
CYP2A13 0 
CYP2A6 
Pent Mutant 0.374 
CYP2A6 
Quad Mutant 0.336 
CYP2A6 0.369 
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Active Site Volumes 
 To begin to compare the active sites of the CYP2A wild type enzymes versus the 
CYP2A6 quad and pent mutants, the probe-occupied volumes were calculated using Voidoo20 
with a probe radius of 1.4 Å. As a point of reference, previous structures revealed that the 
CYP2A6 wild type active site volume was ~250 Å3, which is 15-20% smaller than the CYP2A13 
active site of ~300 Å3.4,9 The CYP2A6 quad mutant crystallized with 3 had an active site volume 
of 305 Å3.  The CYP2A6 pent mutant structure had a volume of 285 Å3.  Both CYP2A6 mutants 
have cavity volumes greater than the CYP2A6 wild type enzyme, with the total volume of the 
CYP2A6 quad mutant being closer to the wild type CYP2A13 enzyme than CYP2A6.  
Distribution of the active site volumes were similar between the enzymes with small 
differences (Figure 4.11), such as both the CYP2A6 quad and pent mutants penetrate slightly 
lower into the active site near I366.  Additionally, the CYP2A6 quad and pent mutant deviate 
from one another near residue 117.  The CYP2A6 quad mutant retains the CYP2A6 wild type 
valine residue, which extends further into the active site than the CYP2A13 alanine residue 
(Figure 4.11A).  The deeper penetration into the active site is reflected in the reduced void 
volumes surrounding V117 in both CYP2A6 and the CYP2A6 quad mutant.  However, the 
CYP2A6 pent mutant has the CYP2A13 wild type alanine residue at the 117 position, which 
allows for CYP2A13 and the CYP2A6 pent mutant to occupy a slightly larger volume in this 
area (Figure 4.11B). 
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Figure 4.11. Comparison of active site cavities for CYP2A13 (maroon) and CYP2A6 (green) 
overlaid with the A) CYP2A6 quad mutant (blue) and B) CYP2A6 pent mutant (yellow) 
demonstrated that the CYP2A6 mutants were more similar to CYP2A13 than CYP2A6.  Cavities 
are probe occupied voids detected with a 1.4 Å probe.  The heme is represented by black sticks 
with the iron atom as a rust colored sphere.  The amino acid residues that are highlighted indicate 
mutated residues or those that are important for substrate binding. 
 
 
A 
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CYP2A6 I208S/I300F/G301A/S369G (quad) mutant and 4-(2-chlorobenzyl)morpholine (3) 
Crystallization and structure determination with the CYP2A6 quad and pent mutants was 
successful as multiple data sets were collected and solved with four different benzylmorpholine 
inhibitors.  The best data set collected with 3 and the CYP2A6 quad mutant yielded a 2.1 Å 
structure.  Of the 4 molecules in the asymmetric unit, molecules A, B, and D displayed moderate 
density for a ligand, while molecule C only had a small amount of electron density at 1 σ.  The 
density provided a rough outline as to the overall placement of the ligand, but the lack of well-
defined density made the precise ligand orientation less definitive.  The ligand was modeled into 
the 2|Fo| - |Fc| electron density map by placing the planar substituted benzene ring in the largest 
and most planar density with the electronegative chlorine substituent in the bulge of the density 
(Figure 4.12).  The morpholine ring was then rotated into the remaining electron density.  The 
data indicated that in each molecule the ligand was oriented with the morpholine ring toward 
N297 with a distance of 3.6-4.0 Å.  The plane of the substituted benzene ring was almost 
perpendicular to the heme, and the chlorine atom was angled between F209 and F300.  Despite 
this overall similar orientation in the three molecules, the ligands did appear to deviate from one 
another with respect to rotations of the morpholine ring.  In molecule B, the plane of the 
morpholine ring through the carbon atoms was perpendicular to the plane of the benzene ring.  
Molecule D displayed the ring planes as parallel, but the electron density coverage was poor.   
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Figure 4.12.  A 2.1 Å structure with the CYP2A6 quad mutant with compound 3 oriented within 
the active site of molecule B.  The mesh represents the 2|Fo| - |Fc| electron density map contoured 
at 1 σ, while the red sticks represent the heme with the iron atom as a rust colored sphere. The 
amino acid residues that are highlighted indicate mutated residues or those that are important for 
substrate binding. 
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CYP2A6 I208S/I300F/G301A/S369G (quad) mutant and 4-(2-ethylbenzyl)morpholine (6) 
The 2.25 Å data set with the CYP2A6 quad mutant and the ethyl substituted 
benzylmorpholine ligand (6) revealed 6 to bind in three different orientations in molecules A, B, 
and C (Figure 4.13).  Molecule D had density for a water molecule located above the heme.  
Modeling of the ligands into the electron density began with the placement of the planar 
substituted benzene ring into the clearly planar portion of the electron density with the ethyl 
group in the bulge.  The morpholine ring was positioned in the remaining electron density, which 
widened to encompass the width of the morpholine ring.  This oriented the morpholine ring 
either near N297 with a distance of 3.6 - 3.9 Å (molecules A and C) or near the heme (molecule 
B).  Molecules A and B had the best coverage of electron density for ligand placement, and the 
two orientations that were observed were vertically rotated 180˚ relative to one another.  
Molecule C did not have as extensive electron density for the ligand, but it was sufficient to 
demonstrate that while the morpholine ring was near N297 as in molecule A, it was rotated 90˚ 
(Figure 4.13 A versus C).   One residue that clearly differs between molecules A and B versus C 
in this structure was the position of L370.  The leucine side chain was angled in towards the 
active site ligand in molecule C but deflected toward N297 in molecules A and B. A similarity 
between the orientations observed in the CYP2A6 quad mutant with 6 and 3 was that the best fit 
of the ligand within the electron density placed the respective ethyl and chlorine substituents on 
the benzene ring between F209 and F300 and away from V117. 
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Figure 4.13. A 2.25 Å structure of 6 bound in the active site of A) molecule A, B) molecule B, 
and C) molecule C of the CYP2A6 quad mutant. The mesh represents the 2|Fo| - |Fc| electron 
density map contoured at 1 σ, while the red sticks represent the heme with the iron atom as a rust 
colored sphere. The amino acid residues that are highlighted indicate mutated residues or those 
that are important for substrate binding. 
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CYP2A6 I208S/I300F/G301A/S369G (quad) mutant and 4-(2-chloro-6-fluorobenzyl)morpholine 
(7) 
 A structure with the chlorine and fluorine disubstituted benzylmorpholine analog proved 
to be more challenging to orient the ligand within the active site due to the poorer definition of 
the ligand density.  Despite data to 1.9 Å with compound 7, only 3 of the 4 molecules had 
moderate ligand density.  Compound 7 was modeled into the active site by positioning the planar 
benzene ring in the largest area of density with the chlorine and fluorine atoms in the adjacent 
bulges.  Molecule A had the most defined electron density for the ligand and placed the 
morpholine ring 3.49 Å from N297 (Figure 4.14).  The data suggested that the chlorine atom was 
positioned towards F300.  Similar ligand placements were observed with the remaining two 
molecules with ligand density. 
 
Figure 4.14. A 1.9 Å structure of the CYP2A6 quad mutant with compound 7 bound within the 
active site of molecule A. The mesh represents the 2|Fo| - |Fc| electron density map contoured at 1 
σ, while the red sticks represent the heme with the iron atom as a rust colored sphere. The amino 
acid residues that are highlighted indicate mutated residues or those that are important for 
substrate binding. 
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CYP2A6 I208S/I300F/G301A/S369G (quad) mutant and 4-(2-chloro-6-methylbenzyl)morpholine 
(9) 
The second disubstituted benzylmorpholine analog that was crystallized with the 
CYP2A6 quad mutant had chlorine and methyl substituents (9) and proved to be more 
problematic to place the ligand than with the previous structure with 7.  A 2.02 Å data set had 
electron density in only two of the four molecules in the asymmetric unit, but only that in 
molecule A provided an outline for ligand orientation (Figure 4.15).  The ligand was oriented in 
the active site by first placing the benzene ring and chlorine substituent in the most well-defined 
planar density.  This position placed the morpholine near the heme rather than N297, and the 
chlorine atom was in a similar position within the active site but angled towards F209 rather than 
toward F300 as in the previous structure.  While the electron density was not as defined for the 
ligand in molecule B, the data suggested that the ligand was oriented with the morpholine ring 
pointing towards N297, and the chlorine atom was pointing towards F300 similar to the CYP2A6 
quad mutant with 7. 
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Figure 4.15. A 2.02 Å structure of the CYP2A6 quad mutant with 9 bound in the active site of 
molecule A.  The mesh represents the 2|Fo| - |Fc| electron density map contoured at 1 σ, while the 
red sticks represent the heme with the iron atom as a rust colored sphere. The amino acid 
residues that are highlighted indicate mutated residues or those that are important for substrate 
binding. 
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CYP2A6 V117A/I208S/I300F/G301A/S369G (pent) mutant and 4-(2-chlorobenzyl)morpholine 
(3) 
The CYP2A6 pent mutant with the benzylmorpholine analogs yielded similar results to 
the CYP2A6 quad mutant.  The 2.21 Å data set for the CYP2A6 pent mutant with the chlorine 
substituted benzylmorpholine (3) displayed ligand density for all four molecules within the 
asymmetric unit. The density supported two orientations previously observed in the CYP2A6 
quad structure with 6 (Molecules A and C) in that the morpholine ring was near N297 or parallel 
to the heme (Figure 4.16 A and B).  The substituted benzene ring was positioned in the dominant 
planar density with the chlorine atom pushing into the bulge of the density.  Placement of the 
morpholine followed into density that widened out to match the width of the morpholine ring in 
all of the molecules except C (Figure 4.16C).  As observed in the previous structures, the 
chlorine atom was best fit angled towards F209 or F300.  Three of the four molecules oriented 
the ligand with the morpholine towards the heme (Figure 4.16A), with molecule C containing the 
most well-defined electron density for a ligand in any structure herein. The orientation of the 
ligand in molecule B (Figure 4.16B) has interesting and distinct differences from the other three 
molecules.  While it could be argued that the ligand could be flipped, it appears that the planes of 
the morpholine and benzene rings were parallel to one another and the morpholine ring was 
oriented towards N297. In addition, L370 clearly adopted two alternate confirmations, which is 
not uncommon for this residue in CYP2A structures and may have affected the orientation of the 
ligand. 
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Figure 4.16. A 2.21 Å structure with the CYP2A6 pent mutant with compound 3 oriented within 
the active sites of A) and C) molecule C and B) molecule B with various orientations and 
degrees of ligand density. The mesh represents the 2|Fo| - |Fc| electron density map contoured at 1 
σ, while the red sticks represent the heme with the iron atom as a rust colored sphere. The amino 
acid residues that are highlighted indicate mutated residues or those that are important for 
substrate binding. 
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CYP2A6 V117A/I208S/I300F/G301A/S369G (Pent) mutant and 4-(2-chloro-6-
fluorobenzyl)morpholine (7)  
Analysis of a 2.06 Å data set with the CYP2A6 pent mutant and 7 revealed the same 
problems as with the other disubstituted ligands with the CYP2A6 quad mutant structures.  Only 
two of the molecules had moderate ligand density while the remaining two molecules had only 
sparse density.  The poor ligand density made it challenging to place the ligands within the active 
site.  The electron density that was present suggested that the morpholine ring was angled 
towards N297 (3.32 Å), where it could form a weak hydrogen bond (Figure 4.17).  The best fit of 
the ligand density positioned the chlorine atom towards F300.   
 
Figure 4.17. A 2.06 Å crystal structure of CYP2A6 pent mutant with 7 bound in the active site. 
The mesh represents the 2|Fo| - |Fc| electron density map contoured at 1 σ, while the red sticks 
represent the heme with the iron atom as a rust colored sphere. The amino acid residues that are 
highlighted indicate mutated residues or those that are important for substrate binding. 
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In conclusion, based upon the observation that N297 hydrogen bonds to multiple 
substrates in both CYP2A13 and CYP2A6,4,5,9,10 it was hypothesized that a hydrogen bond 
would form between N297 and the oxygen of the morpholine ring, but either this was not 
observed or weak in some cases.  Without a hydrogen bond to N297, there were no bonding 
interactions within the active site to lock the ligand into a single orientation, which may allow 
the ligands to bind in multiple orientations.   
Discussion 
Prior to X-ray crystallography, docking studies were performed to gain insight into ligand 
binding orientations within the CYP2A active sites.  While the docking studies accurately 
predicted multiple binding orientations, overall the docking results were not definitive.  The 
docking results were rarely able to accurately predict the selectivity of the ligands or whether the 
benzylmorpholine compounds were able to bind the CYP2A enzymes in a manner that would 
coincide with experimental data.  However, the results may have been affected by the lack of a 
positive charge on the ligand during these studies.  Regardless, the inaccuracy between the 
docking studies and functional experimental data illustrated the need for a co-crystal structure to 
evaluate the interactions between a benzylmorpholine analog and CYP2A13 or CYP2A6 
mutated to function like CYP2A13. 
The purpose of obtaining a co-crystal structure was to evaluate the atomic level 
interactions between a benzylmorpholine ligand and CYP2A13 for rational drug design.  
However, crystallographic attempts with CYP2A13 proved unsuccessful in that electron density 
for the placement of a ligand within the active site was either not observed or insufficient for 
ligand orientation.  The CYP2A13-like enzymes CYP2A6 I208S/I300F/G301A/S369G (quad) 
mutant and CYP2A6 V117A/I208S/I300F/G301A/S369G (pent) mutant proved more 
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advantageous in solving six crystal structures: 3 (CYP2A6 quad 2.1 Å, CYP2A6 pent 2.21 Å), 6 
(CYP2A6 quad 2.25 Å), 7 (CYP2A6 quad 1.9 Å, CYP2A6 pent 2.06 Å), and 9 (CYP2A6 quad 
2.02 Å).  These ligands bound in the active site with varying electron density quality.   
Overall, two orientations were observed for the ligands bound to the CYP2A6 quad and 
pent mutant enzymes.  The predominant disubstituted ligand orientation placed the morpholine 
ring towards the polar residue N297 with a distance of ≥ 3.32 Å, which is in a position to form a 
weak hydrogen bond.  With the singly substituted benzylmorpholine ligands, the most well-
defined ligand density placed the morpholine ring parallel to the heme with the benzene ring 
located near N297.  However, the orientation with the morpholine ring near N297 was also 
observed, but the distance between the ligand and N297 was too great to form a hydrogen bond.  
Additionally, in two of the instances when the morpholine ring was near N297, the plane of the 
morpholine ring through the carbon atoms was rotated to be more parallel with the plane of the 
benzene ring (Figure 4.13C and Figure 4.16B), and L370 was pointing into the active site rather 
than away.  These results indicate that L370 may be important for ligand orientation. 
While the ligand density was not definitive, the best fit of the ligands revealed a common 
feature between the two orientations.  The data suggested that there was a consistent placement 
of the chlorine substituent near the center of the active site and directed towards F209 or F300, 
which line the roof of the active site.  This placement may be indicative of favorable 
hydrophobic interactions between the chlorine atom and the numerous phenylalanine residues 
within the active site.  In addition to F209 and F300, F107 and F480 also line the roof of the 
active site near the chlorine atom (Figure 4.18).  In the CYP2A6 pent mutant with 3, F107, F209, 
and F480 were 4.17 Å – 4.69 Å from the phenyl ring to the chlorine atom.  F300 lies further 
away with distances between 4.64 Å – 5.95 Å.  In addition, this consistent placement of the 
	   126	  
chlorine atom was not observed in the docking studies, further validating the necessity of X-ray 
crystallography. 
 
Figure 4.18. Compound 3 bound within the active site of the CYP2A6 pent mutant illustrates 
potential hydrophobic interactions between the chlorine substituent and the F209 and F300, F107 
and F480.  The heme is represented by red sticks with a rust colored sphere indicating the the 
iron atom.  
 
 
Based upon previous CYP2A13 and CYP2A6 crystal structures, it was anticipated that 
the oxygen of the morpholine ring would hydrogen bond with N297 and orient the 
benzylmorpholine ligands.  However, in most instances the benzylmorpholine ligands were too 
far away for a hydrogen bond.  Thus, it appears that there were no direct bonding interactions 
within the CYP2A quad and pent mutant active sites which allowed for multiple ligand 
orientations resulting in moderate ligand density. 
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Conclusions 
 Binding and inhibition analysis of the benzylmorpholine library with CYP2A13 and 
CYP2A6 provided information as to the behavior of the ligands with these enzymes.  However, 
those results could not provide information pertaining to specific interactions between active site 
residues and the benzylmorpholine analogs.  Thus docking and X-ray crystallography studies 
were performed to obtain a better understanding of the atomic-level interactions controlling the 
binding and orientation of the ligands within the CYP2A13 active site.  While the docking results 
displayed multiple binding orientations, which agreed with the X-ray crystallography results, 
overall, the docking studies proved inconclusive and did not always correlate with experimental 
data.   
X-ray crystallography was able to provide some insight into the ligand binding 
orientations within a CYP2A13-like active site.  Since CYP2A13 crystals could not provide the 
desired co-crystal structure, the focus turned to CYP2A6 mutants that were engineered to 
function like CYP2A13.  For unknown reasons, the ease with which CYP2A6 crystallizes versus 
the 94% identical CYP2A13 indicated that the packing interactions between the CYP2A6 
molecules were more optimal and could be exploited with the CYP2A6 quad and pent mutant 
enzymes.  The best fit of the electron density indicated that these CYP2A13-like enzymes 
oriented the morpholine ring towards N297 or parallel to the heme and placed the chlorine 
substituent in the middle of the active site where it could participate in hydrophobic interactions. 
This consistent placement of the chlorine atom was not observed during the docking studies, 
further indicating that the docking results may not be reliable.  Combination of the structural 
information with the structure-activity relationships provides a more complete understanding of 
the interactions between benzylmorpholine ligands and CYP2A13. 
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 Future directions would include additional attempts in crystallizing the wild type 
CYP2A13 enzyme to alleviate any concerns regarding the differences between the CYP2A6 
mutants and CYP2A13.  Recent work in the Scott lab has indicated that the presence of 
cytochrome b5 during CYP2A13 crystallization in 0.5 M sucrose and 0.25 M potassium 
phosphate buffer resulted in consistent crystals with higher symmetry, fewer molecules in the 
asymmetric unit, and low 2 Å data with ligand present.  The inclusion of cytochrome b5 could 
yield the desired structural data of a benzylmorpholine analog bound to CYP2A13.  An 
alternative strategy would be to mutate the CYP2A13 hydrophobic surface residues to 
hydrophilic residues to improve protein packing interactions, which has worked for other P450 
enzymes.23 However, should these techniques prove unsuccessful, binding and inhibition studies 
with CYP2A13 mutants could identify the amino acid residues controlling benzylmorpholine 
binding and inhibition.  Correlation of these results with the current crystallographic data could 
provide more insight into the structure/function relationships between CYP2A13 and 
benzylmorpholine analogs. 
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Chapter 5 
Expression, Purification, and Crystallization of CYP21A2 
Introduction  
In the pursuit of selective CYP17A1 inhibitors for the treatment of prostate cancer, it is 
imperative to screen potential drug candidates against protein targets that may also bind 
compounds of interest. In the case of CYP17A1, potentially selective inhibitors should be 
evaluated with CYP21A2, as a CYP17A1 substrate and product are substrates for CYP21A2 
(Scheme 5.1).  CYP17A1 metabolizes progesterone to 17α-hydroxyprogesterone1 while 
CYP21A2 metabolizes progesterone to 11-deoxycorticosterone and 17α-hydroxyprogesterone to 
11-deoxycortisol.  Thus CYP21A2 is an important counter-target.1  However, in order to 
evaluate the selectivity of drug candidates and conduct biochemical studies of CYP21A2, large 
quantities of purified P450 enzyme are necessary.  Escherichia coli is the desired expression 
system for the production of large quantities of enzyme as E. coli does not contain cytochromes 
P450 and has proven successful for expression of other P450 enzymes.2,3 However, human 
CYP21A2 has only been purified from E. coli in low yield of 40-50 nmol/L.4 Thus until now 
information pertaining to the biochemical properties of CYP21A2 has primarily relied upon 
genetic studies,5-7 homology models,8-10 studies in microsomes,3,8 or comparison to the 79% 
identical bovine CYP21A2 enzyme.11,12  
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Scheme 5.1.  Substrate overlap between CYP17A1 and CYP21A2 in the steroid biosynthetic 
pathway.1 
 
 
CYP21A2 is expressed in the adrenal cortex and is bound to the membrane of the 
endoplasmic reticulum.  Expression of CYP21A2 is regulated by adrenocorticotropic hormone 
(ACTH) via a G-protein coupled receptor and the cAMP-dependent signaling pathway.1 The 
human enzyme catalyzes the 21-hydroxylation of progesterone to 11-deoxycorticosterone with a 
Vmax of 0.12 pmol/min/mg of protein and a Km value of 1.1 µM in yeast microsomes.8 
Additionally, CYP21A2 converts 17α-hydroxyprogesterone to 11-deoxycortisol with a a Vmax of 
3.3 pmol/min/mg of protein and a Km value of 1.6 µM with the same expression system.8 A 
deficiency in 21-hydroxylase activity is responsible for 90-95% of cases of congenital adrenal 
hyperplasia (CAH) resulting from excessive ACTH stimulation and the overproduction of 
androgens.7,13 Classic CAH involves genital ambiguity in the simple virilizing form of the 
disease or an aldosterone biosynthetic defect resulting in a more severe form called salt-wasting.6 
An asymptomatic individual with excess androgen synthesis is described as a non-classical 
form.6  Recombination of CYP21A2 on chromosome 6 with the pseudogene CYP21A1 leads to 
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insertions and deletions resulting in missense and nonsense mutations.1  There are over 150 
mutations reported for CYP21A2.14  These mutations can affect the solubility and stability of the 
enzyme through interruptions of reductase, heme, or substrate binding depending upon the 
location of the mutation.1,10,15  
While significant research has been performed on the clinical role of CYP21A2 
deficiencies and corresponding mutations, biochemical studies have been limited due to the lack 
of large-scale expressions and purifications.8,11 E. coli expression of human CYP21A2 has been 
reported in low yields (40-50 nmol/L),4 but the kcat and Km values were higher than recently 
reported values.8 Progesterone and 17α-hydroxyprogesterone were metabolized with a kcat of 
192.9 and 198 min-1, respectively, with Km values of 14.7 µM for progesterone and 13.1 µM for 
17α-hydroxyprogesterone.  Additionally the Kd value was significantly higher for both 
progesterone (>100-fold) and 17α-hydroxyprogesterone (45-fold)4 than experimentally 
determined herein, illustrating the need for a more thorough biochemical evaluation of 
CYP21A2.   
Recent work has focused on the bovine CYP21A2 enzyme as sufficient quantities have 
been successfully expressed and purified from E. coli.11,15 Bovine CYP21A2 is 79% identical to 
human CYP21A2 and was able to catalyze the conversion of progesterone to 11-
deoxycorticosterone with a kcat of 12.9 ± 5.8 min-1 and a Km value of 1.88 ± 0.85 µM.11  
Additionally this enzyme catalyzed the conversion of 17α-hydroxyprogesterone to 11-
deoxycortisol with a kcat of 10.8 ± 5.3 min-1 and a Km value of 1.04 ± 0.53 µM.11 17α-
Hydroxyprogesterone was reported to be the preferred substrate for bovine CYP21A2 due to the 
slightly lower Km value,8,11 but the difference in Km values between the substrates is less than 2-
fold. 8,11 8,11 Comparison of the human and bovine kinetic values for progesterone and 17α-
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hydroxyprogesterone (Table 5.1) reveal that the Vmax and kcat values for human CYP21A2 are 
>10-fold higher than the bovine enzyme, an important difference which is not yet understood, 
supporting the need for direct studies of the human CYP21A2 enzyme. 
 
Table 5.1. Summary of the progesterone and 17α-hydroxyprogesterone kinetic values for human 
and bovine CYP21A2.4,8,15 
Species Expression System Progesterone 17α-hydroxyprogesterone 
  Vmax or kcat Km Vmax Km 
Human Yeast Microsomes 0.12 pmol/min/mg 1.1 µM 
3.3 
pmol/min/mg 1.6 µM 
Human E. coli 192.9  min-1 14.7 µM 
198  
min-1 13.1 µM 
Bovine E. coli 12.9 ± 5.8  min-1 
1.88 ± 0.85 
µM 
10.8 ± 5.3 
min-1 
1.04 ± 0.53 
µM 
 
The large scale E. coli expression of bovine CYP21A2 was also instrumental in solving 
the first CYP21A2 structure, a 3 Å crystal structure reported recently.11,15 The structure was 
consistent with the overall P450 fold with 12 α-helices and reported to contain two rather than 
four beta sheets.15  However, a unique feature of the CYP21A2 structure was the observation that 
two substrates were bound with the proximal substrate located above the heme and the distal 
substrate located in the entrance of the substrate access channel.  Even with the relatively high 
sequence similarity, it is unknown whether human CYP21A2 will share this feature. 
The goal of this project is the expression, purification, and characterization of human 
CYP21A2 in order to 1) evaluate the structure/function relationships of CYP21A2 and 2) 
evaluate CYP21A2 as a counter-target for developing selective CYP17A1 inhibitors.  The 
characterization of CYP21A2 can provide an in depth understanding of the biochemical 
interactions governing CYP21A2 activity.  This chapter describes the first large-scale expression 
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of human CYP21A2 in E. coli.  Additionally, purifications were successfully completed with 
multiple detergents and buffers leading to the first crystals of human CYP21A2. 
Materials and Methods 
Protein Modifications:  Codon-optimized CYP21A2 cDNA was synthesized (Blue Heron 
Biotechnology, Bothel, WA) with NdeI and HindIII restriction sites at the 5´ and 3´ sites, 
respectively, a Δ2-28 amino acid N-terminal transmembrane deletion, addition of an N-terminal 
MAKKTSSKGK solubility tag, and a C-terminal 6-histidine tag in a Blue Heron pUCminusMCS 
vector.  Figure 5.1 illustrates the modifications from the full length enzyme. 
 
Figure 5.1. Amino acid sequence alignment of CYP21A2 modified and full length enzyme.  
Deleted residues are highlighted in red with added residues in blue. 
             10         20         30         40         50  
Full Length MLLLGLLLLP LLAGARLLWN WWKLRSLHLP PLAPGFLHLL QPDLPIYLLG 
Truncated MAKKTSSKGK ...................LP PLAPGFLHLL QPDLPIYLLG  
 
            490        500   
Full Length QPRGMGAHSP GQNQ  
Truncated	   	  	  	  	  	  	  	  	  QPRGMGAHSP GQNQHHHHHH 
 
Cloning: A one-hour restriction digest of the pUC21A2 vector with NdeI and HindIII (New 
England Biolabs, Ipswich, MA) resulted in the desired CYP21A2 DNA fragment.  An 0.8% 
agarose gel was used to separate the DNA fragments before the 1458 base pair CYP21A2 gene 
insert was extracted from the gel and subsequently purified with a QIAquick Gel Extraction Kit 
(Qiagen, Germantown, MD).  Similar restriction digest and gel extraction were used to obtain the 
empty pCW vector (5038 base pairs).  The purified CYP21A2 insert and pCW vector were 
ligated together using a quick ligation kit (New England Biolabs, Ipswich, MA).  Ligation 
products were transformed into DH5α competent cells and plated on LB agar media with 50 
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µg/mL ampicillin.  Isolated colonies were grown overnight at 37 ˚C with shaking at 250 rpm in 
separate 5 mL LB cultures containing 50 µg/mL ampicillin.  The plasmid DNA was purified 
using QIAprep spin miniprep kit (Qiagen, Valencia, CA) and screened by restriction digest with 
MfeI, since the CYP21A2 gene would incorporate this unique restriction site into plasmid DNA.  
If a single cut was observed following restriction digest and gel electrophoresis, the complete 
cDNA in the pCW vector was sequenced by ACGT (ACGT, Wheeling, IL) with the forward (5´ 
GGAAACAGGATCAGCTTACTCCC-3´) and reverse (5´ 
GGCGTATCACGAGGCCCTTTCG-3´) pCW primers. 
Expression:11 The resulting pCW21A2 vector was transformed into DH5α Escherichia coli 
competent cells containing the pGro7 plasmid for expression of the GroEL chaperone protein.  
Cells were plated on LB agar plates containing 50 µg/mL ampicillin and 20 µg/mL 
chloramphenicol for selection of colonies containing both the pCW21A2 and pGro7 plasmids, 
respectively, using the methods described in chapter 2.  Initially, 250 mL TB media in 1 L flasks 
containing 50 µg/mL ampicillin, 20 µg/mL chloramphenicol, and 500 µg/mL arabinose (for 
induction of the GroEL chaperone) were inoculated with 5 mL from a 200 mL LB overnight 
culture.  However, later expressions were performed in 1L TB cultures in 2.5 L flasks and 
inoculated with 15 mL from an overnight culture as the size of the flask and culture did not 
impact the quality of the expression.  Following incubation at 37 ˚C and shaking at 250 rpm for 
2-3 hours an OD600 of 1.0-1.5 was reached and CYP21A2 expression was induced with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG).  In addition, heme synthesis was facilitated by 
the addition of delta aminolevulinic acid (ALA) to a final concentration of 1 mM.  Following 
induction and ALA addition, the temperature and shaking were reduced to 27 ˚C and 190 rpm, 
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respectively, and cultures were incubated for 48 hours.  Cells were pelleted at 6400 x g for 10 
minutes at 4 ˚C, and the cell pellets were stored at -80 ˚C. 
Purification: Purification of CYP21A2 for assays was based on the protocol outlined in chapter 2 
for CYP2A enzymes with major changes including omission of the flash freeze step and 
utilization of Tris-based buffers.  Harvested pellets were thawed and resuspended with 180-200 
mL of resuspension buffer #1 (50 mM Tris-HCl and 20% glycerol).  Lysozyme was added to a 
final concentration of 3 mg/mL and stirred at 4 ˚C for 30 minutes followed by the addition of 200 
mL of distilled water and centrifugation at 10,000 x g and 4 ˚C for 15 minutes.  The supernatant 
was discarded, and the pellet was resuspended with resuspension buffer #2 (50 mM Tris-HCl, 
20% glycerol, and 300 mM NaCl) with a tissue homogenizer.  This mixture was sonicated 3 
times for 30 seconds before centrifugation at 10,000 x g for 15 minutes at 4 ˚C.  The membrane-
associated CYP21A2 enzyme was extracted from the membrane using 1% Emulgen 913 (Desert 
Biologicals, Phoenix, AZ) with stirring at 4 ˚C for a minimum of one hour.  Ultracentrifugation 
at 4 ˚C and an average speed of 70,400 x g for 1 hour pelleted membranes, and the CYP21A2 
containing supernatant was applied to a Ni-NTA affinity column with Ni-NTA loading buffer 
(50 mM Tris-HCl, 20% glycerol, 300 mM NaCl, and 0.2% Emulgen 913), washed with Ni-NTA 
wash buffer (50 mM Tris-HCl, 20% glycerol, 300 mM NaCl, 100 mM glycine, and 0.2% 
Emulgen 913), and eluted with Ni-NTA elution buffer (50 mM Tris-HCl, 20% glycerol, 300 mM 
NaCl, 100 mM glycine, 80 mM histidine and 0.2% Emulgen 913).  Eluted heme protein from Ni-
NTA chromatography was diluted 5-fold with CM wash buffer (50 mM Tris-HCl, 20% glycerol, 
and 100 mM glycine) containing 0.2% Emulgen 913 to decrease the salt concentration.  Affinity 
chromatography was followed by cation exchange with a carboxymethyl (CM) cellulose resin.  
Protein that bound to the CM column was washed 10 times with CM wash buffer followed by 
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elution with CM elution buffer (50 mM Tris-HCl, 20% glycerol, 100 mM glycine, and 500 mM 
NaCl).  Protein prepared for X-ray crystallography included a third chromatographic step 
consisting of size exclusion chromatography with CM elution buffer.  A variation from the 
protocol used for the CYP2A enzymes was the increase in sample loading volume from 1 mL to 
4 mL to reduce the risk of protein precipitation, which was observed in initial purification.   In 
addition to purification with Tris buffers, twice the purification was performed with the 
potassium phosphate buffers described in chapter 2 but using the protocol described above.  The 
only alteration to the potassium phosphate buffers was the reduction to 4 mM histidine in the Ni-
NTA wash buffer and the substitution of 0.2% Emulgen 913 for 4.8 mM Cymal-5.   
Polyacrylamide Gel Electrophoresis: The purity of the protein samples during the various 
purification stages was evaluated through sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).  In addition, this technique was used to separate proteins in 
expression samples for further use in western blot analysis. Protein samples were denatured by 
diluting 1:1 with reducing sample-loading buffer (100 mM Tris-HCl, pH 6.8, 4% SDS, 200 mM 
dithiothreitol, and 20% glycerol) and heating for 3-5 minutes at 95 ˚C.  The denatured protein 
was centrifuged up to 10 minutes at 18,000 x g at room temperature before loading 20 µL onto a 
10% pre-cast Mini-protein TGX Gel (Bio-Rad, Hercules, CA).  In addition 10 µL of a Page-
Ruler Plus Pre-stained Protein Ladder (Thermo scientific, Dubuque, IA) was loaded onto the gel.  
If the SDS-PAGE gel was to be used for western blot analysis, 2.5 µL of 6xHis Protein ladder 
(Qiagen, Germantown, MD) was also loaded.  Two hundred millivolts was applied to the gel 
submerged in SDS-PAGE running buffer (25 mM Tris, base, 192 mM glycine, and 0.1% SDS) 
for ~ 30 min.  Following electrophoresis separation, the gel was developed or transferred to the 
western blot using the procedure described below.  Development of the gel involved staining 
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with Coomassie stain (45% methanol, 10% acetic acid, and 0.1% w/v Coomassie) for 30 minutes 
followed by soaking in a strong destaining solution (45% methanol and 10% acetic acid) for 30 
minutes and a weak destaining solution (10% methanol and 5% acetic acid) overnight. 
Western Blot:  Western blot analysis was used to determine the presence of a histidine tagged 
protein in expression samples.  Samples run on an SDS-PAGE gel were transferred to a 
polyvinylidine difluoride (PVDF) membrane (Bio-Rad, Hercules, CA) by placing the gel against 
an activated PVDF membrane between filter paper (Bio-Rad, Hercules, CA), foam pads, and a 
holder cassette for use in a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad, Hercules, 
CA).  The hydrophobic PDVF membrane was activated by soaking in 100% methanol for 1 
minute followed by immersion in water for 3 minutes.  The holder cassette was submerged in 
western transfer buffer (20% v/v methanol, 150 mM glycine, and 20 mM Tris base) and oriented 
with the gel towards the cathode and PVDF membrane to the anode. A current of 100 mA 
overnight at 4 ˚C or at 200 mV for 1 hour at room temperature with an ice pack in the apparatus 
was applied to complete the protein transfer to the PDVF membrane.   
 Following electrophoretic transfer, the membrane was washed with TBS buffer (10 mM 
Tris-HCl, pH 7.5, 150 mM sodium chloride) twice for 10 minutes before blocking with 10 mL of 
0.3% bovine serum albumin (BSA) in TBS buffer for 1 hour with gentle rocking to prevent non-
specific binding of the antibody to the membrane.  After blocking, the membrane was washed 
with TBS-TX buffer (20 mM Tris-HCl, 500 mM sodium chloride, 0.05% Tween 20, and 0.2% 
Triton X-100) twice and TBS buffer once for 10 minutes each. The washing procedure was 
repeated following incubation of the membrane with a 1:2,000 ratio of the penta-His primary 
mouse antibody (Qiagen, Germantown, MD) in 0.3% BSA TBS solution for 1 hour.  A 
secondary anti-mouse IgG-alkaline phosphatase antibody was applied to the blot with a 1:4,000 
	   141	  
ratio in a 0.3% BSA TBS solution and reacted for 1 hour before washing for 10 minutes with 
TBS-TX buffer four times.  The bands on the western blot were visualized through incubation 
with the 5-bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium (BCIP/NBT) color 
development solution (Sigma Aldrich, St. Louis, MO) for 20-30 minutes without rocking before 
the reaction was quenched with 1% acetic acid for 15 minutes followed by rinsing with water. 
Absolute Absorption Assay and Carbon Monoxide Difference Assay:  The absolute absorption 
and carbon monoxide difference assays for the determination of P450 concentration followed the 
protocol described in chapter 2 with one modification.  Additionally, when Tris buffers were 
used, 50 µM progesterone was required in the assay buffer as no absorbance maxima was 
observed without a ligand present. 
Spectral Ligand Binding Assays: Determination of the spectral dissociation constant for 
CYP21A2 with progesterone (Acros Organics via Fisher Scientific, Pittsburgh,VA) and 17α-
hydroxyprogesterone (MP Biomedials, Solon, OH) used five centimeter path length cuvettes and 
the tight binding equation to determine Kd values as described in chapter 2. 
Kinetic analysis:  Metabolism assays utilized progesterone as the substrate with 11-
deoxycorticosterone (Sigma Aldrich, St. Louis, MO) as the metabolic product.  As with the 
CYP2A enzymes, CYP21A2 required the presence of P450 oxidoreductase (POR) for 
metabolism, but the ratio of P450 to POR needed to be established along with the necessity of 
the presence of cytochrome b5.  P450, POR, and cytochrome b5 comprise the reconstituted 
protein system (RPS).  Evaluation of the RPS ratio and incubation times and temperatures is 
described in the results section.  Reaction times with substrate, RPS, 1 mM NADPH, and buffer 
(50 mM Tris, HCl pH 7.4 and 5 mM magnesium chloride) were also varied as described in the 
results section.  The final assay volume was 500 µL, and all reactions were terminated with 300 
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µL of 20% trichloroacetic acid.  The samples were centrifuged at 4 ˚C and 4,500 x g for 8 
minutes and 600 µL was transferred into HPLC vials.  Fifteen microliters were injected onto a 
Luna C18 reverse phase column (Phenomenex).  The mobile phase consisted of 64% solvent A 
(0.2% acetic acid) and 36% solvent B (100% acetonitrile).  Each sample was analyzed for 
absorption at 248 nm over the course of 20 minutes at 1.5 mL/min.  Under these conditions, 11-
Deoxycorticosterone eluted at 4.1 minutes, while progesterone eluted at 14.6 minutes. 
Crystallography: De novo screening was performed with purified CYP21A2 protein 
concentrated to 14-25 mg/mL. The protein solutions were mixed in a 1:1 ratio with the 
commercial sparse matrix screen in a 1.2 µL drop.  Crystal screens 1 and 2 (Hampton Research, 
Aliso Viejo, CA), Wizard screens 1-4 (Emerald Biosystems, Bainbridge	  Island,	  WA), PEG/Ion 
(Hampton Research, Aliso Viejo, CA), and MembFac 2 (Hampton Research, Aliso Viejo, CA) 
comprised the panel of screens that were used in Corning 96 well sitting drop plates (Hampton 
Research, Aliso Viejo, CA).  Crystallization conditions were optimized with 24 well plates 
(Hampton Research, Aliso Viejo, CA) utilizing hanging drop vapor diffusion as detailed in the 
results section. 
Results  
Protein Modifications11 
 The CYP21A2 gene was modified from the full-length form by a Δ2-28 amino acid N-
terminal transmembrane deletion and additions of a N-terminal MAKKTSSKGK solubility tag, a 
6 residue C-terminal histidine tag, 5´ NdeI restriction site, and a 3´ HindIII restriction site.  The 
modified gene was cloned into a pCW vector and transformed in DH5α/pGro7 E. coli competent 
cells. 
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Expressions and Purifications 
 CYP21A2 expressed well in DH5α/pGro7 E. coli competent cells resulting in ~30 g of 
dark brown cell pellet from 2.25 L of culture.  A western blot with an anti-His antibody 
confirmed the presence of histidine-tagged protein at ~55 kDa at 24 and 48 hours after induction, 
which correlates well with the expected molecular weight of 54.5 kDa for CYP21A2.  Due to the 
lack of specificity of the anti-His antibody, multiple dark bands were observed, but it was clear 
that expression of a ~55 kDa histidine-tagged protein was induced. 
The CYP21A2 purifications followed the CYP2A purification protocol with cell lysis 
mediated through lysozyme, homogenization, and sonication and then followed by detergent 
extraction and ultracentrifugation.  The enzyme was purified through Ni-NTA affinity and cation 
exchange chromatography, followed by size exclusion chromatography when the protein was to 
be used for crystallography.  Primary changes to the CYP2A protocol included the use of Tris-
based buffers in addition to potassium phosphate buffers, 0.2% Emulgen 913, and the presence 
of progesterone during some purifications.  Purity of the protein samples was determined through 
SDS-PAGE. 
The first purification used Tris buffers with 4.8 mM Cymal-5 and resulted in CYP21A2 
protein with only trace impurities after cation exchange chromatography according to SDS-
PAGE (Figure 5.2 CM).  Unfortunately, a significant quantity of the CYP21A2 protein was not 
stable during the purification and ultimately precipitated, resulting in substantial losses.  This can 
be visualized by comparing the amount of active P450 enzyme and inactive P420 enzyme using 
the reduced carbon monoxide difference spectra at the various purification stages (Figure 5.3).  
For example, the supernatant from ultracentrifugation contained 664 nmol of solubilized 
CYP21A2, but Ni-NTA affinity chromatography elution fractions contained 12 nmol P450 and 
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80 nmol P420.  After cation exchange chromatography, the sample consisted of 20 nmol of P450 
and 20 nmol of P420. 
Another interesting observation was the elution of several green fractions from the Ni-
NTA column followed by the normally observed red fractions.  Absolute absorption and carbon 
monoxide difference assay spectra indicated that the 67 nmol of P420 that was present in this 
green fraction was bound to a type II ligand, which is attributed to the histidine present in the Ni-
NTA wash and elution buffers.  In addition, these green fractions contained more impurities 
according to SDS-PAGE (Figure 5.2 Ni E. (Green)) and were not included in the remainder of 
the purification.  At this stage it was unclear if the purer red fractions (Figure 5.2 Ni (Red)) also 
had a type II ligand bound (λmax = 420 nm), but after the CM column, CYP21A2 had a Soret 
peak at 422 nm indicative of a type II ligand bound in the active site.  
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Figure 5.2. SDS-PAGE results for the purification of CYP21A2 with Tris buffers and 4.8 mM 
Cymal-5 indicate that the samples contained only trace impurities following cation exchange 
chromatography.  SDS-PAGE gel key is as follows (S): Solubilized CYP21A2 following 
detergent extraction and ultracentrifugation, (Ni FT): Ni-NTA flow through during sample 
loading, (Ni W): Ni-NTA wash fractions, (Ni E.): Ni-NTA elution (Green) and (Red) fractions, 
(CM): cation exchange elution fractions, (X): empty lane or unrelated sample, and (MW): dual 
color molecular weight ladder. 
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Figure 5.3. Reduced carbon monoxide difference assay spectra from the purification of 
CYP21A2 with Tris buffers and 4.8 mM Cymal-5 following A) ultracentrifugation, B) Ni-NTA 
affinity chromatography, and C) cation exchange chromatography.  
A       B 
  
C  
 
 
 The second purification with CYP21A2 used 0.2% Emulgen 913 rather than 4.8 mM 
Cymal-5 and resulted in 10-fold more P450 following cation exchange chromatography for a 
total of 220 nmol.  Absolute spectra were consistent with water-bound iron with a Soret peak at 
418 nm after Ni-NTA affinity and cation exchange chromatography even though progesterone 
was present in the cuvette but not purification buffers.  Since progesterone is a type I ligand,11 a 
Soret peak should have shifted to 393 nm but no shift was observed.  Additionally, both red 
(Figure 5.4 Ni E. (Red)) and green fractions (Figure 5.4 Ni E. (Green)) were again observed 
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eluting during Ni-NTA affinity chromatography, but only the red fractions were purified further.  
SDS-PAGE analysis indicated trace impurities following cation exchange but the most 
prominent band was at 55 kDa (Figure 5.4 CM), and this protein was aliquotted for use with 
initial binding and kinetic analysis.  These results indicated that 0.2% Emulgen 913 was a better 
detergent for purification of CYP21A2 even though 4.8 mM Cymal-5 resulted in slightly purer 
protein.  Additional purification results for CYP21A2, which included size exclusion 
chromatography for use in protein crystallography can be found under the crystallography 
subsection.   These results indicate that human CYP21A2 was successfully expressed and 
purified in sufficient quantities for use in initial biochemical studies. 
 
Figure 5.4. SDS-PAGE results for the purification of CYP21A2 with Tris buffers and 0.2% 
Emulgen 913 indicate that the final sample contained only trace impurities following cation 
exchange chromatography. SDS-PAGE gel key is as follows (S): Solubilized CYP21A2, (Ni 
FT): Ni-NTA flow through, (Ni W): Ni-NTA wash, (Ni E.): Ni-NTA elution (Green) and (Red) 
fractions, (CM): cation exchange, and (MW): dual color molecular weight ladder. 
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Protein Crystallography 
 Protein crystallography requires large quantities of monodisperse pure enzyme.  The 
previous purification results demonstrated that large quantities could be obtained.  However, size 
exclusion chromatography was added as an orthogonal purification step to remove any remaining 
impurities.  Size exclusion chromatography has also been known to separate P420 and P450, 
(Personal communication with Dr. Natasha DeVore) and some P450 enzymes require this 
chromatographic step for crystal formation.   Additionally, in the process of producing protein 
for crystallography with size exclusion chromatography, we learned some additional information 
about the earlier steps of CYP21A2 purifications.  
Protein crystallization is an iterative process and often requires the evaluation of 
numerous variations to find the optimal conditions for crystal growth.  In the case of CYP21A2, 
purification trials with various buffers, detergents, and the presence or absence of ligand were 
evaluated.  The purified protein was concentrated to 14-25 mg/mL with either 50 µM 
progesterone or 50 µM 17α-hydroxyprogesterone and used in de novo screening in 96 well 
plates. 
Tris Buffers 
The first purification of CYP21A2 for crystallography used Tris buffers with 4.8 mM 
Cymal-5, and included 50 µM progesterone in every stage of the purification in an effort to 
stabilize the enzyme.  While 4.8 mM Cymal-5 was not optimal for stabilizing CYP21A2, this 
detergent has been successfully used with other P450 enzymes resulting in crystal structures.16,17 
Unfortunately, the inclusion of ligand did not prevent protein precipitation as precipitate was 
observed at each purification step, yielding only 37.4 nmol of pure enzyme following size 
exclusion chromatography (Figure 5.5 cymal-5 SEC (red)).  This yield was a significant 
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reduction from the 1160 nmol of solubilized P450 initially present following ultracentrifugation.  
However, this was sufficient protein to concentrate CYP21A2 bound to progesterone to 14 
mg/mL and survey the panel of available crystallization screens: Crystal screens I and II, Wizard 
screens I, II, III, IV, PEG Ion, and Memb Fac, but no crystal hits were observed.   
The next two purification protocols for crystallography used Tris buffers, 50 µM 
progesterone, and 0.2% Emulgen 913 as this detergent was more successful in stabilizing 
CYP21A2.  Following size exclusion chromatography, the elution fractions contained ≥78 nmol 
and 386 nmol of P450 enzyme respectively.  The protein from the first purification appeared to 
contain a smaller quantity of a 70 kDa impurity (Figure 5.5 SEC (black versus green)), but this 
may have been due to a well loading effect.  The purified protein was concentrated to 25 mg/mL 
and screened against the entire panel of available screens, but only phase separation and 
precipitate were observed.  The screening process did not require the entire quantity of purified 
CYP21A2, and the unused protein was stored at -80 ˚C for later use as described below. 
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Figure 5.5. SDS-PAGE gel evaluating protein purity for CYP21A2 purified with either 0.2% 
Emulgen (black and green) or 4.8 mM Cymal-5 (red) in Tris buffers.  Gel key is as follows (S): 
Solubilized CYP21A2, (Ni): Ni-NTA affinity elution fractions, (CM): cation exchange elution 
fractions, (SEC): size exclusion elution fractions and (MW): dual color molecular weight ladder. 
 
 
 Since the initial purification protocols for crystallography did not yield crystals, an 
alternative strategy was employed with thawed CYP21A2 protein.  In crystallization of the 
CYP2A enzymes, detergent combinations such as Anapoe-X-405 with either 0.5% Anapoe-35 or 
4.8 mM Cymal-5 proved to be successful.  This method was attempted prior to screening with 
the addition of 4.8 mM Cymal-5 to CYP21A2 purified with 0.2% Emulgen 913, but this method 
was also unsuccessful in producing crystals.  Figure 5.6 summarizes the crystallography attempts 
with Tris-based buffers. 
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Figure 5.6. Flow chart summary for the crystallography attempts with Tris based buffers. 
 
 
Potassium Phosphate Buffers 
The next step in crystallography was to exchange the Tris-based buffers for potassium 
phosphate buffers as buffers can also effect crystal formation.  Twice the purification of 
CYP21A2 was performed with 0.2% Emulgen 913 in the absence of ligand.  Following size 
exclusion chromatography, the first purification yielded 67 nmol of P450 and 57 nmol of P420.  
This was the first time a P450 peak was observed with purified CYP21A2 without a ligand 
present for stabilization, indicating that potassium phosphate buffers may be superior to Tris 
buffers for stabilization of the CYP21A2 enzyme.  The second purification yielded ≥419 nmol of 
P450 following size exclusion chromtography in the presence of ligand, which was a higher 
yield than any of the purification trials with Tris buffers.  The purified protein was concentrated 
with either 50 µM progesterone or 50 µM 17α-hydroxyprogesterone to 25 mg/mL.  In both 
cases, however, little or no shift was observed in the Soret peak λmax upon ligand addition. 
Cymal-5 Pufication 
SEC Yield: 37.4 nmol 
Ligand: 50 µM Progesterone 
Panel Screen: Crystal I/II, Wizard 
I/ II/III/IV, PEG Ion, Memb Fac 
No Crystal formation  
Emulgen 913 
Pufication 
SEC Yields: ≥78 and 386 nmol 
Ligand: 50 µM Progesterone 
Panel Screen: Crystal I/II, Wizard 
I/ II/III/IV, PEG Ion, Memb Fac 
No Crystal formation  
Detergent Combination 
 4.8 mM Cymal-5 added to 
CYP21A2 purified with 0.2% 
Emulgen 913 
Ligand: 50 µM Progesterone 
Panel Screen: Crystal I/II, Wizard 
I/ II/III/IV, PEG Ion, Memb Fac 
No Crystal Formation 
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De novo screening with the panel of crystallization screens resulted in multiple wells with 
phase separation and the first crystal hit with Wizard screen I #42.  Red plates with progesterone 
or 17α-hydroxyprogesterone formed with 15% ethanol and 0.1 M Tris, pH 7.0 (Figure 5.7).  It is 
unknown as to which ligand is bound because of a labeling error.  
 
Figure 5.7. Red plates formed with Wizard screen I #42 with CYP21A2 purified with 0.2% 
Emulgen 913 in potassium phosphate buffers.  Image contrast and brightness were adjusted for 
better visualization of the crystals. 
 
 
 The next step was to duplicate these crystals to demonstrate reproducibility and to 
optimize crystallization conditions with the goal of generating larger single crystals that were of 
diffraction quality.  Unfortunately, attempts to duplicate the original crystal did not yield the 
same results, and attempts at optimizing the precipitant solution in either 24 or 96 well plates 
have been unsuccessful to date.  Optimization included varying the ethanol content from 1-15% 
with 0.05 M – 0.175 M Tris, pH 7.0. However, it should be noted that these duplication and 
optimization attempts used CYP21A2 protein that had been previously stored at -80 ˚C rather 
than freshly purified.  In addition, a new precipitant solution was used rather than the older 
original stock solution, and only precipitated protein was observed.  Subsequent screening of the 
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original precipitant solution with a lower protein concentration also did not yield success.  The 
original stock solution and protein concentration will be examined once more with a future 
purification. 
 Due to the lack of success with optimization conditions, and the recent publication of the 
bovine CYP21A2 structure, additional crystallization solutions were examined.15 The bovine 
CYP21A2 enzyme was crystallized with 5-15% PEG 3350, 0.5 M ammonium sulfate, and 0.1 M 
HEPES, pH 7.0 with a protein concentration of 11 mg/mL.15  This solution was used as a starting 
point for a 24 well plate optimization screen with 5-15% PEG 3350, 0.5 M ammonium sulfate, 
and 0.075 M – 0.15 M HEPES, pH 7.0.   Protein previously stored at -80 ˚C was thawed and 
diluted to 11 mg/mL with CM elution buffer containing either 50 µM progesterone or 50 µM 
17α-hydroxyprogesterone.  The diluted protein solution also contained either 0.2% Emulgen 913 
or a combination of 0.2% Emulgen 913 with 4.8 mM Cymal-5.  Unfortunately no crystals were 
observed, but this could have been because the human enzyme was not freshly purified, 
differences between bovine and human CYP21A2, or differences in the purification detergent.  
Compared to human CYP21A2 which was purified with 0.2% Emulgen 913, the bovine 
CYP21A2 was purified with 1% cholate and 1% Tween 20 and later combined with ~ 5 mM 
Cymal-5 for crystallization.  
Finally, the bovine CYP21A2 crystallization solution was similar to the CYP2A and 
CYP17A1 crystallization solutions (30% PEG 3350, 0.2-0.3 M ammonium sulfate, 0.175 M Tris 
pH 7.0-8.5, and +/-3% glycerol).  Thawed CYP21A2 purified with potassium phosphate buffers 
was diluted to a final concentration of 11 mg/mL with either 0.2% Emulgen 913 or in 
combination with 4.8 mM Cymal-5 in buffer containing 50 µM progesterone or 50 µM 17α-
hydroxyprogesterone.  The protein solution was equilibrated against 30% PEG 3350, 0.175 M 
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Tris pH 7.0, 0.3 M ammonium sulfate, and +/-3% glycerol with hanging drop vapor diffusion in 
a 24 well plate.  Only the wells containing progesterone and 0% glycerol resulted in phase 
separation, but no crystals were observed.  Figure 5.8 summarizes the crystallization 
experimentation with CYP21A2. 
 
Figure 5.8.  Flow chart summary for the crystallography with potassium phosphate buffers that 
led to the first protein crystals for human CYP21A2.  All screens included 50 µM progesterone 
or 50 µM 17α–hydroxyprogesterone in the protein drops. 
 
 
 
In summary, CYP21A2 was successfully purified and crystallized with potassium 
phosphate buffers, but these crystals have not been replicated to date (Figure 5.8).  Time has 
been the limiting factor thus far, but future experiments will include purifying CYP21A2 with 
1% cholate and 1% Tween-20 for use with the bovine CYP21A2 precipitant solutions or with 
0.2% Emulgen 913 for replication of the original precipitant conditions that resulted in the 
crystal hit.  Fresh protein will be used with these conditions to eliminate questions regarding 
fresh versus frozen protein as crystallography can be sensitive to freeze/thaw cycles.   
Substrate Binding 
 The equilibrium dissociation constants for the substrates progesterone and 17α-
hydroxyprogesterone were determined as described in chapter 2 with purified CYP21A2, 5 cm 
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path length cuvettes, and the tight binding equation.  Titration data was not optimal due to the 
small change in absorbance upon ligand addition, consistent with no observable shift in absolute 
spectra when ligand was present in purification samples.  However in difference mode, it was 
apparent that addition of progesterone resulted in a blue shift in the Soret peak, causing a small 
increase at ~390 nm and decrease at ~430 nm indicative of a type I ligand (Figure 5.9A).  Fitting 
the change in absorbance versus progesterone concentration with the tight binding equation 
yielded a Kd value of 0.11 µM (Figure 5.9B).  However, this value may be higher than the true 
value.  The protein concentration was 0.1 µM indicating that the assay detection limits may have 
been reached.  Addition of 17α-hydroxyprogesterone to CYP21A2 also resulted in low 
absorption changes and an increase and decrease in the Soret peaks at 390 nm and 423 nm, 
respectively, indicating that 17α-hydroxyprogesterone was also a type I ligand (Figure 5.9C).  
However plotting the change in absorption versus 17α-hydroxyprogesterone concentration with 
the tight binding equation was more accurate in determining the Kd value as the curve fit resulted 
in a dissociation constant of 0.68 µM (Figure 5.9D), which was >6-fold above the protein 
concentration.   
To determine if the CYP17A1 inhibitor and prostate cancer drug abiraterone is selective 
versus CYP21A2, a preliminary binding assay was performed with CYP21A2 and abiraterone.  
Addition of abiraterone to 0.1 µM purified CYP21A2 yielded only a small decrease in 
absorbance at 411 nm and no increase at 385 nm (Figure 5.9E).  By comparison, abiraterone 
bound tightly to CYP17A1 with a strong increase in absorbance at 432 nm and a corresponding 
decrease in absorbance at 409 nm, resulting in a Kd value <100 nm (Figure 5.9F). This result was 
promising for abiraterone selectivity for CYP17A1 over CYP21A2. 
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Figure 5.9. Spectral ligand binding assays and equilibrium dissociation constant determination 
of CYP21A2 with A) and B) progesterone, C) and D) 17α-hydroxyprogesterone, and E) 
abiraterone. F) Titration of CYP17A1 with abiraterone for comparison with CYP21A2 (Data 
courtesy of Dr. Natasha DeVore).  
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Steady-state Kinetics 
 Evaluation of steady-state kinetics for purified human CYP21A2 has been an iterative 
process.  Before the kcat and Km values can be determined for this enzyme, a series of 
experiments was necessary to establish optimal assay conditions and confirm linearity of product 
formation over time.  Based largely on prior experience with the CYP2A enzyme assays, initial 
reactions were performed using 50 pmol P450 enzyme, 50 µM progesterone, a 20 minute 
incubation of reconstituted protein system (RPS) at 4 ˚C, and a reaction time of 10 minutes 
initiated by 1 mM NADPH at 37 ˚C.  The first set of experiments investigated the optimal ratio 
of P450 enzyme to POR in the RPS and determined the impact of cytochrome b5.  Ratios of 
P450: POR were varied as follows: 1:1, 1:2, 1:4, 1:6.  Additionally, the influence of cytochrome 
b5 was evaluated by repeating the assay with P450: POR: cytochrome b5 ratios of 1:1:2, 1:2:2, 
1:4:2, and 1:6:2.  These results demonstrated that the P450:POR ratio of 1:4 ratio was optimal as 
determined by maximal product formation (Figure 5.10).  Since the inclusion of cytochrome b5 
did not increase product formation, it was subsequently excluded from metabolism assays.  
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Figure 5.10. Results from the evaluation of RPS ratios with CYP21A2 with duplicate samples.  
Sample #1 is in blue and sample #2 is in red. 
 
 
An observation made during the RPS ratio test above was that although the trends were 
relatively the same, duplicate samples for almost all ratios were not consistent.  The only 
difference between duplicate samples was the pre-incubation time at 37 ˚C prior to NADPH 
reaction initiation.  Samples were analyzed with pre-incubation times of 1, 2, 3, 4, 5, 6, 7, 8, 9, 
and 10 minutes, but the results did not yield any significant difference between the time points, 
indicating that the pre-incubation times was not the source for the variation between samples.  
The next step in assay optimization was to evaluate the time and temperature of the RPS 
incubation. Samples were incubated at room temperature and at 4 ˚C for 20, 30, 40, 50, or 60 
minutes.  RPS samples incubated at 4 ˚C yielded inconsistent product formation (Figure 5.11A), 
while room temperature incubations were much more consistent (Figure 5.11B).  Additionally, 
product formation did not significantly increase between 30-60 minutes, and 30 minute 
incubations were used in subsequent assays.  This analysis revealed the source of the 
inconsistencies observed above.   
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Figure 5.11.  Results from the evaluation of the RPS incubation conditions at A) 4˚C and at 
B)room temperature with varying time points. 
            
 
 Once the protein ratios and incubation conditions were established, the next step towards 
determining the kcat and Km values was the determination of steady state conditions with linear 
product formation and less than 10% substrate depletion.  This has proven to be more 
challenging due to rapid substrate turnover resulting in significant substrate depletion.   When 50 
pmol of CYP21A2 in a 1:4 ratio with POR was incubated with 5 µM progesterone, the substrate 
was completely depleted within 5 minutes.  The progesterone concentration was increased to 100 
µM and indicated the reaction was linear through 10 minutes, but linearity began to deteriorate 
between 10 and 20 minutes (Figure 5.12A).  In addition the substrate concentration was 
significantly reduced to 63%, 52%, 32%, 19%, and 12% of the initial concentration over the 
course of 5, 10, 20, 30, and 40 minutes, respectively (Figure 5.12B). 
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Figure 5.12.  A) Analysis of product formation with 100 µM progesterone and 50 pmol of 
CYP21A2 indicated the reaction was linear through perhaps 10 minutes.  B) However, the HPLC 
chromatogram revealed significant substrate decrease in the reactions from 0-40 minutes, with 
only 63% remaining after 5 minutes.             
 
 
 
 In an attempt to maintain sufficient progesterone levels for steady state analysis, the 
protein concentration was reduced to 20 pmol and reaction times of 0, 2, 4, 6, 8, and 10 minutes 
with 10, 20, 40, 60, 80 and 100 µM progesterone were evaluated.  Reactions were linear through 
6 minutes at all concentrations (Figure 5.13), but the progesterone concentration was reduced 
>50% at 10 µM progesterone and 6 minutes.  
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Figure 5.13.  Representative results for progesterone metabolism with linear product formation 
from 0-6 minutes with A) 10 µM, B) 40 µM, and C) 80 µM initial substrate concentrations.  
	  	   	    
 
 The CYP21A2 concentration was further reduced to 2 pmol, but with a reaction volume 
of 500 µL, the product formation was inconsistent.  The next step is to reduce the reaction 
volume to 250 µL and will be completed in the near future. 
Discussion 
Protein Modifications 
 The human CYP21A2 gene was modified to generate a CYP21A2 protein with a Δ2-28 
amino acid N-terminal transmembrane truncation, a MAKKTSSKGK N-terminal solubility tag, 
and a 6-residue C-terminal histidine tag and was cloned into the pCW vector.  These 
modifications were consistent with the bovine CYP21A2 construct11 and similar to other P450 
constructs that resulted in large quantities of purified enzyme.18,19 This construct was 
transformed into DH5α/pGro7 competent cells as this cell line proved advantageous for bovine 
CYP21A2 expression.11  
Expressions, Purifications, and Crystallography  
The modified construct expressed at 27 ˚C for 48 hours in DH5α/pGro7 competent E. coli 
cells appeared to result in significant production of CYP21A2 protein.  Western blots confirmed 
the presence of a histidine tagged enzyme at the expected molecular weight of 55 kDa after 
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induction.  CYP21A2 was purified with various combinations of detergents and buffers, and 
each variation proved advantageous in a specific area.  Initially Tris buffers were used with 
either 4.8 mM Cymal-5 or 0.2% Emulgen 913. Emulgen 913 (0.2%) was more successful in 
stabilizing CYP21A2 as measured by reduced carbon monoxide difference spectra (P450 versus 
P420) compared to Cymal-5.  However, the use of 4.8 mM Cymal-5 resulted in purer protein 
following cation exchange, but protein was lost to precipitation at each purification step.  Trace 
impurities were present in CYP21A2 purified with 0.2% Emulgen 913 following cation 
exchange chromatography.  However, with Emulgen 913 the 55 kDa band for CYP21A2 was 
very prominent, and this protein was then used for initial functional characterization of the 
enzyme.  
Of particular note is that CYP21A2 required the presence of a substrate in the assay 
buffer to generate the expected P450 (or even P420) maxima.  It appears that CYP21A2 requires 
a ligand for stabilization, at least to form the traditional carbon monoxide complex. 
Purification of CYP21A2 through size exclusion chromatography with Tris buffers and 
4.8 mM Cymal-5 or 0.2% Emulgen 913 for protein crystallography mimicked the results 
described above.  The purification with 4.8 mM Cymal-5 resulted in purer protein, but with a 
loss of 1120 nmol of P450 between solubilization and size exclusion due to precipitation.  
CYP21A2 purified with 0.2% Emulgen 913 resulted in larger quantities of protein, but the 
protein samples had trace impurities ≥70 kDa.  However, protein purified with Tris buffers did 
not yield crystals following de novo screening with or without detergent combinations. 
The next substantial modification of the purification protocol exchanged Tris buffers for 
potassium phosphate buffers.  This exchange proved advantageous.  Potassium phosphate buffers 
were more successful in stabilizing CYP21A2 as P420 and P450 peaks were observed in reduced 
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carbon monoxide difference spectra at each stage of the purification without a ligand present.  In 
addition, the use of potassium phosphate buffers was able to increase the yield when comparing 
the best purification results from each buffer system.  In the presence of either 50 µM 
progesterone or 50 µM 17α-hydroxyprogesterone, the Tris buffer purification sample contained 
536 nmol of protein by absolute absorption assay and 386 nmol of P450 by reduced carbon 
monoxide difference spectra, while the potassium phosphate buffers had 1018 nmol of protein by 
absolute absorption assay and ≥419 nmol by reduced carbon monoxide difference spectra.  The 
yield of ≥419 nmol is likely lower than the actual value as the assay did not go to completion in 
that only a single scan was completed for this sample rather than several scans over the course of 
40 minutes until the P450 peak no longer increased.  The purpose of the reduced carbon 
monoxide assay at this point in the purification was to confirm the presence of active enzyme 
before crystallography rather than to determine the final P450 concentration since the absolute 
absorption spectra is more consistent between purification runs in determining the final protein 
concentration for crystallography.   
Finally, the primary advantage of the potassium phosphate buffers was the formation of 
CYP21A2 crystals in the form of red plates with Wizard screen I solution #42 (15% ethanol and 
0.1 M Tris, pH 7.0).  Unfortunately, attempts to optimize or reproduce the crystals in both 96 and 
24 well plates have been unsuccessful to date.  However, reproducibility attempts were 
performed with previously frozen CYP21A2 rather than freshly purified, and it is unknown 
whether a freeze/thaw cycle influences crystal growth.  Frozen protein was used due to time 
constraints, as three days were required to complete a single purification, and to not waste the 
large quantities of CYP21A2 obtained during the purification.  Other crystallization efforts 
included optimization of this precipitant solution by varying the individual components with both 
	   164	  
of the known CYP21A2 substrates, and use of the precipitant solutions that led to the bovine 
CYP21A2 and human CYP17A1 crystal structures, as these solutions were similar. 
 In summary, CYP21A2 was successfully expressed, purified, and crystallized.  The 
DH5α/pGro7 cell line with the pCW plasmid was conducive for the expression of large 
quantities of CYP21A2.  The 21-hydroxylase enzyme tolerated purification with 4.8 mM Cymal-
5 or 0.2% Emulgen 913 with either Tris and potassium phosphate buffers, but 0.2% Emulgen 
913 with potassium phosphate buffers proved more advantageous in stabilizing CYP21A2 and 
resulted in crystal formation.  However, protein crystals have been difficult to reproduce and 
future crystallization attempts should include freshly purified CYP21A2 with the original protein 
concentration and the stock solution from the Wizard screening kit.  In addition, a purification 
with 1% cholate and 1% Tween-20 would be interesting as this was successfully used in 
purifying bovine CYP21A2 for structure determination. 
Dissociation Constant Determination: 
 Initial characterization of the purified CYP21A2 enzyme included the spectral 
determination of equilibrium dissociation constants for the CYP21A2 substrates progesterone 
and 17α–hydroxyprogesterone.  The results indicated that 17α–hydroxyprogesterone did not bind 
CYP21A2 (Kd = 0.68 µM) as tightly as progesterone (Kd = ≤0.11 µM).  It is also worth noting 
that the dissociation constant for progesterone is likely to be lower than the value indicated due 
to the limitations of the binding assay.  Regardless, these values are significantly lower than the 
only known dissociation constants for human CYP21A2 reported in the literature.4  Guzov et al 
reported Kd values for progesterone (Kd = 14.7 µM) and 17α–hydroxyprogesterone (Kd = 31.1 
µM) that were >100-fold and 45-fold, respectively, higher than the values that I experimentally 
determined.  However, the reliability of the literature results is questionable.  In comparison to 
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the results that I determined, bovine CYP21A2 and CYP17A1, which does not metabolize 
progesterone as efficiently, also have submicromolar binding constants with 17α–
hydroxyprogesterone (Kd ≈ 50 nM)15 and progesterone (Kd = 229 ± 14 nM),16 respectively. 
 While the submicromolar Kd values are consistent between the human and bovine 
CYP21A2 enzymes, a direct comparison may not be entirely accurate. First, Zhao et al reported 
a Kd value of ≈ 50 nM for 17α–hydroxyprogesterone for bovine CYP21A2, but the experimental 
conditions contained only 2 µM CYP21A2, indicating that the determination of a submicromolar 
Kd was beyond the detection limits of their assay.  Additionally, the experimental values reported 
in this dissertation were determined with the tight binding equation for saturation binding with 
ligand depletion, which only accounts for a single substrate bound within the active site.  This 
distinction is important as the CYP21A2 bovine structure had two molecules of 17α–
hydroxyprogesterone bound,15 which would deplete the substrate in solution more quickly, and it 
is unknown whether substrates bind in the same manner or if the human enzyme differs in this 
respect.  We did not observe the sigmoidal trends for 17α–hydroxyprogesterone binding to 
human CYP21A2, but the distal 17α–hydroxyprogesterone binds far enough away from the iron 
that no direct spectral change is expected from this interaction.  A crystal structure with human 
CYP21A2 and progesterone or 17α–hydroxyprogesterone would help to clarify these questions 
regarding the number and orientation of the substrates. 
Steady-state Kinetics 
 In addition to needing functional enzyme for investigation of CYP21A2 structure and 
function itself, the evaluation of CYP21A2 as a counter-target for CYP17A1 inhibitors requires 
the development of a metabolism assay and determination of kcat and Km values.  However, 
before these values can be determined the assay conditions need to be established.  First, the 
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optimal ratio of P450 to its redox partner POR was determined.  A 1:4 ratio of P450 to POR 
resulted in the highest product formation.  The inclusion of cytochrome b5, which has been 
known to facilitate catalytic activity for some P450 enzymes,20 did not enhance the rate of 
reaction and was not included in subsequent assays. The temperature and time of the RPS 
incubation did significantly impact the reactions.  Incubation at 4 ˚C yielded inconsistent results 
at every time point, while 30 minutes at room temperature provided consistent results.  However, 
these conditions may need to be revised due to the significant substrate turnover rate described 
below. 
The final step was the establishment of steady state conditions for the progesterone 
metabolism, which is still ongoing.  In order for steady state conditions to be achieved, product 
formation must remain linear over time and substrate depletion must be ≤ 10%.  Achieving a 
linear reaction rate is proving to be easier than maintaining substrate concentrations in the 
reactions.  Fifty picomoles of protein completely metabolized 5 µM of progesterone within 5 
minutes and significantly reduced the substrate concentration of 100 µM progesterone to 12% of 
the starting concentration over the course of 40 minutes.  The protein concentration in the 
reactions was subsequently reduced to 20 pmol, and the rate of product formation was linear with 
concentration ranges of 10-100 µM progesterone for 0-6 minutes.  However, after 6 minutes the 
substrate was depleted by ≥50% compared to its original substrate concentration of 10 µM, 
suggesting a further decrease in protein concentration is necessary.  The utility of using 2 pmol 
of CYP21A2 in each assay remains undetermined, as a reaction volume of 500 µL was too large 
to obtain consistent product formation.  Future assays will reexamine 2 pmol of CYP21A2 with a 
smaller reaction volume of 250 µL.  Reducing the amount of protein present should decrease 
substrate depletion in metabolism assays with CYP21A2.  Reported kinetic values with the 
	   167	  
bovine CYP21A2 enzyme utilized 2 pmol of P450 with a radiography assay.15 Finally, future 
assay development will include the use of the substrate 17α–hydroxyprogesterone, which is 
expected to have equal or greater catalytic activity. 
Conclusions 
 In the development of CYP17A1 inhibitors for prostate cancer, it is important to evaluate 
obvious protein counter-targets that could challenge the selectivity of potential drug candidates.  
CYP21A2 binds a substrate and product of CYP17A1,1 and thus could potentially bind 
CYP17A1 inhibitors.  However, biochemical studies and thus screening of potential of 
CYP17A1 inhibitors with the human CYP21A2 enzyme have been limited due to the lack of 
available enzyme.  Expression of human CYP21A2 in E. coli has previously been achieved in 
low levels,4 but minimal research has been performed beyond evaluating genetic mutations and 
the determination of steady-state kinetic parameters and equilibrium dissociation constants for 
progesterone and 17α-hydroxyprogesterone. 
 The successful large-scale expression and purification of stable human CYP21A2 
described in this chapter has laid the foundation for evaluating the biochemical properties of 
CYP21A2.  This protein can be used to evaluate key amino acid residues impacting metabolic 
activity or evaluating CYP21A2 as a counter-target for CYP17A1 inhibitors.  In addition, the 
determination of a human CYP21A2 crystal structure is expected to elucidate the atomic level 
interactions governing substrate binding and provide insight into the differences between the 
human CYP17A1 and CYP21A2 enzymes that enable selectivity between the two enzymes.  In 
addition it would be interesting to compare the bovine and human CYP21A2 crystal structures 
and determine if the human enzyme also concurrently binds multiple substrates.   
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Chapter 6 
Cloning, Expression, and Purification of CYP11B1 
Introduction  
 As introduced in chapter 1, human cytochrome P450 11B1 (CYP11B1) is involved in the 
biosynthesis of cortisol. Understanding the structure and function of CYP11B1 is important for 
two reasons.  First, CYP11B1 is a potential therapeutic target for the treatment of cortisol-
dependent diseases such as Cushing’s disease.  Second, CYP11B1 is an important counter-target 
in the development of selective inhibitors of other steroidogenic P450 enzymes that bind and 
metabolize very similar substrates.  Both rational drug design of CYP11B1 inhibitors and the 
evaluation of CYP11B1 as a counter-target require a biochemical and biophysical understanding 
of the enzyme.  Unfortunately, biochemical interactions governing CYP11B1 activity remain 
poorly understood.  This is due to the lack of protein availability and in part to the instability of 
the enzyme during E. coli expression, purification,1 and detergent solubilization.2  
Cytochrome P450 11B1 is a β-hydroxylase enzyme that can act at either the C11 or C18 
position of select steroids.  Specifically, CYP11B1 primarily catalyzes the conversion of 11-
deoxycortisol to cortisol (kcat = 1.67 s-1, Km = 338.4 ± 30.2 µM) (Scheme 6.1A).  Additionally, 
although CYP11B1 is not the primary enzyme involved in 11-deoxycorticosterone metabolism in 
vivo, it has been shown to convert 11-deoxycorticosterone to either corticosterone (kcat = 0.85 s-1, 
Km = 179.5 ± 19.1 µM) or 18-hydroxy-11-deoxycorticosterone to a minor extent (Scheme 
6.1B).1,3 The metabolites, corticosterone and 18-hydroxy-11-deoxycorticosterone, can be further 
converted to 18-hydroxycorticosterone by CYP11B1.3  In vivo, however, the 11-
deoxycorticosterone reactions are primarily catalyzed by a second human P450 enzyme, 
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CYP11B2, which is 93% identical to CYP11B1 and plays an important role in the formation of 
mineralocorticoids (Scheme 6.1B).3-7  
 
Scheme 6.1. Metabolic conversions of A) 11-deoxycortisol and B) 11-deoxycorticosterone by 
CYP11B enzymes ultimately resulting in the formation of aldosterone and cortisol.3,5,6,8 The 
larger arrow size indicates the enzyme primarily responsible for the catalytic conversion in vivo.  
 
 
The two human mitochondrial CYP11B enzymes differ in 32 out of 503 amino acids.4 
Previous research has shown that their activities can be interconverted through key amino acid 
substitutions.  For example, the S288G and V320A mutations impart CYP11B1 with the 18 
hydroxylation and oxidation steps, respectively, that are typically catalyzed by CYP11B2.9  
Meanwhile the CYP11B2 triple mutant L301P/E302D/A320V/ is able to increase cortisol 
production from wild type levels of 5% to 85% of CYP11B1 activity.5,6 Additional differences 
between CYP11B1 and CYP11B2 arise from gene regulation and location of expression.  
CYP11B1 is synthesized in the adrenal zona fasciculata and is controlled by 
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adrenocorticotrophic hormone (ACTH).4  CYP11B2 is expressed in the adrenal zona 
glomerulosa and regulated by angiotensin II and potassium as part of the renin angiotensin 
system.4 
Due to the critical role of CYP11B1 in cortisol production and maintaining homeostasis, 
aberrant activity in CYP11B1 can have severe impacts on human health.  Significant research 
has been performed towards the underlying genetic role of CYP11B1 deficiencies, which result 
in 5-8% of congenital adrenal hyperplasia (CAH) cases and is manifested by genital ambiguity 
and salt wasting.10  In addition, CYP11B1 deficiencies decrease cortisol secretion, and both CAH 
and cortisol reduction result in excess androgen production.11,12 Several CYP11B1 mutations 
such as P94L, S217I, T318R, and A368D have been identified as causing clinical CYP11B1 
deficiencies.13-15 Additionally, it has been found that hyperactive CYP11B1 results in an 
overproduction of cortisol and causes Cushing’s disease, presenting CYP11B1 as a therapeutic 
target.12 While Cushing’s disease is rare (2-3 cases per 1 million individuals),16 it is commonly 
caused by exogenous glucocorticoids or adenoma in the pituitary gland (70% of all cases), which 
secretes the CYP11B1 regulator.17 Treatments involve removal of the glucocorticoid source, 
surgical tumor removal, and/or the inhibition of cortisol formation through inhibition of the 
steroid biosynthetic pathway.17   
The available steroid-suppressing agents for the treatment of Cushing’s disease are 
limited to four FDA approved drugs and one in clinical trials (Figure 6.1).  The most commonly 
used inhibitor is the antifungal drug ketoconazole, which is a non-selective P450 inhibitor.17  
Secondly, metyrapone has been used in the diagnosis and treatment of Cushing’s disease, but is 
not widely administered due to excess mineralocorticoid formation resulting from CYP11B1 
inhibition.8,18 While this CYP11B1 inhibitor is not optimal, inhibition of CYP11B1 still remains 
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a promising target.  LC1699, which is still in clinical trials, inhibits the 11β-hydroxylase activity 
of both CYP11B1 and CYP11B2 for the treatment of hypertension and potentially Cushing’s 
Disease.19 Etomidate is the fourth drug, The typical use of etomidate is as a general anesthetic 
and as such requires extensive monitoring if used for the treatment of Cushing’s disease.8,17 
Finally, mifepristone is a glucocorticoid receptor antagonist and was recently approved by the 
FDA in February 2012.17  Wide scale effectiveness is yet to be determined. While these methods 
have been proven effective for the treatment of Cushing’s disease, none are optimal due to 
efficacy and non-selectivity. 
 
Figure 6.1. Inhibitors of steroid biosynthesis for the treatment of Cushing’s Disease.8,17 
 
 
Unfortunately, biochemical studies providing insight into CYP11B1 function leading to 
the design of novel CYP11B1 inhibitors and the evaluation of CYP11B1 as a counter-target have 
been limited.  Identification of key amino acid residues and subsequent site-directed mutagenesis 
studies have relied upon homology models based upon bacterial mitochondrial cytochromes 
P450.5,8,20 Biochemical studies have also been limited by the lack of reproducible large-scale 
expression of stable human CYP11B1. Most studies have been conducted in mammalian cell 
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lines such as V79,3,8 COS-1,5 and COS-7.9 Mammalian cell studies can result in valuable 
knowledge, but they cannot easily produce the large quantities that are necessary for structural 
and functional studies.  Only one large scale E. coli purification was reported to result in 400 
nmol/L.1  However, the reproducibility of the procedure may be questionable.  There has been no 
additional work citing this protocol, and experimentation described herein was unable to match 
the reported quantities.  Additional knowledge about the CYP11B1 enzyme has been inferred 
from homologous enzymes, which vary in activity from the human isozyme.  For example, there 
is only a single bovine β hydroxylase enzyme that is 73% identical to CYP11B1 and catalyzes 
the formation of corticosterone with a catalytic efficiency 1/10 of the human enzyme.1,21 Rats 
have 4 isoforms (CYP11B1, CYP11B2, CYP11B3, and CYP11B4).  While rat CYP11B1 and 
CYP11B2 have the same function as the human counterparts, CYP11B3 has the same function as 
CYP11B2 in neonatal rats, and CYP11B4 is a pseudogene.8,22 Rat CYP11B1 is 64% identical to 
the human CYP11B1 enzyme8 and possesses the additional ability to hydroxylate 11-
deoxycorticosterone at the C19 position.22  However, the rate of corticosterone formation for rat 
CYP11B1 is ~2.5 fold greater than the human recombinant enzyme.1  
The lack of information pertaining to the structure/function relationships of CYP11B1 
and the lack of availability of the enzyme has hindered the development of CYP11B1 inhibitors 
and evaluation of CYP11B1 as a counter-target.  The aim of my project was to further the 
biochemical understanding of the human CYP11B1 β hydroxylase.  This knowledge can be used 
towards the design of novel CYP11B1 inhibitors for the treatment of cortisol dependent diseases 
such as Cushing’s disease or to evaluate the selectivity of potential CYP17A1 inhibitors.  The 
work herein describes the necessary groundwork in evaluating expression and purification 
systems to enable functional and structural characterization of CYP11B1. 
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Materials and Methods 
Protein Modifications:  Codon-optimized human CYP11B1 cDNA was synthesized by Blue 
Heron Biotechnology (Bothel, WA) and engineered in the Blue Heron pUCminusMCS vector to 
contain a Δ3-25 amino acid N-terminal truncation, a C-terminal 4-residue histidine tag, and NdeI 
(CATATG) and HindIII (AAGCTT) restriction sites at the 5´ and 3´ flanking sites, respectively, 
to yield pUC11B1. These modifications from the full-length gene were identical to previous 
work that reported the generation of large quantities of purified enzymes. 1,4 Figure 6.2 displays 
an alignment of the full length and truncated human CYP11B1 enzymes.  
 
Figure 6.2. Amino acid sequence alignment of the full length and modified CYP11B1 gene.4  
Deleted residues from the N-terminal transmembrane region are colored red, while mutated or 
added residues in the N- and C-terminal regions are shown in blue. 
             10         20         30         40         50  
Full Length MALRAKAEVC MAVPWLSLQR AQALGTRAAR VPRTVLPFEA MPRRPGNRWL  
Truncated MA........ .......... .....TKAAR VPRTVLPFEA MPRRPGNRWL  
 
            490        500   
Full Length IKMVYSFILR PSMFPLLTFR AIN  
Truncated IKMVYSFILR PSMFPLLTFR AINHHHH  
 
 
Cloning: The pET17b and pUC11B1 plasmids were digested with NdeI and HindIII for one hour 
at 37 ˚C.  The DNA fragments were separated on a 0.8% agarose gel. The desired 3,256 base pair 
pET17b and the 1,464 base pair CYP11B1 fragments were excised and purified using the 
QIAquick Gel Extraction Kit (Qiagen, Germantown, MD).  The CYP11B1 insert and digested 
pET17b plasmid were ligated together using a quick ligation kit (New England Biolabs, Ipswich, 
MA), and the mixture was transformed into DH5α competent cells.  The cells were plated on LB 
plates containing 50 µg/mL ampicillin.  Individual colonies were grown in 5 mL LB cultures 
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containing 50 µg/mL ampicillin, and the plasmid DNA was isolated using QIAprep spin 
miniprep kit (Qiagen, Valencia, CA) and screened with restriction digest as the CYP11B1 gene 
introduces a unique MfeI restriction site.  Following restriction digest and gel electrophoresis, 
the entire CYP11B1 gene was sequenced by ACGT (ACGT, Wheeling, IL) using ACGT primers 
for the pET17b vector with the plasmid DNA that illustrated a single cut site.  This same 
protocol was also used to clone the truncated, histidine tagged CYP11B1 gene into a pCW 
plasmid, which was then sequenced with the forward pCW (5´ 
GGAAACAGGATCAGCTTACTCCC-3´) and reverse pCW (5´ 
GGCGTATCACGAGGCCCTTTCG-3´) primers. 
Site-Directed Mutagenesis: Site-directed mutagenesis was later used to insert the codons for two 
additional histidine residues at the C-terminus in order to extend the histidine tag from four to six 
amino acid residues.  QuikChange Site Directed Mutagenesis Kit (Agilent Technologies, Santa 
Clara, CA) was used with the forward primer 5´ 
CCACTCCTCACATTTCGCGCGATTAACCACCACCATCATCATCATTAAAAGCTTATG, 
reverse primer 5´ 
CGATAAGCTTTTAATGATGATGATGGTGGTGGTTAATCGCGCGAAATGTGAGGAGT
GG (where bold indicates the inserted nucleotides), and the pCW11B1 DNA template.  The 
mutation was confirmed by sequencing through ACGT. 
Expression: The pCW11B1 and pET17b11B1 plasmids were individually transformed into 
BL21(DE3)pLysS, JM109, DH5α, and Topp3 E. coli competent cells that already contained the 
pGro7 expression plasmid for GroEL, a chaperone protein.  Cells were plated on LB agar plates 
containing 50 µg/mL ampicillin and 20 µg/mL chloramphenicol to select for the CYP11B1 and 
pGro7 plasmids, respectively, following the transformation protocol in chapter 2.  Individual 
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colonies were used to start 5 mL LB cultures containing 50 µg/mL ampicillin and 20 µg/mL 
chloramphenicol incubated at 37 ˚C with shaking at 250 rpm.  These 5 mL cultures were used to 
inoculate 250 mL TB media containing 50 µg/mL ampicillin and 20 µg/mL chloramphenicol.  
Arabanose (500 µg/mL) was also included to induce expression of GroEL.  Later expression 
trials utilized larger 1 L cultures in either 2.5 L baffled or non-baffled flasks, as the size of the 
flask did not appear to effect the expression yield.  Baffled flasks were used for expression of the 
BL21(DE3)pLysS/pGro7 cell line as a slight increase in expression yield was observed over the 
non-baffled flasks.  Expression in the remaining cell lines did not appear to depend on whether 
the flasks were baffled or not and the non-baffled flasks were used.  In addition, the 1 L cultures 
were inoculated with a minimum of 15 mL from the overnight LB culture.   
Large-scale cultures were incubated at 37˚C with shaking at 250 rpm and P450 
expression was induced with 1 mM IPTG when an OD600 of 1.0-1.8 was reached, typically after 
2-3 hours.  Following induction and the addition of 1 mM of the heme precursor delta 
aminolevulinic acid, the temperature was reduced to 27 ˚C or 30 ˚C with shaking at 190 rpm.  
The cultures were allowed to grow for 48 hours before harvesting by centrifugation at 6,400 x g 
and storage of the cell pellets at -80 ˚C.  The cell pellets from two liters of the 
BL21pLysS/pGro7 expression were combined and resuspended with Tris resuspension buffer #2 
(50 mM Tris-HCl, 20% glycerol, and 300 mM NaCl) prior to storage at -80 ˚C since in this cell 
line natural production of lysozyme promotes cell lysis upon thawing. 
SDS-PAGE: SDS-PAGE gels followed the protocol detailed in chapter 5 for determining purity 
of purification samples or in preparation for western blot analysis. 
Western Blot:  Western blot analysis determined the presence of histidine tagged protein in 
expression samples used the procedure described in chapter 5. 
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Purification: Initial CYP11B1 purification protocols followed a published procedure1 with only 
minor changes. Changes included cell lysis following -80 ˚C storage rather than prior to storage 
in addition to the exchange of adenosine monophosphate for adenosine triphosphate in wash 
buffer B due to compound availability.  The purification trials began with resuspension of the 
BL21(DE3)pLysS/pGro7/pET17b11B1 cells either before or after -80 ˚C storage in resuspension 
buffer (50 mM Tris-HCl, pH 7.4, 250 mM sucrose, 0.5 mM EDTA, and 1 mg/mL lysozyme) 
with homogenization to lyse the cells and create a homogeneous solution.  Centrifugation at 
8,700 x g for 10 minutes was used to remove the cytosolic contents.  The pellet was resuspended 
in resuspension buffer 2 (50 mM potassium phosphate pH 7.4, 20% glycerol, 0.1 mM EDTA, 0.1 
mM dithiothreitol, 500 mM sodium acetate, 1.5% w/v sodium cholate, 1% v/v Tween 20, and 0.1 
mM phenylmethanesulfonyl fluoride) and sonicated 3 times for 30 seconds to further lyse the 
cells and extract the P450 enzyme with the detergent in the resuspension buffer.  
Ultracentrifugation at an average speed of 70,400 x g and 4 ˚C for one hour was used to separate 
the extracted P450 enzyme from the membranes.  The P450-containing supernatant was applied 
to a Ni-NTA resin (Qiagen, Valencia, CA) equilibrated with 3 column volumes of buffer A (50 
mM potassium phosphate, pH 7.4, 500 mM sodium acetate, 20% glycerol, 0.1 mM EDTA, 0.1 
mM dithiothreitol, 1% sodium cholate, 1% Tween 20, and 0.1 mM phenylmethanesulfonyl 
fluoride).  The column was washed with 2 column volumes of buffer A, washed with 6 column 
volumes of buffer A with 40 mM imidazole and 2 column volumes of buffer B (50 mM 
potassium phosphate, pH 7.4, 500 mM sodium acetate, 20% glycerol, 0.1 mM EDTA, 0.1 mM 
dithiothreitol, 1% sodium cholate, 1% Tween 20, 0.1 mM phenylmethanesulfonyl fluoride, 40 
mM imidazole, and 0.1 mM adenosine monophosphate), and eluted with 5 column volumes of 
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buffer C (200 mM imidazole acetate, pH 7.4, 20% glycerol, 0.1 mM EDTA, 0.1 mM 
dithiothreitol, 1% sodium cholate, and 1% Tween 20).  
Subsequent purification protocols followed the general procedure outlined in chapter 2 
with the exclusion of the flash freeze step unless otherwise indicated.  In addition, the Tris 
buffers described in chapter 5 were also used in the purifications when indicated.  Finally, 
additional variations to the purification trials such as detergents and inclusion of a substrate or 
inhibitor are reported in the results section.   
Results  
CYP11B1 modifications  
The human 11β-hydroxylase enzyme CYP11B1 was initially designed with a Δ3-25 
amino acid N-terminal transmembrane truncation and 4-residue histidine tag on the C-terminus 
to aid in expression and purification of the enzyme.  The N-terminal modifications emulated 
previous CYP11B1 work that resulted in 400 nmol/L of purified protein.1 Cloning of the 
synthesized and modified CYP11B1 gene into the pET17b and pCW plasmids with NdeI and 
HindIII restriction sites was accomplished without difficulties.   
BL21(DE3)pLysS/pGro7/pET17b11B1 Expressions and Purifications 
 The expression and purification of the CYP11B1 enzyme was an iterative process as 
alterations were made to the protocols in an attempt to obtain large quantities of purified enzyme 
for structure/function studies.  Initial emphasis was placed on the pET17b vector and the 
BL21(DE3)pLysS/pGro7 cell line because literature had reported this to be the optimal 
combination for obtaining large quantities (400 nmol/L) of purified human CYP11B1 protein.1 
In order to establish that protein was expressed and induced, samples of cell culture were 
collected before and after CYP11B1 induction with IPTG.  A western blot using a histidine tag 
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antibody confirmed the presence of strong new band at 50-55 kDa corresponding to a histidine 
tagged protein at 24 and 48 hours following induction and incubation at 27 ˚C with shaking at 
250 rpm (Figure 6.3).  This band is slightly lower than the expected 55.6 kDa molecular weight 
for CYP11B1, but hydrophobic enzymes such as CYP11B1 can run lower than the expected 
molecular weight due to excessive SDS binding.1,23 Also, the high background illustrated by 
multiple bands is due to the lack of specific binding by the anti-His antibody. 
 
Figure 6.3. Western blot of BL21(DE3)pLysS/pGro7 pET17b11B1 expressions at pre and post 
inductions.  The Anti-His ladder is labeled in white (Lane 9) while the dual color ladder is 
labeled in black (Lane 10). 
 
 
This western blot indicated strong expression, and cells harvested from 2.25 L culture 
resulted in a 16.2 g cell pellet (wet weight) following a 24 hour incubation and 19.6 g cell pellet 
from a 48 hour incubation.  The first purification followed the published protocol which utilized 
endogenous lysozyme from the BL21(DE3)pLysS/pGro7 cell line, homogenization, sonication, 
and ultracentrifugation with 1% sodium cholate and 1% Tween 20.  The second purification had 
only minor changes from the original protocol in an effort to enhance solubility and extraction.  
Lane Sample Time  (hour) 
1 Expression #1 0 
2 Expression #1 24 
3 Expression #1 48 
4 Expression #2 0 
5 Expression #2 24 
6 Expression #2 48 
7 Blank  
8 11B1dH Control:  Ni-NTA purified sample 
9 Anti-His Ladder 
10 Dual Color molecular weight Ladder 
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These minor changes included increasing the centrifugation speed from 8,700 x g to 10,000 x g 
to increase the cohesiveness of the pellet.  Additionally, the incubation time with resuspension 
buffer #2, which already contained detergent, was increased prior to ultracentrifugation to 
enhance enzyme extraction.  Regardless, following enzyme solubilization and membrane 
removal by ultracentrifugation, the supernatant contained only 44 nmol and 23 nmol of inactive 
P420 enzyme determined by reduced carbon monoxide difference spectra from the first and 
second purification trials, respectively.  After the Ni-NTA affinity column, only 3.2 nmol of 
P420 enzyme were obtained from the first purification (Figure 6.4A).  The second purification 
contained small amounts overall, and similar amounts of inactive P420 with a small amount of 
active P450 (0.31 nmol) (Figure 6.4B).   
 
Figure 6.4. Reduced carbon monoxide difference spectra of the Ni-NTA elution fractions from 
the A) first purification and B) second purification of the CYP11B1 enzyme demonstrate only 
minimal quantities of inactive P420 and active P450 following published procedures.1 
A      B 
	   	  
 
In an attempt to troubleshoot the purification, samples from various stages of Ni-NTA 
affinity chromatography were analyzed by SDS-PAGE gel electrophoresis (Figure 6.5).  All 
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samples had bands between 50-55 kDa.  The Ni-NTA elution fraction #1 (Figure 6.5 Ni. E #1) 
had two bands between 50-55 kDa.  The Ni-NTA elution fraction #2 (Figure 6.5 Ni. E #2) also 
had two bands near 55 kDa. This same sample was used in the western blot as a control (Figure 
6.3 Lane 8) as this sample contained active P450 enzyme.  The lower band of the two bands 
between 50-55 kDa in lane Ni. E #2 of the SDS-PAGE gel appears to correspond to the darker 
band in the western blot, which also aligned with the dark expression bands resulted from P450 
induction.  These results indicate that CYP11B1 may run lower than 55 kDa during gel 
electrophoresis, but the results were not conclusive as the western blot also contained a light 
band at 55 kDa.  
 
Figure 6.5. SDS-PAGE gel from the second purification of 
BL21(DE3)pLysS/pGro7/pET17b11B1. Gel key is as follows: (S): solubilized enzyme contained 
in ultracentrifugation supernatant, (Ni. FT): Ni-NTA flow through from sample loading, (Ni. W): 
Ni-NTA wash fractions, (Ni E): Ni-NTA elution fractions, (MW): dual color molecular weight 
ladder. 
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Unfortunately, while the western blot indicated that large amounts of protein were being 
expressed, this purification protocol did not result in the desired quantities of purified protein, 
and the yields of 1.4 nmol/L and 0.14 nmol/L did not compare well to the 400 nmol/L of culture 
that was reported.1 The comparatively light bands at 50-55 kDa from SDS-PAGE analysis may 
indicate while the protein is being expressed, the enzyme is not being efficiently extracted from 
the bacterial membranes in the steps prior to Ni-NTA affinity chromatography. 
Therefore, additional detergents, buffers, and the addition of ligand were investigated for 
increased solubilization and stabilization of the CYP11B1 enzyme during purification.  The 
success of the CYP21A2 purification led to purification trials with Tris based buffers described 
in chapter 5 with 4.8 mM Cymal-5 or 0.2% Emulgen 913.  Additionally, the substrate 11-
deoxycortisol was added to some purification attempts because ligands can often aid in 
stabilization of P450 enzymes.  To help prevent any protein degradation, the protease inhibitor 
phenylmethanesulfonyl fluoride (0.1 mM) was present during all stages of cell lysis and enzyme 
extraction.  Unfortunately, none of these changes resulted in significant quantities of enzyme.  
The use of 4.8 mM Cymal-5 during the purification did increase the yield to 7.4 nmol P420 
following Ni-NTA affinity chromatography, but this quantity was insufficient to continue the 
purification with cation exchange chromatography. In contrast, 0.2% Emulgen 913 was not an 
optimal detergent with a lower yield of 1.65 nmol of the P420 form.  The presence of 11-
deoxycortisol may aid in stabilizing CYP11B1, as the yield increased from 2.2 nmol to 24 nmol 
of P420 following ultracentrifugation.  However, the final yield determined from the Ni-NTA 
elution fractions was only ~1 nmol of P420 in the presence of substrate.   
SDS-PAGE was inconclusive in identifying whether CYP11B1 was being efficiently 
extracted but suggested that what CYP11B1 was solubilized might not be binding very tightly to 
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Ni-NTA resin (Figure 6.6).  When using Cymal-5 for extraction and stabilization there was a 
band in the Ni-NTA wash step at the expected 55 kDa (Figure 6.6A Ni. W vs. Ni. FT).  This 
band was very light in the elution fractions (Figure 6.6A Ni. E #1 and #2).  Instead, the elution 
fractions have a more prominent band at ~50 kDa, which might also be CYP11B1.  Previous 
SDS-PAGE and western blot results indicate that CYP11B1 may run lower at ~50 kDa 
indicating CYP11B1 was present in the elution fractions.  When instead 0.2% Emulgen was used 
to extract and stabilize CYP11B1, several bands were observed in the wash step between 50-55 
kDa (Figure 6.6B Ni. W) and no bands near 50-55 kDa in the elution fraction.  These results 
demonstrated the poor yield and purity of CYP11B1 after Ni-NTA column chromatography with 
both 4.8 mM cymal-5 and 0.2% Emulgen 913 detergents. 
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Figure 6.6. SDS-PAGE gels from the CYP11B1 purifications with A) 4.8 mM Cymal-5 and B) 
0.2% Emulgen 913 indicates the 55 kDA protein may be eluting in the wash step or running at 
~50 kDA. Gel key is as follows: (S): solubilized enzyme, (Ni. FT): Ni-NTA flow through, (Ni. 
W): Ni-NTA wash, (Ni E): Ni-NTA elution, (MW): dual color molecular weight ladder.  
 
       
 
B 
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Finally, one purification was performed with Tris buffers, 1% cholate, 1% Tween 20, and 
10 µM of the CYP11B1 inhibitor etomidate. While the supernatant from ultracentrifugation 
contained ≥89 nmol of P420 (Figure 6.7A), only 4.4 nmol of P420 and 1.4 nmol P450 remained 
following Ni-NTA affinity chromatography (Figure 6.7B).  This yield was the highest yield 
following ultracentrifugation at that time and twice that of the other purifications, but only a 
small amount of protein was collected following Ni-NTA chromatography.  In retrospect, this 
may have been the first indication that CYP11B1 bound poorly to the Ni-NTA resin, but the 
primary problem of expression masked this indicator. 
 
Figure 6.7. Reduced carbon monoxide assay spectra of CYP11B1 following A) 
ultracentrifugation and B) Ni-NTA elution purified with Tris buffers, 1% cholate, 1% Tween 20, 
and 10 µM etomidate.  
 
 
The foregoing attempts at purifying CYP11B1 from BL21(DE3)pLysS/pGro7 were not 
successful.  Initially, it was hypothesized that extraction of the protein with detergent was the 
primary problem because the western blot indicated the presence of a histidine-tagged protein of 
approximately the correct molecular weight in whole cell lysate.   
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CYP11B1 Expression Test 
To determine if other cell lines or expression plasmids would yield good quantities of 
protein that could be readily purified, additional expression systems were investigated.  The cell 
lines of JM109, Topp3, and DH5α were selected for test expressions of CYP11B1 with the pCW 
plasmid.  All cell lines contained the pGro7 plasmid encoding the GroES/GroEL chaperone.  
These cell lines were chosen based upon their success in expressing CYP17A1, CYP2A13, and 
CYP21A2, respectively.24-26 TB cultures (250 mL), grown as described for 
BL21(DE3)pLysS/pGro7/pET17b11B1 with expression at 27 ˚C for 48 hours, resulted in a range 
of cell pellet weights (Table 6.1).  The cell pellets varied in coloration from a light to dark tan 
pellets.  Typical cell pellets with significant amounts of P450 expression are tan in color with 
dark tops or a dark tan throughout and often correlate to larger cell pellet weights.  A light pellet 
color as in the case of BL21(DE3)pLysS/pGro7 cell line is usually an indicator of poor 
expression. 
 
Table 6.1.  Cell pellet mass from the CYP11B1 expression tests with the pET17b11B1 and 
pCW11B1 plasmids transformed into BL21(DE3)pLysS, JM109, Topp3, and DH5α, all with 
pGro7, and expressed in 250 mL TB cultures for 48 hours. 
Cell Line Co-chaperone P450 Expression Plasmid Cell Mass (g)/ 0.25 L 
BL21(DE3)pLysS pGro7 pET17b11B1 1.93 
BL21(DE3)pLysS pGro7 pCW11B1 2.34 
JM109 pGro7 pET17b11B1 3.66 
JM109 pGro7 pCW11B1 2.60 
Topp3 pGro7 pET17b11B1 4.02 
Topp3 pGro7 pCW11B1 3.20 
DH5α pGro7 pET17b11B1 3.92 
DH5α pGro7 pCW11B1 3.16 
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 Samples of each growth were collected prior to P450 induction and at 24 and 48 hours 
after P450 induction and normalized to an OD600 of 1.  The 48-hour samples were compared by 
western blot analysis.  Aside from the BL21(DE3)pLysS attempt previously described, 
comparison of the eight samples indicated that the pCW11B1 plasmid resulted in the highest 
expression of a 50-55 kDa protein in each cell line (data not shown).  Thus, the 48-hour sample 
with the darkest band at 50-55 kDa from each cell line was compared to its respective pre-
induction sample on a separate western blot (Figure 6.8).  In each case a dark band existed at 50-
55 kDa.  Of these, the darkest band on the western blot arguably continues to be the 
BL21(DE3)pLysS/pGro7/pET17b11B1 expression system described previously (Figure 6.8 Lane 
2).  However, since this expression system has not afforded much success, the JM109/pGro7 and 
DH5α/pGro7 cell lines with the pCW plasmid were chosen for further experimentation. 
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Figure 6.8. Western blot of samples before and after P450 induction for the CYP11B1 
expression test with BL21(DE3)pLysS/pET17b11B1, JM109/pCW11B1, Topp3/pCW11B1, and 
DH5α/pCW11B1 all with the pGro7 plasmid and probed with an anti-His antibody.  Image 
transparency was altered for clarity upon printing.  
 
Lane Cell Line Chaperone P450 Expression Plasmid Time (hour) 
1 BL21(DE3)pLysS pGro7 pET17b11B1 0 
2 BL21(DE3)pLysS pGro7 pET17b11B1 48 
3 JM109 pGro7 pCW11B1 0 
4 JM109 pGro7 pCW11B1 48 
5 Topp3 pGro7 pCW11B1 0 
6 Topp3 pGro7 pCW11B1 48 
7 DH5α pGro7 pCW11B1 0 
8 DH5α pGro7 pCW11B1 48 
9 X X X X 
10 Ni Elution Control - - - 
11 Anti-His Ladder - - - 
12 Dual Color Ladder - - - 
 
  
1 2 8 9 12 10
0 
11 3 6 7 5 4 
15 kDA 
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130 kDA 
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JM109/pGro7/pCW11B1 and DH5α/pGro7/pCW11B1 Expressions and Purifications 
 CYP11B1 was expressed in JM109/pGro7 or DH5α/pGro7 E. coli competent cells for 48 
hours at 27 ˚C or 30 ˚C.  While the size and color of a cell pellet does not always correlate to 
good expression levels, it was apparent that these expression systems were more effective in 
expressing CYP11B1 than BL21(DE3)pLysS/pGro7 as larger, darker cell pellets were obtained.   
 Generally, purification of 2 L of cell culture using Tris buffers with either 4.8 mM 
Cymal-5 or 0.2% Emulgen 913 resulted in larger quantities of P450 enzyme in the early 
purification stages than with BL21(DE3)pLysS/pGro7/pET17b11B1 and could be carried 
through Ni-NTA affinity and cation exchange chromatography.  In addition, all purification 
stages included 50 µM 11-deoxycortisol to stabilize CYP11B1, and the protease inhibitor 
phenylmethanesulfonyl fluoride was added to a final concentration of 0.1 mM to decrease 
degradation of the enzyme during cell lysis and protein extraction.   
CYP11B1 expressed in DH5α/pGro7 at 27 ˚C and purified with 4.8 mM Cymal-5 
resulted in 30 nmol of active P450 enzyme following Ni-NTA chromatography.  This was a 
significant improvement over the BL21(DE3)pLysS/pGro7 expressions which yielded less than 1 
nmol of P450 at this stage.  This was sufficient protein that CYP11B1 could be further purified 
with cation exchange chromatography, resulting in a final yield of 2.2 nmol of P450.  Expression 
at 30˚C with JM109/pGro7 competent cells slightly improved the yield to 3.5 nmol following 
cation exchange chromatography with 4.8 mM Cymal-5.  However, the ultracentrifuge 
supernatant from the 30 ˚C expression that was applied to the Ni-NTA resin was a significantly 
darker red color indicative of a higher protein concentration in comparison to the 27 ˚C 
expression.  Unfortunately, the majority of the protein did not bind to the Ni-NTA column.  
Additionally, the Ni-NTA flow through fractions were collected and diluted 5-fold with CM 
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wash buffer, 4.8 mM Cymal-5, and 50 µM 11-deoxycortisol.  The diluted sample was applied to 
the carboxymethyl resin for cation exchange, but the protein did not bind to the CM column 
either. 
Since detergents can affect column chromatography the DH5α/pGro7 30 ˚C expression 
was purified with 0.2% Emulgen 913 in an attempt to enhance binding to the Ni-NTA resin.  In 
addition the glycine content in the Ni-NTA wash buffer was reduced from 100 mM to 20 mM to 
reduce premature elution of the enzyme during the wash step.   However, the dark red cell lysate 
with >365 nmol of P450 still bound poorly to the Ni-NTA resin resulting in only 5 nmol of P450 
enzyme in the elution fractions.  The yields at the various purification stages are summarized in 
table 6.2.  It should be noted that the JM109/pGro7/pCW11B1 expression at 27 ˚C was not 
purified due to time constraints. 
 
Table 6.2. Purification summaries for pCW11B1 expressed in DH5α/pGro7 E. coli competent 
cells.   
Cell Line DH5α/pGro7 DH5α/pGro7 JM109/pGro7 
Expression Temperature (˚C) 27 30 30 
Detergent 4.8 mM Cymal-5 0.2 % Emulgen 913 4.8 mM Cymal-5 
Post Ultracentrifugation (nmol) - > 365 (P450) 64.3 (P450) 77.1 (P420) 
Ni-NTA (nmol) 30 (P450) 5 (P450) 25.3 (P450) 12.7 (P420) 
CM (nmol) 2.2 (P450) - 3.5 (P450) 
 
These results indicate that CYP11B1 expresses well in both DH5α/pGro7 and 
JM109/pGro7 E. coli competent cells with 30 ˚C being the optimal expression temperature.  
However, purified enzyme could not be attained due to the poor affinity to the Ni-NTA resin. 
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Six Residue Histidine Tag 
 Site-directed mutagenesis was used to incorporate two additional histidine residues at the 
C-terminus in order to extend the histidine tag and facilitate binding of CYP11B1 to the Ni-NTA 
resin.  The 6X histidine tagged enzyme was expressed in JM109/pGro7 competent E. coli cells at 
30 ˚C for 48 hours and purified with potassium phosphate buffers described in chapter 2, with 
4.8 mM Cymal-5 and 50 µM 11-deoxycortisol.  Tris buffers were exchanged for potassium 
phosphate buffers as this variable had yet to be attempted with the pCW expression systems.  It 
also aided in the stabilization of CYP21A2 and may improve the yield following column 
chromatography. Unfortunately, the supernatant from ultracentrifugation following cell lysis 
with lysozyme, flash freeze, homogenization, and sonication was lighter in color than the 
previous 30 ˚C expressions and resulted in only 15.4 nmol of P450 and 13.5 nmol of P420 
following Ni-NTA chromatography (Figure 6.9).  While the potassium phosphate buffers could 
have affected the yield, it is more likely that the expression was the primary problem.  The only 
difference between the expression with the 6X histidine tagged enzyme and the previous 
expressions was the induction of the 6X histidine tag at an OD600 of ~1.1 versus 1.8.  A second 
expression was performed with induction of the CYP11B1 enzyme at 1.8, but the cell pellet was 
also lighter in color, which leads me to believe that the expression levels were not very high.  As 
a result the impact of the 6X histidine tag on affinity for the Ni-NTA resin has yet to be 
determined.  Future efforts will need to focus on both increasing the consistency of expression 
and the yield during purification.  
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Figure 6.9. Reduced carbon monoxide spectra of Ni-NTA purified CYP11B1 with a 6X 
histidine tag demonstrated both P450 and P420 peaks. 
 
 
Discussion 
CYP11B1 Modifications 
 Modifications to the CYP11B1 gene included a Δ3-25 deletion, R27K mutation, and a 4 
amino acid residue histidine tag.1  The truncation of the N-terminal transmembrane helix was 
based upon previous work and secondary structure predictions as CYP11B1 lacks the proline-
rich region that often follows the transmembrane helix.7 The modified enzyme was easily cloned 
into both pCW and pET17b vectors through NdeI and HindIII restriction sites and transformed 
into BL21(DE3)pLysS, JM109, DH5α, and Topp3 E. coli competent cells along with the pGro7 
chaperone for protein expression trials.  
BL21(DE3)pLysS/pGro7 pET17b11B1 
 Initial expression and purification of CYP11B1 followed a published protocol that 
reported 400 nmol/L of purified enzyme.   Western blots indicated that a histidine tagged protein 
of the expected molecular weight was expressed following induction.  However, several 
purification trials with varying detergents, buffers, and ligand present failed to produce a single 
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nmol of active P450 following NiTNA chromatography. Table 6.3 summarizes the purification 
yields with CYP11B1 expressed in BL21(DE3)pLysS/pGro7 competent E. coli cells.  It remains 
unclear as to how the authors were able to produce their reported yield.  In my experiments, the 
lack of expression appeared to be the primary problem.  One possibility is that the induction of 
the enzyme at the incorrect OD600 value is critical, but the authors did not publish this 
information.  If the BL21(DE3)pLysS/pGro7/pET17b expression is to be considered in the 
future, an expression test with varying induction times could provide insight as to the optimal 
OD600 value. 
 
Table 6.3. Purification summary for BL21(DE3)pLysS/pGro7 expressed CYP11B1.  The 
purification trials with cholate and Tween 20 followed a published protocol.1  The remaining 
purification trials utilized Tris based buffers with 4.8 mM Cymal-5 or 0.2% Emulgen 913 in the 
presence or absence of ligand. 
Detergent 1% 
Cholate/ 
1% Tween 
20 
Trial 1 
(nmol) 
1% 
Cholate/ 
1% Tween 
20 
Trial 2 
(nmol) 
4.8 mM 
Cymal-5 
(nmol) 
0.2% 
Emulgen 
913 
(nmol) 
0.2% 
Emulgen 913  
(nmol) 
Ligand  - - - -  50 µM 11-
deoxycortisol 
Ultracentrifugaiton 
Supernatant 44 (P420) 23 (P420) 17.3 (P420) 2.2 (P420) 24 (P420) 
Ni-NTA Elution 3.2 (P420) 0.31 (P450) 7.4 (P420) 1.65 (P420) ~1 (P420) 
 
 
Expression Evaluations 
 Due to the poor expression and purification of CYP11B1 from the 
BL21(DE3)pLys/pGro7 cell line, several expression systems were evaluated.  Individually, 
pET17b11B1 and pCW11B1 were transformed into BL21(DE3)pLysS, JM109, DH5α, and 
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Topp3 E. coli competent cells containing pGro7.  Western blot comparisons revealed that the 
BL21(DE3)pLysS/pGro7/pET17b11B1 expression system arguably had the darkest band 
correlating to a 50-55 kDa histidine tagged enzyme.  However, CYP11B1 also appeared to 
express in both JM109/pGro7 and DH5α/pGro7 cell lines with the pCW expression plasmid, and 
large-scale expression confirmed this.  A 48-hour expression in DH5 pGro7 at 27 ˚C resulted in 
30 nmol of P450 following Ni-NTA chromatography, which was enough protein for the 
purification to be continued through cation exchange chromatography.  Additional expression 
temperatures were evaluated, and while the purification yields are not indicative of the quality of 
expression, the deep red color of the ultracentrifugation supernatant indicated that a 30 ˚C 
incubation was optimal.  However, the yield was significantly reduced due to the lack of 
interactions between the four histidine C-terminal tag and the Ni-NTA resin. 
Six Residue Histidine Tag 
 Site-directed mutagenesis was used to extend the 4 residue histidine tag to 6 residues to 
enhance purification through affinity chromatography.  Only one purification has been 
completed thus far with CYP11B1 expressed in JM109/pGro7 at 30˚, but no improvements to the 
yield were observed following Ni-NTA affinity chromatography with 15.4 nmol of P450 and 
13.5 nmol of P420. However, the effect of the 6X histidine tag cannot be determined, as it 
appeared that the overall expression was poor.  While the size and color of a cell pellet does not 
necessarily correlate to the quality of expressions, qualitative observations through empirical 
experimentation can be valuable.  The cell pellet from the previous 30 ˚C expression with the 4X 
histidine tag were darker in color following harvesting resulting in a deep red supernatant after 
ultracentrifugation.  One explanation for subsequent decreased expression levels might be that a 
poor colony was selected for expression. Inconsistent expression levels between colonies have 
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been observed for other P450 expressions.  Future expression of CYP11B1 should begin from a 
fresh transformation rather than glycerol stocks to evaluate this variable.  In addition, expression 
in DH5α/pGro7 competent E. coli cells should be performed.  Should the 6X His tag ultimately 
prove unsuccessful, additional chromatographic steps will be pursued.  P450 enzymes have 
previously been purified with DEAE-cellulose, hydoxyapetite, and octyl sepharose column 
chromatography.27,28 Additionally, affinity chromatography with CYP11B1’s redox partner, 
adrenodoxin, could be used as this approach was successful in purifying the mitochondrial P450 
CYP11A1.29 
Conclusions 
 Biochemical studies of human CYP11B1 have been hampered by protein availability and 
the instability of the enzyme during expression, detergent solubilization, and purification in 
previous work1,2 and the results described herein.  However, the results described in this chapter 
also illustrate progress towards obtaining purified CYP11B1.  This is necessary to provide 
sufficient quality and quantity of protein to support biochemical studies to elucidate 
structure/function relationships and evaluate CYP11B1 as a counter-target for CYP17A1 
inhibitors.  Expression tests completed thus far reveal that the JM109/pGro7 and DH5α/pGro7 
cell lines with pCW11B1 prefer incubations at 30 ˚C rather than 27 ˚C for 48 hours, but the 
expression is inconsistent at present.  Purification of CYP11B1 has also proven to be problematic 
due to poor column affinity, but ongoing experimentation will focus on resolving this obstacle.  
Advancing knowledge on CYP11B1 could provide a more thorough understanding of the 
underlying structural interactions of CYP11B1 contributing to normal or impaired CYP11B1 
activity and lead to advanced therapeutic treatments for cortisol dependent diseases such as 
Cushing’s disease.  In addition, the structural and functional knowledge could aid in the 
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development of CYP17A1 inhibitors for the treatment of prostate cancer by testing the 
selectivity of the potential drug candidates against CYP11B1 as a counter-target. 
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Chapter 7 
Conclusions 
 Cytochrome P450 enzymes are involved in both endogenous and exogenous metabolism 
in maintaining homeostasis and clearance of foreign chemicals from the body.  There are 57 
human cytochrome P450 enzymes that participate in the metabolism of steroids, xenobiotics, 
fatty acids, eicosanoids, vitamins, or unknown substrates.1  While these oxidations are usually 
advantageous, aberrant activity or activation of procarcinogens can be detrimental to human 
health. However, these problems can often be addressed through therapeutic intervention.  The 
rational design of inhibitors for modification of disease states requires a biochemical 
understanding of the enzyme, and the evaluation of potential drug candidates against both targets 
and counter-targets.  The work described thus far has involved the evaluation of selective 
inhibitors for the therapeutic target CYP2A13, and the biochemical evaluation of cytochromes 
P450 involved in the steroid biosynthetic pathway as both therapeutic targets and counter-targets. 
Lung Cancer Chemoprevention  
 Lung cancer is the leading cause of all cancer related deaths.2  With only a 15% 5-year 
survival rate,3 current research has been focused on preventative methods. Since tobacco use is 
responsible for >80% of all lung cancer incidence,2 the role of specific tobacco carcinogens 
warrants investigation. NNK is one of the most prevalent procarcinogens in tobacco products and 
is selectively activated by CYP2A13 metabolism.4  Therefore, the selective inhibition of 
CYP2A13 offers a novel therapeutic target.  Evaluation of a benzylmorpholine library revealed 
selective binders and inhibitors of CYP2A13 versus the 94% identical CYP2A6, with Kd and Ki 
values for CYP2A13 in the low micromolar range.  Substitution at the ortho position on the 
benzene ring proved to be vital for selectivity, affinity, and potency.  X-ray crystallography with 
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select benzylmorpholine analogs suggested that the ligands may bind in multiple orientations 
with a consistent placement of the chlorine substituent in the center of the active site of 
CYP2A13-like enzymes.  Combination of the binding and enzymatic analysis with the structural 
data could facilitate the design of more potent inhibitors with an emphasis placed at the ortho 
substitution.  However, further characterization of benzylmorpholine analogs is necessary to 
determine the utility of this scaffold. 
 The next step in the development of benzylmorpholine analogs as drug candidates was 
the determination of an initial safety profile for cytotoxicity, mutagenicity, and hERG interaction 
in addition to evaluation against a panel of xenobiotic-metabolizing P450 enzymes to determine 
the metabolic stability in mammalian microsomes.  This work was performed for our study by 
Cerep, Xenotech, or Pfizer as they had the necessary expertise to complete these studies.  4-(2-
Chlorobenzyl)morpholine (3) and/or 4-(2-chloro-6-fluorobenzyl)morpholine (7) were used as 
test compounds as they were both potent and selective inhibitors of CYP2A13 and represented 
both the single and disubstituted analogs.  First, aqueous solubility was determined since 
precipitation during subsequent dilutions and incubations can lead to erroneous or irreproducible 
results.  Consistent with our own experience with these compounds, the aqueous solubility was 
relatively high.  Both 3 and 7 were soluble up to 180 µM in phosphate buffered saline, pH 7.4.  
 Both 3 and 7 were tested for bacterial cytotoxicity and genetic and cardiac toxicity.  
These compounds were not cytotoxic with Salmonella typhimurium strains TA98, TA100, and 
TA1535 at concentrations ranging from 0.63 – 100 µM with survival rates of ≥86% of control 
samples at all concentrations.  A compound is considered toxic if the bacterial cell growth is less 
than 60% of control samples at the respective concentrations.   
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For genetic toxicity, the Ames test was also employed with Salmonella typhimurium 
strains TA98, TA100, and TA1535, which detect frame shifts and base substitutions.  Assays 
were completed +/- S9 fraction to detect toxicity requiring metabolic activation.  Growth on 
selective agar plates revealed that in compound concentrations ranging from 5-100 µM few to no 
revertants were detected.  These negative results suggest that the genetic toxicity of these 
compounds is very low.   
The potential of 3 and 7 to cause cardiac toxicity via inhibition of the hERG channel was 
evaluated because this can be a major reason for drug withdrawal or limitation.  The potential for 
prolongation of the QT interval associated with sudden cardiac death was determined by 
exposing mammalian CHO-K1 cells expressing the hERG channel gene to 0.1-10 µM of either 3 
or 7 and using an automated patch clamp assay.  The percent of inhibition is obtained by 
measuring the tail current amplitude before and after addition of compound.  Using this 
approach, compounds 3 and 7 inhibited the tail current by 13.9% and 24.8%, respectively, at the 
highest concentration tested, 10 µM.  These results suggest the hERG IC50 is >10 µM, placing 
the potency in the low category and suggesting that cardiac toxicity is unlikely to be relevant for 
these compounds.  Of course, the effective therapeutic plasma concentrations should be 
considered.  The target would be for a drug’s hERG IC50 to be ≥30-fold higher than the plasma 
concentration to maximize safety. 
The metabolic stability of compounds 3, 7, and 8 were evaluated with a panel of 
recombinant hepatic cytochromes P450 at Pfizer.  Compound (1 µM) was incubated with 
recombinant human CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, CYP2D6, 
and human liver microsomes over the course of 45 minutes.  The percent compound remaining 
was detected at 0, 5, 10, 20, 30, and 45 minutes.  The average half life for the compounds ranged 
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from <5 minutes with CYP2B6 (3 and 7) to 2,317 minutes with CYP1A2 (3) (Table 7.1).  
CYP2B6 was the fastest metabolizer of the benzylmorpholine compounds with 0% compound 
remaining after only 5 minutes while 100% remained in the control samples, which were not 
initiated with NADPH (Figure 7.2).  These results suggest that the benzylmorpholine compounds 
herein will be cleared very rapidly from circulation if delivered systematically. All of these 
enzymes are predominantly hepatic enzymes while CYP2A13 is expressed in the respiratory 
tract.  If a benzylmorpholine inhibitor could be directly administered to the lungs through the use 
of an inhaler, it would be able to reach its target before the first pass effect would decrease 
compound concentrations in circulation.   
 
Table 7.1. Results for the average half life of compounds 6, 7, and 8 with a panel of human 
recombinant hepatic cytochromes P450. 
Compound Average T1/2 (min) 
 CYP1A2 CYP2C8 CYP2C9 CYP2D6 CYP3A4 CYP2C19 CYP2B6 HLM 
3 2317 62 476 61 33 13 <5 23 
7 1214 51 230 78 25 18 <5 13 
8 244 42 150 55 10 14 12 16 
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Figure 7.1.  Representative data of the metabolic studies with a benzylmorpholine compound (3) 
and CYP2B6. 
 
 
Therefore it was important next to determine the metabolic stability of these compounds 
in lung microsomes compared to liver microsomes with not only the target organism (human), 
but also for our potential pre-clinical models, rats and mice.  Xenotech performed the metabolic 
studies with mouse, rat, and human lung and liver microsomes with 3 and 7.  The first concern 
was that the compounds might not be stable in human lung tissue long enough to have a 
sustained desired effect of CYP2A13 inhibition.  To evaluate this, an assay was performed to 
detect benzylmorpholine compounds after 5, 10, and 20 minutes with +/- NADPH controls with 
the microsomes listed above.  Since CYP2A13 is located in the respiratory tract, it was 
reassuring to observe that the benzylmorpholine analogs were very stable in human lung 
microsomes as minimal or no loss of substrate was observed after 20 minutes (Table 7.2).  
Following the 20-minute incubations with the mouse and rat lung and liver microsomes, no 
substrate was detected, indicating that the mouse and rat isozymes metabolize the 
benzylmorpholine analogs very quickly while the human enzymes result in much slower 
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clearance. However, there may be some variability in the assay as >100% of compound was 
detected in human lung microsomes after the allotted time.  Regardless, the data was sufficient to 
illustrate the differences in metabolic stability of the samples between species and different 
tissues, and the results suggested that dosing in human lung is not problematic and that the 
compounds will then be quickly cleared from systemic circulation to reduce side effects and 
toxicity.  However, the rat and mouse data raises a concern about the validity of testing these 
compounds in animal models.  The rat and mouse P450 enzymes do not reflect the human case 
we are targeting.  This would make it very difficult to collect in vivo data for an investigational 
new drug (IND) application, which is required before clinical trials.   
 
Table 7.2. Metabolic stability following a 20 minute incubation of 3 (black) and 7 (red) with 
mouse, rat, and human lung and liver microsomes.   
Species Test System Percent Loss of Substrate (%) 
Percent 
Remaining (%) 
Estimated in vitro 
intrinsic clearance 
(µL/min/mg protein) 
Human 
Liver 47.0/85.5 53.1/14.5 152/91.4 
Lung No Loss/No Loss 111/137 NA/NA 
Mouse 
Liver 100/100 0/0 3430/916 
Lung 99.9/100 0.1/0 2160/551 
Rat 
Liver 96.7/97.3 3.3/2.7 744/173 
Lung 99.8/100 0.2/0 1420/478 
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 However, this hurdle of variation between species may be overcome by the use of a 
humanized mouse model in which the mouse CYP2A enzymes are knocked out and the human 
CYP2A enzymes are knocked in.  Dr. Xinxin Ding from the Wadsworth Center is pioneering this 
work. In the process of creating the humanized mouse model, Dr. Ding created a CYP2A and 
CYP2B knockout mouse and generously provided lung and liver microsomes for evaluation.  
Metabolic studies similar to those described above were conducted by Xenotech to determine the 
stability of our compounds with lung and liver microsomes.  In comparison to wild type 
microsomes, the compounds were more stable in the knockout mice in both the lung and liver 
samples and had a similar metabolic profile to the human lung and liver samples with minimal 
compound disappearance in lung microsomes and a higher rate of metabolism in the liver 
microsomes (Figure 7.2).  The next step would be to analyze benzylmorpholine compounds with 
a humanized mouse model, which has the human CYP2A13, CYP2B6, and CYP2F1 genes 
knocked in.5  This model demonstrated that CYP2A13 and CYP2F1 were expressed in the 
respiratory tract, while CYP2B6 expression was localized to the liver as is reflective of human 
enzymes.5  Noteably, these transgenic mice had a higher rate of NNK metabolism over wild type 
mice which is consistent with CYP2A13 having a higher catalytic efficiency over the mouse 
CYP2A5 ortholog.6 Analysis of benzylmorpholine drug candidates with this humanized mouse 
model could provide insight into the in vivo efficacy of these compounds.	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Figure 7.2.  Disappearance of 7 during incubation with A) liver and B) lung microsomes from 
CYP2A/CYP2B knockout (transgenic) mice versus wild type mice (control).   
 
 
 The results above summarize the development of benzylmorpholine analogs for the 
chemoprevention of lung cancer.  Benzylmorpholine analogs 3 and 7 were soluble, did not show 
toxicity in Ames and hERG, and although rapidly metabolized by human liver microsomes, 
predominately by CYP2B6, persist in human lung microsomes.  Drug delivery through 
inhalation and decreased systemic exposure is promising for minimal side effects and toxicity.  
Concerns with rapid clearance in pre-clinical rat and mouse models is seemingly obviated by the 
development of humanized mouse models that better reflect human CYP activity.  In vivo studies 
in humanized mouse models is the next stage in development and can be used to evaluate the 
protective effects of a benzylmorpholine drug candidate against NNK-induced lung tumors.  If 
successful, our compound could be used individually or in concert with the suppressing agent 
myo-inosotol to reduce the risk of lung cancer in tobacco users.3 
A B 
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Development of CYP21A2 and CYP11B1 for the Counter-target Evaluation of Selective 
CYP17A1 Inhibitors 
 CYP2A13 is not the only therapeutic target that has been of interest to the Scott lab. 
Recent work has resulted in the crystal structure of CYP17A1.  Combination of this structural 
knowledge with biochemical studies is being used to develop selective inhibitors for the 
treatment of prostate cancer.  In order to determine the selectivity for potential drug candidates, 
these compounds will need to be evaluated against obvious counter-targets. In addition to 
CYP17A1, CYP21A2 and CYP11B1 are involved in the steroid biosynthetic pathway, and 
substrate overlap exists between CYP21A2 and CYP17A1.  However, biochemical studies for 
both CYP21A2 and CYP11B1 have been limited in the current literature.  The work described in 
this dissertation lays the groundwork for the structure/function evaluation of these enzymes.  
Human CYP21A2 was successfully cloned, expressed, purified, and crystallized for the first 
time.  Crystal optimization and development of metabolism assays are still ongoing, and the 
finalization of the metabolism protocol is vital for determining if new CYP17A1 inhibitors are 
selective for CYP17A1 over CYP21A2.  The structural knowledge that could be gained through 
X-ray crystallography would provide insight into the active site residues governing substrate 
selectivity, and comparison to the bovine CYP21A2 structure could inform final differences 
between species and either validate or invalidate inferences made from the 79%-identical bovine 
CYP21A2 enzyme.   
Biochemical evaluation of CYP11B1 is not only necessary for counter-target evaluation, 
but the knowledge could be additionally useful in designing selective inhibitors of CYP11B1 for 
the treatment of Cushing’s disease resulting from overproduction of cortisol.  Large-scale 
expression and purification of this enzyme are necessary to complete the desired biochemical 
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studies.  Only one E. coli expression and purification resulting in 400 nmol/L of purified enzyme 
has been reported in the literature.7  However, we were unable to reproduce these results, and no 
additional work with this protocol has been published. Therefore, I evaluated different 
expression systems and purification modifications such as detergents, buffers, and inclusion of 
ligand.  While CYP11B1 has been successfully cloned, expressed, and extracted, expression has 
been inconsistent, and the purification of this enzyme has proven to be difficult due to the lack of 
affinity during metal-affinity and cation exchange column chromatography.  Future work will 
include evaluation of expressions at 30˚ C and the ability of a new CYP11B1 construct with a 
lengthened histidine tag to bind to Ni-NTA resin.  Additional chromatographic steps such as 
DEAE-cellulose, octyl sepharose, hydroxyapatite, and adrenodoxin affinity will be pursued if the 
extended histidine tag proves unsuccessful. 
These results with CYP21A2 and CYP11B1 describe the foundational work that is 
necessary for the biochemical evaluation of these enzymes in addition to determining their utility 
as counter-targets.  Advancing the knowledge of these enzymes would help provide a more 
complete picture of the enzymes involved in the steroid biosynthetic pathway. 
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